|
G |
Drd1 |
dopamine receptor D1 |
multiple interactions affects localization |
ISO |
A 77636 binds to and results in increased activity of DRD1 protein; SCH 23390 inhibits the reaction [A 77636 affects the localization of DRD1 protein]; SCH 23390 inhibits the reaction [A 77636 results in increased activity of DRD1 protein] |
CTD |
PMID:15985612 |
|
NCBI chr17:10,540,440...10,544,971
Ensembl chr17:10,540,558...10,545,002
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
Duloxetine Hydrochloride inhibits the reaction [Indomethacin results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:38701902 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
Duloxetine Hydrochloride binds to and results in decreased activity of AR protein |
CTD |
PMID:25752796 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Cd48 |
Cd48 molecule |
multiple interactions |
EXP |
Duloxetine Hydrochloride inhibits the reaction [Indomethacin results in increased expression of CD48 protein] |
CTD |
PMID:38701902 |
|
NCBI chr13:84,184,884...84,209,144
Ensembl chr13:84,185,532...84,209,142
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
decreases activity multiple interactions |
ISO |
Duloxetine Hydrochloride results in decreased activity of CYP17A1 protein Duloxetine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased hydroxylation of Pregnenolone] which results in increased chemical synthesis of 17-alpha-Hydroxypregnenolone]; Duloxetine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased hydroxylation of Progesterone] which results in increased chemical synthesis of 17-alpha-Hydroxyprogesterone]; Duloxetine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxypregnenolone] which results in increased chemical synthesis of Dehydroepiandrosterone]; Duloxetine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxyprogesterone] which results in increased chemical synthesis of Androstenedione]; Duloxetine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased hydroxylation of Pregnenolone]; Duloxetine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased hydroxylation of Progesterone]; Duloxetine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxypregnenolone]; Duloxetine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxyprogesterone] |
CTD |
PMID:29100959 |
|
NCBI chr 1:255,476,861...255,484,547
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity |
ISO |
Duloxetine Hydrochloride results in decreased activity of CYP1A1 protein |
CTD |
PMID:33814510 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
EXP |
[furafylline results in decreased activity of CYP1A2 protein] which results in decreased glutathionylation of Duloxetine Hydrochloride; CYP1A2 protein results in increased activity of and results in increased glutathionylation of Duloxetine Hydrochloride |
CTD |
PMID:20669986 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity |
ISO |
Duloxetine Hydrochloride results in decreased activity of CYP1B1 protein |
CTD |
PMID:33814510 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
multiple interactions |
EXP |
[Quinidine results in decreased activity of CYP2D6 protein] which results in decreased glutathionylation of Duloxetine Hydrochloride; CYP2D6 protein results in increased activity of and results in increased glutathionylation of Duloxetine Hydrochloride |
CTD |
PMID:20669986 |
|
NCBI chr 7:115,762,662...115,771,832
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
Duloxetine Hydrochloride results in increased expression of HMOX1 mRNA |
CTD |
PMID:29134401 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
EXP |
Duloxetine Hydrochloride inhibits the reaction [Indomethacin results in increased expression of IL1A protein] |
CTD |
PMID:38701902 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
Duloxetine Hydrochloride results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Kcnj3 |
potassium inwardly-rectifying channel, subfamily J, member 3 |
multiple interactions |
ISO |
Duloxetine Hydrochloride results in decreased activity of [KCNJ3 mRNA co-treated with KCNJ5 mRNA]; Duloxetine Hydrochloride results in decreased activity of [KCNJ3 mRNA co-treated with KCNJ6 mRNA] |
CTD |
PMID:22164246 |
|
NCBI chr 3:39,944,896...40,106,646
Ensembl chr 3:39,945,351...40,109,124
|
|
G |
Kcnj5 |
potassium inwardly-rectifying channel, subfamily J, member 5 |
multiple interactions |
ISO |
Duloxetine Hydrochloride results in decreased activity of [KCNJ3 mRNA co-treated with KCNJ5 mRNA] |
CTD |
PMID:22164246 |
|
NCBI chr 8:30,724,923...30,753,083
Ensembl chr 8:30,724,925...30,753,518
|
|
G |
Kcnj6 |
potassium inwardly-rectifying channel, subfamily J, member 6 |
multiple interactions |
ISO |
Duloxetine Hydrochloride results in decreased activity of [KCNJ3 mRNA co-treated with KCNJ6 mRNA] |
CTD |
PMID:22164246 |
|
NCBI chr11:34,061,702...34,308,758
Ensembl chr11:34,061,708...34,308,758
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
affects localization |
ISO |
Duloxetine Hydrochloride affects the localization of NFE2L2 protein |
CTD |
PMID:29134401 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Prl |
prolactin |
increases expression |
ISO |
Duloxetine Hydrochloride results in increased expression of PRL protein |
CTD |
PMID:17606668 |
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
EXP |
Duloxetine Hydrochloride inhibits the reaction [Indomethacin results in decreased expression of VEGFA protein] |
CTD |
PMID:38701902 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Gpc1 |
glypican 1 |
decreases degradation |
ISO |
3-beta-(2-(diethylamino)ethoxy)androst-5-en-17-one results in decreased degradation of GPC1 protein |
CTD |
PMID:21642435 |
|
NCBI chr 9:93,396,234...93,424,047
Ensembl chr 9:93,396,234...93,424,047
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
3-beta-(2-(diethylamino)ethoxy)androst-5-en-17-one inhibits the reaction [[Lipopolysaccharides results in increased susceptibility to Silicon Dioxide] which results in increased secretion of IL1B protein] |
CTD |
PMID:36860548 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
|
G |
Htr1a |
5-hydroxytryptamine receptor 1A |
multiple interactions |
EXP |
[1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to 1-(3-chlorophenyl)piperazine; [1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Apomorphine; [1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Physostigmine; tertatolol inhibits the reaction [[1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Apomorphine]; tertatolol inhibits the reaction [[1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Physostigmine] |
CTD |
PMID:8539317 |
|
NCBI chr 2:36,693,462...36,698,026
Ensembl chr 2:36,694,174...36,695,442
|
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases response to substance |
ISO |
BAX protein results in increased susceptibility to Acridine Orange |
CTD |
PMID:16177561 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions |
ISO |
[Acridine Orange binds to Platinum Compounds] which results in increased expression of GSTP1 mRNA; [Acridine Orange binds to Platinum] which results in increased expression of GSTP1 mRNA |
CTD |
PMID:16814760 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
Acridine Orange results in increased stability of and results in increased activity of TP53 protein |
CTD |
PMID:16177561 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
increases hydroxylation multiple interactions increases metabolic processing |
ISO |
CYP2D6 protein results in increased hydroxylation of Atomoxetine Hydrochloride Quinidine inhibits the reaction [CYP2D6 protein results in increased metabolism of Atomoxetine Hydrochloride] |
CTD |
PMID:17470523 PMID:34431675 |
|
NCBI chr 7:115,762,662...115,771,832
Ensembl chr 7:113,881,618...113,891,759
|
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
multiple interactions increases expression |
ISO |
ALDH1A1 protein promotes the reaction [Benzophenoneidum results in increased lipidation of and results in increased cleavage of MAP1LC3B protein] Benzophenoneidum results in increased expression of ALDH1A1 protein |
CTD |
PMID:28722353 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Ano6 |
anoctamin 6 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of ANO6 protein |
CTD |
PMID:28722353 |
|
NCBI chr 7:126,933,919...127,113,588
Ensembl chr 7:126,933,936...127,113,589
|
|
G |
Araf |
A-Raf proto-oncogene, serine/threonine kinase |
increases expression |
ISO |
Benzophenoneidum results in increased expression of ARAF protein |
CTD |
PMID:28722353 |
|
NCBI chr X:1,227,392...1,292,356
Ensembl chr X:1,227,392...1,239,073
|
|
G |
Atp6ap2 |
ATPase H+ transporting accessory protein 2 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of ATP6AP2 protein |
CTD |
PMID:28722353 |
|
NCBI chr X:10,183,983...10,210,948
Ensembl chr X:10,183,068...10,210,918
|
|
G |
Ccdc22 |
coiled-coil domain containing 22 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of CCDC22 protein |
CTD |
PMID:28722353 |
|
NCBI chr X:14,898,296...14,910,244
Ensembl chr X:14,898,296...14,910,244
|
|
G |
Ccdc39 |
coiled-coil domain 39 molecular ruler complex subunit |
increases expression |
ISO |
Benzophenoneidum results in increased expression of CCDC39 protein |
CTD |
PMID:28722353 |
|
NCBI chr 2:116,665,651...116,703,354
Ensembl chr 2:116,665,261...116,703,350
|
|
G |
Cd44 |
CD44 molecule |
increases expression |
ISO |
Benzophenoneidum results in increased expression of CD44 protein |
CTD |
PMID:28722353 |
|
NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620
|
|
G |
Chtf18 |
chromosome transmission fidelity factor 18 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of CHTF18 protein |
CTD |
PMID:28722353 |
|
NCBI chr10:14,743,006...14,751,044
Ensembl chr10:14,742,621...14,751,050
|
|
G |
Commd1 |
copper metabolism domain containing 1 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of COMMD1 protein |
CTD |
PMID:28722353 |
|
NCBI chr14:96,880,463...96,984,494
Ensembl chr14:96,880,463...96,984,501
|
|
G |
Cops7b |
COP9 signalosome subunit 7B |
increases expression |
ISO |
Benzophenoneidum results in increased expression of COPS7B protein |
CTD |
PMID:28722353 |
|
NCBI chr 9:87,238,132...87,263,967
Ensembl chr 9:87,238,375...87,263,967
|
|
G |
Cul3 |
cullin 3 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of CUL3 protein |
CTD |
PMID:28722353 |
|
NCBI chr 9:81,592,641...81,670,428
Ensembl chr 9:81,592,641...81,670,462
|
|
G |
Dynlt1 |
dynein light chain Tctex-type 1 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of DYNLT1 protein |
CTD |
PMID:28722353 |
|
NCBI chr 1:46,887,017...46,893,956
Ensembl chr 1:46,887,017...46,893,881
|
|
G |
Eif4g3 |
eukaryotic translation initiation factor 4 gamma, 3 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of EIF4G3 protein |
CTD |
PMID:28722353 |
|
NCBI chr 5:150,197,410...150,418,862
Ensembl chr 5:150,195,226...150,418,363
|
|
G |
Fastkd2 |
FAST kinase domains 2 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of FASTKD2 protein |
CTD |
PMID:28722353 |
|
NCBI chr 9:65,166,148...65,188,184
Ensembl chr 9:65,168,228...65,188,174
|
|
G |
H2ax |
H2A.X variant histone |
increases phosphorylation |
EXP |
Benzophenoneidum results in increased phosphorylation of H2AX protein |
CTD |
PMID:37527026 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239 Ensembl chr 4:44,671,786...44,673,239
|
|
G |
Hook3 |
hook microtubule-tethering protein 3 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of HOOK3 protein |
CTD |
PMID:28722353 |
|
NCBI chr16:65,954,293...66,058,812
Ensembl chr16:65,954,350...66,061,338
|
|
G |
Hsd17b7 |
hydroxysteroid (17-beta) dehydrogenase 7 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of HSD17B7 protein |
CTD |
PMID:28722353 |
|
NCBI chr13:82,170,079...82,190,018
Ensembl chr13:82,173,179...82,190,017
|
|
G |
Htt |
huntingtin |
increases expression |
ISO |
Benzophenoneidum results in increased expression of HTT protein |
CTD |
PMID:28722353 |
|
NCBI chr14:75,845,836...75,996,094
Ensembl chr14:75,845,836...75,995,070
|
|
G |
Iqgap3 |
IQ motif containing GTPase activating protein 3 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of IQGAP3 protein |
CTD |
PMID:28722353 |
|
NCBI chr 2:173,542,151...173,583,956
Ensembl chr 2:173,542,110...173,583,956
|
|
G |
Kifap3 |
kinesin-associated protein 3 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of KIFAP3 protein |
CTD |
PMID:28722353 |
|
NCBI chr13:76,127,702...76,264,654
Ensembl chr13:76,127,696...76,264,650
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions |
ISO |
ALDH1A1 protein promotes the reaction [Benzophenoneidum results in increased lipidation of and results in increased cleavage of MAP1LC3B protein]; Benzophenoneidum results in increased lipidation of and results in increased cleavage of MAP1LC3B protein |
CTD |
PMID:28722353 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690 Ensembl chr16:49,665,791...49,677,690
|
|
G |
Map2k4 |
mitogen activated protein kinase kinase 4 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of MAP2K4 protein |
CTD |
PMID:28722353 |
|
NCBI chr10:50,343,227...50,447,956
Ensembl chr10:50,344,915...50,447,993
|
|
G |
Mbd3 |
methyl-CpG binding domain protein 3 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of MBD3 protein |
CTD |
PMID:28722353 |
|
NCBI chr 7:9,312,961...9,320,166
Ensembl chr 7:9,313,098...9,320,165
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
increases expression |
EXP |
Benzophenoneidum results in increased expression of MKI67 protein |
CTD |
PMID:37527026 |
|
NCBI chr 1:199,926,150...199,952,847
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Noa1 |
nitric oxide associated 1 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of NOA1 protein |
CTD |
PMID:28722353 |
|
NCBI chr14:30,835,264...30,851,294
Ensembl chr14:30,835,247...30,851,293
|
|
G |
Nup62 |
nucleoporin 62 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of NUP62 protein |
CTD |
PMID:28722353 |
|
NCBI chr 1:95,298,995...95,314,902
Ensembl chr 1:95,295,526...95,315,174
|
|
G |
Plcg1 |
phospholipase C, gamma 1 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of PLCG1 protein |
CTD |
PMID:28722353 |
|
NCBI chr 3:149,385,587...149,416,330
Ensembl chr 3:149,385,587...149,416,330
|
|
G |
Ppp4r1 |
protein phosphatase 4, regulatory subunit 1 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of PPP4R1 protein |
CTD |
PMID:28722353 |
|
NCBI chr 9:105,391,271...105,450,626
Ensembl chr 9:105,391,412...105,450,633
|
|
G |
Prim2 |
DNA primase subunit 2 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of PRIM2 protein |
CTD |
PMID:28722353 |
|
NCBI chr 9:35,692,376...35,904,521
Ensembl chr 9:35,692,376...35,903,030
|
|
G |
Prom1 |
prominin 1 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of PROM1 protein |
CTD |
PMID:28722353 |
|
NCBI chr14:66,989,545...67,094,534
Ensembl chr14:66,990,160...67,094,527
|
|
G |
Prorp |
protein only RNase P catalytic subunit |
increases expression |
ISO |
Benzophenoneidum results in increased expression of PRORP protein |
CTD |
PMID:28722353 |
|
NCBI chr 6:72,669,659...72,762,419
Ensembl chr 6:72,670,847...72,762,416
|
|
G |
Shmt1 |
serine hydroxymethyltransferase 1 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of SHMT1 protein |
CTD |
PMID:28722353 |
|
NCBI chr10:45,468,698...45,490,833
Ensembl chr10:45,468,700...45,497,820
|
|
G |
Srsf11 |
serine and arginine rich splicing factor 11 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of SRSF11 protein |
CTD |
PMID:28722353 |
|
NCBI chr 2:247,074,623...247,101,460
Ensembl chr 2:247,074,631...247,101,425
|
|
G |
Tbc1d15 |
TBC1 domain family, member 15 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of TBC1D15 protein |
CTD |
PMID:28722353 |
|
NCBI chr 7:50,804,553...50,860,272
Ensembl chr 7:50,804,012...50,860,175
|
|
G |
Tfam |
transcription factor A, mitochondrial |
increases expression |
ISO |
Benzophenoneidum results in increased expression of TFAM protein |
CTD |
PMID:28722353 |
|
NCBI chr20:17,356,243...17,368,293
Ensembl chr20:17,356,197...17,368,292
|
|
G |
Usp24 |
ubiquitin specific peptidase 24 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of USP24 protein |
CTD |
PMID:28722353 |
|
NCBI chr 5:121,080,687...121,210,321
Ensembl chr 5:121,080,470...121,210,311
|
|
G |
Washc5 |
WASH complex subunit 5 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of WASHC5 protein |
CTD |
PMID:28722353 |
|
NCBI chr 7:90,884,192...90,936,096
Ensembl chr 7:90,884,197...90,936,103
|
|
|
G |
Bmal1 |
basic helix-loop-helix ARNT like 1 |
decreases expression |
ISO |
cocaine hydrochloride decreases expression of Bmal1 mRNA in caudate-putamen |
RGD |
PMID:15994025 |
RGD:405866348 |
NCBI chr 1:167,331,756...167,430,235
Ensembl chr 1:167,331,633...167,430,231
|
|
G |
Clock |
clock circadian regulator |
increases expression |
ISO |
cocaine hydrochloride increases expression of Clock mRNA in caudate-putamen |
RGD |
PMID:15994025 |
RGD:405866348 |
NCBI chr14:31,908,542...31,992,673
Ensembl chr14:31,908,566...31,990,400
|
|
G |
Cry1 |
cryptochrome circadian regulator 1 |
decreases expression increases expression |
ISO |
cocaine hydrochloride decreases expression of Cry1 mRNA in caudate-putamen cocaine hydrochloride increases expression of Cry1 mRNA in hippocampal formation |
RGD |
PMID:15994025 PMID:15994025 |
RGD:405866347, RGD:405866347 |
NCBI chr 7:18,529,823...18,594,092
Ensembl chr 7:18,529,823...18,594,091
|
|
G |
Cry2 |
cryptochrome circadian regulator 2 |
decreases expression |
ISO |
cocaine hydrochloride decreases expression of Cry2 mRNA in caudate-putamen |
RGD |
PMID:15994025 |
RGD:405866347 |
NCBI chr 3:78,374,995...78,405,001
Ensembl chr 3:78,374,995...78,404,965
|
|
G |
Npas2 |
neuronal PAS domain protein 2 |
decreases expression |
ISO |
cocaine hydrochloride decreases expression of hippocampal formation and caudate-putamen |
RGD |
PMID:15994025 |
RGD:405866347 |
NCBI chr 9:41,463,361...41,642,322
Ensembl chr 9:41,463,830...41,642,320
|
|
G |
Per1 |
period circadian regulator 1 |
increases expression |
ISO |
cocaine hydrochloride increases expression of Per1 mRNA in hippocampal formation and caudate-putamen |
RGD |
PMID:15994025 |
RGD:405866348 |
NCBI chr10:53,800,126...53,814,963
Ensembl chr10:53,805,535...53,814,431
|
|
G |
Per2 |
period circadian regulator 2 |
increases expression decreases expression |
ISO |
ocaine hydrochloride increases expression of Per2 mRNA in hippocampal formation cocaine hydrochloride decreases expression of Per2 mRNA in caudate-putamen |
RGD |
PMID:15994025 PMID:15994025 |
RGD:405866348, RGD:405866348 |
NCBI chr 9:92,007,289...92,049,551
Ensembl chr 9:92,007,296...92,049,459
|
|
G |
Per3 |
period circadian regulator 3 |
increases expression |
ISO |
cocaine hydrochloride increases expression of Per3 mRNA in hippocampal formation and caudate-putamen |
RGD |
PMID:15994025 |
RGD:405866348 |
NCBI chr 5:161,460,228...161,495,404
Ensembl chr 5:161,459,533...161,495,607
|
|
|
G |
Crp |
C-reactive protein |
decreases expression |
ISO |
Colesevelam Hydrochloride results in decreased expression of CRP protein |
CTD |
PMID:16616026 |
|
NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions increases expression |
ISO |
Colesevelam Hydrochloride promotes the reaction [Simvastatin results in increased expression of HMGCR mRNA] Colesevelam Hydrochloride results in increased expression of HMGCR mRNA |
CTD |
PMID:22120639 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Ldlr |
low density lipoprotein receptor |
increases expression |
ISO |
Colesevelam Hydrochloride results in increased expression of LDLR mRNA |
CTD |
PMID:22120639 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
multiple interactions |
ISO |
Colforsin promotes the reaction [Diethylhexyl Phthalate results in decreased expression of ABCA1 mRNA] |
CTD |
PMID:37536456 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions increases expression |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased expression of ABCB1 mRNA] |
CTD |
PMID:12926078 |
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
multiple interactions decreases expression |
ISO |
Colforsin inhibits the reaction [Doxorubicin results in increased expression of ABCB4 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in decreased expression of ABCB4 mRNA] |
CTD |
PMID:12926078 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases expression |
ISO |
Colforsin results in increased expression of ABCC2 mRNA; Colforsin results in increased expression of ABCC2 protein |
CTD |
PMID:19580841 PMID:26049102 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
decreases expression multiple interactions |
ISO |
Colforsin results in decreased expression of ABCC4 mRNA Valproic Acid inhibits the reaction [Colforsin results in decreased expression of ABCC4 mRNA] |
CTD |
PMID:37385477 |
|
NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
increases expression multiple interactions |
ISO |
Colforsin results in increased expression of ABCG2 mRNA Colforsin inhibits the reaction [anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]] |
CTD |
PMID:19580841 PMID:30610963 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
increases phosphorylation |
ISO |
Colforsin results in increased phosphorylation of ACACA protein |
CTD |
PMID:18390901 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Ache |
acetylcholinesterase |
increases activity increases expression |
EXP |
Colforsin results in increased activity of ACHE protein; Colforsin results in increased activity of ACHE protein alternative form Colforsin results in increased expression of ACHE mRNA |
CTD |
PMID:18514641 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Acsl3 |
acyl-CoA synthetase long-chain family member 3 |
increases expression |
ISO |
Colforsin results in increased expression of ACSL3 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr 9:80,115,164...80,164,636
Ensembl chr 9:80,115,112...80,164,627
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
decreases expression multiple interactions |
ISO EXP |
Colforsin results in decreased expression of ACTA2 protein Colforsin inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 protein] |
CTD |
PMID:21603974 PMID:27590029 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Adam12 |
ADAM metallopeptidase domain 12 |
decreases expression |
ISO |
Colforsin results in decreased expression of ADAM12 mRNA |
CTD |
PMID:15313392 PMID:15967414 |
|
NCBI chr 1:188,686,984...189,014,206
Ensembl chr 1:188,686,989...189,020,667
|
|
G |
Adamts1 |
ADAM metallopeptidase with thrombospondin type 1 motif, 1 |
decreases expression |
ISO |
Colforsin results in decreased expression of ADAMTS1 mRNA |
CTD |
PMID:15313392 PMID:15967414 |
|
NCBI chr11:24,932,227...24,941,068
Ensembl chr11:24,931,761...24,941,103
|
|
G |
Adcy5 |
adenylate cyclase 5 |
multiple interactions |
ISO |
ADCY5 protein results in increased susceptibility to [Colforsin co-treated with Quinpirole] |
CTD |
PMID:12223546 |
|
NCBI chr11:65,471,612...65,618,877
Ensembl chr11:65,471,612...65,618,974
|
|
G |
Adcy6 |
adenylate cyclase 6 |
affects response to substance |
ISO |
ADCY6 protein affects the susceptibility to Colforsin |
CTD |
PMID:12393090 |
|
NCBI chr 7:129,742,827...129,763,922
Ensembl chr 7:129,742,838...129,763,754
|
|
G |
Adcy9 |
adenylate cyclase 9 |
multiple interactions increases activity |
ISO |
[Colforsin co-treated with Miconazole] results in increased activity of ADCY9 protein Colforsin results in increased activity of ADCY9 protein |
CTD |
PMID:30607468 |
|
NCBI chr10:11,138,966...11,262,067
Ensembl chr10:11,139,446...11,262,066
|
|
G |
Adm |
adrenomedullin |
multiple interactions increases expression |
ISO |
cobaltous chloride inhibits the reaction [Valproic Acid inhibits the reaction [Colforsin results in increased expression of ADM mRNA]]; Valproic Acid inhibits the reaction [Colforsin results in increased expression of ADM mRNA] |
CTD |
PMID:38296531 |
|
NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654
|
|
G |
Adra1a |
adrenoceptor alpha 1A |
multiple interactions |
ISO |
[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] affects the reaction [[Phenylephrine binds to and results in increased activity of ADRA1A protein] which affects the transport of Potassium] |
CTD |
PMID:19419905 |
|
NCBI chr15:40,830,125...40,935,902
Ensembl chr15:40,832,534...40,927,500
|
|
G |
Adra2c |
adrenoceptor alpha 2C |
multiple interactions affects localization increases expression |
ISO |
AKAP13 protein modified form affects the reaction [Colforsin affects the localization of ADRA2C protein]; AKAP13 protein modified form affects the reaction [Colforsin results in increased expression of ADRA2C mRNA] |
CTD |
PMID:24701590 |
|
NCBI chr14:75,470,884...75,472,846
Ensembl chr14:75,471,143...75,472,846
|
|
G |
Adrb1 |
adrenoceptor beta 1 |
affects response to substance multiple interactions |
ISO |
ADRB1 protein polymorphism affects the susceptibility to Colforsin [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of [ADRB1 protein binds to ADRB2 protein]] affects the reaction [KCNH2 protein results in increased transport of Potassium]; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] promotes the reaction [[ADRB1 protein binds to ADRB2 protein] which results in increased abundance of Cyclic AMP]; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of [ADRB1 protein binds to ADRB2 protein] |
CTD |
PMID:14502278 PMID:19419905 |
|
NCBI chr 1:265,777,103...265,780,114
Ensembl chr 1:255,771,597...255,807,259
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
multiple interactions increases expression increases phosphorylation |
ISO |
[[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of [ADRB1 protein binds to ADRB2 protein]] affects the reaction [KCNH2 protein results in increased transport of Potassium]; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] promotes the reaction [[ADRB1 protein binds to ADRB2 protein] which results in increased abundance of Cyclic AMP]; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of [ADRB1 protein binds to ADRB2 protein] Colforsin results in increased expression of ADRB2 mRNA Colforsin results in increased phosphorylation of ADRB2 protein |
CTD |
PMID:14722251 PMID:19419905 PMID:24705868 |
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Adrb3 |
adrenoceptor beta 3 |
decreases expression |
ISO |
Colforsin results in decreased expression of ADRB3 mRNA |
CTD |
PMID:10725275 |
|
NCBI chr16:64,839,820...64,844,552
Ensembl chr16:64,841,788...64,844,552
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions affects localization |
ISO |
[Colforsin results in increased activity of AHR protein] which results in increased expression of CXCL8 mRNA; [Colforsin results in increased activity of AHR protein] which results in increased expression of CXCL8 protein; [Colforsin results in increased activity of AHR protein] which results in increased secretion of CXCL8 protein; Colforsin promotes the reaction [[AHR protein binds to RELB protein] which binds to CXCL8 promoter]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin promotes the reaction [[AHR protein binds to RELB protein] which binds to CXCL8 promoter]]; PDE2A protein inhibits the reaction [Colforsin affects the localization of AHR protein] AHR protein inhibits the reaction [[Colforsin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of PER1 mRNA] |
CTD |
PMID:15972329 PMID:17329248 PMID:17823304 PMID:23291558 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Akap13 |
A-kinase anchoring protein 13 |
multiple interactions |
ISO |
AKAP13 protein modified form affects the reaction [Colforsin affects the localization of ADRA2C protein]; AKAP13 protein modified form affects the reaction [Colforsin results in increased expression of ADRA2C mRNA]; AKAP13 protein modified form inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein] |
CTD |
PMID:24701590 |
|
NCBI chr 1:129,313,183...129,619,647
Ensembl chr 1:129,314,402...129,619,646
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
decreases expression |
ISO |
Colforsin results in decreased expression of AKR1C3 mRNA |
CTD |
PMID:28235592 |
|
NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
Colforsin inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:16339297 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Akt2 |
AKT serine/threonine kinase 2 |
multiple interactions |
EXP |
Colforsin inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT2 protein] |
CTD |
PMID:16339297 |
|
NCBI chr 1:82,877,228...82,933,828
Ensembl chr 1:82,883,547...82,933,817
|
|
G |
Akt3 |
AKT serine/threonine kinase 3 |
multiple interactions |
EXP |
Colforsin inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT3 protein] |
CTD |
PMID:16339297 |
|
NCBI chr13:88,943,708...89,225,831
Ensembl chr13:88,946,091...89,225,708
|
|
G |
Alb |
albumin |
multiple interactions |
EXP |
Colforsin inhibits the reaction [Carbon Tetrachloride results in decreased expression of ALB protein] |
CTD |
PMID:27590029 |
|
NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Alpi |
alkaline phosphatase, intestinal |
multiple interactions |
ISO |
Colforsin inhibits the reaction [Methotrexate results in increased activity of ALPI protein] |
CTD |
PMID:16598758 |
|
NCBI chr 9:87,773,411...87,776,877
Ensembl chr 9:87,773,411...87,776,877
|
|
G |
Alpp |
alkaline phosphatase, placental |
increases expression multiple interactions |
ISO |
Colforsin results in increased expression of ALPP mRNA [Colforsin results in increased abundance of Cyclic AMP] which results in increased expression of ALPP mRNA; Chlorpromazine inhibits the reaction [Colforsin results in increased expression of ALPP mRNA]; Clozapine inhibits the reaction [Colforsin results in increased expression of ALPP mRNA]; Desipramine inhibits the reaction [Colforsin results in increased expression of ALPP mRNA] |
CTD |
PMID:16036225 |
|
NCBI chr 9:87,765,846...87,768,606
Ensembl chr 9:87,765,860...87,768,606
|
|
G |
Aoc1 |
amine oxidase, copper containing 1 |
increases activity |
EXP |
Colforsin results in increased activity of AOC1 protein |
CTD |
PMID:2860926 |
|
NCBI chr 4:77,812,260...77,831,846
Ensembl chr 4:77,812,260...77,831,840
|
|
G |
Appbp2 |
amyloid beta precursor protein binding protein 2 |
decreases expression |
ISO |
Colforsin results in decreased expression of APPBP2 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr10:70,057,774...70,099,877
Ensembl chr10:70,057,774...70,099,835
|
|
G |
Ar |
androgen receptor |
multiple interactions increases expression |
ISO |
AR protein affects the reaction [Colforsin results in decreased expression of SESN1 protein]; AR protein promotes the reaction [Colforsin results in increased expression of HMGCR protein]; AR protein promotes the reaction [Colforsin results in increased expression of INSIG1 protein]; AR protein promotes the reaction [Colforsin results in increased expression of KLK2 protein]; AR protein promotes the reaction [Colforsin results in increased expression of KLK3 protein]; Colforsin promotes the reaction [Metribolone results in increased activity of AR protein] Colforsin results in increased expression of AR protein |
CTD |
PMID:16751804 PMID:17219378 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Areg |
amphiregulin |
increases expression multiple interactions |
ISO |
Colforsin results in increased expression of AREG mRNA N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased expression of AREG mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased expression of AREG protein] |
CTD |
PMID:15284208 PMID:15313392 PMID:15474502 PMID:15967414 PMID:20378682 |
|
NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535
|
|
G |
Arrb1 |
arrestin, beta 1 |
multiple interactions |
ISO |
Colforsin inhibits the reaction [[carvedilol co-treated with ARRB1 protein] results in increased expression of MIR190A mRNA] |
CTD |
PMID:24334028 |
|
NCBI chr 1:153,837,964...153,912,111
Ensembl chr 1:153,838,078...153,904,061
|
|
G |
Atxn3 |
ataxin 3 |
decreases expression |
ISO |
Colforsin results in decreased expression of ATXN3 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr 6:121,072,228...121,107,902
Ensembl chr 6:121,074,448...121,107,902
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
[S-(1,2-dichlorovinyl)cysteine co-treated with Colforsin] results in decreased expression of BCL2 mRNA; S-(1,2-dichlorovinyl)cysteine inhibits the reaction [Colforsin results in increased expression of BCL2 mRNA] |
CTD |
PMID:36336211 PMID:37544576 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions increases expression |
ISO EXP |
1-bromopropane inhibits the reaction [Colforsin results in increased expression of BDNF mRNA]; 1-bromopropane inhibits the reaction [Colforsin results in increased expression of BDNF protein] Colforsin inhibits the reaction [Caffeine results in decreased expression of BDNF mRNA]; Colforsin inhibits the reaction [Caffeine results in decreased expression of BDNF protein] Colforsin results in increased expression of BDNF mRNA; Colforsin results in increased expression of BDNF protein |
CTD |
PMID:19189864 PMID:35917217 |
|
NCBI chr 3:116,619,633...116,670,212
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Bmal1 |
basic helix-loop-helix ARNT like 1 |
increases expression |
ISO |
Colforsin results in increased expression of BMAL1 mRNA |
CTD |
PMID:30524225 |
|
NCBI chr 1:167,331,756...167,430,235
Ensembl chr 1:167,331,633...167,430,231
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
multiple interactions |
ISO |
BMP6 protein inhibits the reaction [Colforsin results in increased expression of CYP11A1 mRNA]; BMP6 protein inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; BMP6 protein inhibits the reaction [Colforsin results in increased expression of HSD3B1 mRNA]; BMP6 protein inhibits the reaction [Colforsin results in increased expression of OXT mRNA]; BMP6 protein inhibits the reaction [Colforsin results in increased expression of STAR mRNA]; BMP6 protein inhibits the reaction [Colforsin results in increased secretion of Progesterone]; FST protein inhibits the reaction [BMP6 protein inhibits the reaction [Colforsin results in increased secretion of Progesterone]] |
CTD |
PMID:18936084 |
|
NCBI chr17:26,318,121...26,469,691
Ensembl chr17:26,318,569...26,470,365
|
|
G |
C4a |
complement C4A |
multiple interactions |
ISO |
[Colforsin co-treated with Diethylhexyl Phthalate] affects the expression of C4A mRNA |
CTD |
PMID:35892601 |
|
NCBI chr20:4,005,731...4,020,083
Ensembl chr20:4,005,731...4,020,080
|
|
G |
Cacna1g |
calcium voltage-gated channel subunit alpha1 G |
multiple interactions |
EXP |
Mibefradil inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of CACNA1G protein]; Nickel inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of CACNA1G protein] |
CTD |
PMID:17110049 |
|
NCBI chr10:79,354,998...79,422,960
Ensembl chr10:79,355,008...79,422,752
|
|
G |
Cacna1h |
calcium voltage-gated channel subunit alpha1 H |
multiple interactions |
EXP |
Mibefradil inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of CACNA1H protein]; Nickel inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of CACNA1H protein] |
CTD |
PMID:17110049 |
|
NCBI chr10:14,390,104...14,448,204
Ensembl chr10:14,390,113...14,448,376
|
|
G |
Cacna1i |
calcium voltage-gated channel subunit alpha1 I |
multiple interactions |
EXP |
Mibefradil inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of CACNA1I protein]; Nickel inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of CACNA1I protein] |
CTD |
PMID:17110049 |
|
NCBI chr 7:111,835,996...111,947,418
Ensembl chr 7:111,836,012...111,944,688
|
|
G |
Calcrl |
calcitonin receptor like receptor |
multiple interactions |
ISO |
Colforsin inhibits the reaction [EDN1 protein results in increased expression of CALCRL mRNA] |
CTD |
PMID:25194819 |
|
NCBI chr 3:69,428,348...69,525,910
Ensembl chr 3:69,430,120...69,525,910
|
|
G |
Camkk2 |
calcium/calmodulin-dependent protein kinase kinase 2 |
increases expression |
ISO |
Colforsin results in increased expression of CAMKK2 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr12:33,791,023...33,845,000
Ensembl chr12:33,791,052...33,843,279
|
|
G |
Cask |
calcium/calmodulin dependent serine protein kinase |
multiple interactions increases phosphorylation |
EXP |
Colforsin promotes the reaction [CASK protein modified form binds to TBR1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of CASK protein] |
CTD |
PMID:20067577 |
|
NCBI chr X:8,899,500...9,243,014
Ensembl chr X:8,899,833...9,238,694
|
|
G |
Casp1 |
caspase 1 |
increases activity |
EXP |
Colforsin results in increased activity of CASP1 mRNA; Colforsin results in increased activity of CASP1 protein |
CTD |
PMID:21832250 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
increases activity multiple interactions |
ISO EXP |
Colforsin results in increased activity of CASP3 protein Colforsin inhibits the reaction [Puromycin Aminonucleoside results in increased activity of CASP3 protein] KT 5720 inhibits the reaction [Colforsin results in increased activity of CASP3 protein] Colforsin inhibits the reaction [Cisplatin results in increased cleavage of and results in increased activity of CASP3 protein] |
CTD |
PMID:16396944 PMID:20131233 PMID:21745194 PMID:31278978 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
Colforsin inhibits the reaction [mancozeb results in decreased activity of CAT protein] |
CTD |
PMID:29283200 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
Colforsin inhibits the reaction [Reactive Oxygen Species results in increased expression of CCL5 mRNA]; Colforsin inhibits the reaction [TNF protein results in increased expression of CCL5 mRNA] |
CTD |
PMID:10495789 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Cd55 |
CD55 molecule (Cromer blood group) |
multiple interactions increases expression |
ISO |
3',4'-dimethoxy-alpha-naphthoflavone inhibits the reaction [Colforsin results in increased expression of CD55 mRNA] |
CTD |
PMID:22553215 |
|
NCBI chr13:41,857,242...41,885,966
Ensembl chr13:41,857,395...41,885,831
|
|
G |
Cdc6 |
cell division cycle 6 |
increases expression |
ISO |
Colforsin results in increased expression of CDC6 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr10:83,864,189...83,878,011
Ensembl chr10:83,864,638...83,878,011
|
|
G |
Cdh1 |
cadherin 1 |
affects activity decreases expression increases expression |
ISO |
Colforsin affects the activity of CDH1 protein Colforsin results in decreased expression of CDH1 protein Colforsin results in increased expression of CDH1 protein |
CTD |
PMID:10413674 PMID:30983542 PMID:38301883 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdrt4 |
CMT1A duplicated region transcript 4 |
multiple interactions |
ISO |
[Colforsin co-treated with Diethylhexyl Phthalate] affects the expression of CDRT4 mRNA |
CTD |
PMID:35892601 |
|
NCBI chr10:47,625,470...47,657,493
Ensembl chr10:47,625,470...47,657,493
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions increases expression |
ISO EXP |
Colforsin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CEBPA mRNA] Colforsin inhibits the reaction [mono-(2-ethylhexyl)phthalate results in decreased expression of CEBPA protein] Colforsin results in increased expression of CEBPA protein |
CTD |
PMID:17407152 PMID:21832167 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
increases expression multiple interactions |
ISO EXP |
Colforsin results in increased expression of CEBPB mRNA [Atrazine co-treated with Colforsin] results in increased expression of CEBPB protein |
CTD |
PMID:14684744 PMID:25253736 |
|
NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
|
|
G |
Cftr |
CF transmembrane conductance regulator |
affects localization increases activity multiple interactions |
ISO EXP |
Colforsin affects the localization of CFTR protein Colforsin results in increased activity of CFTR protein [Colforsin co-treated with Genistein] results in increased activity of CFTR protein; AICA ribonucleotide inhibits the reaction [Colforsin results in increased activity of CFTR protein] [1-Methyl-3-isobutylxanthine co-treated with Colforsin] results in increased activity of CFTR protein; Colforsin promotes the reaction [Nimodipine results in increased activity of CFTR protein] 3-((3-trifluoromethyl)phenyl)-5-((3-carboxyphenyl)methylene)-2-thioxo-4-thiazolidinone inhibits the reaction [[[Colforsin co-treated with Genistein] results in increased activity of CFTR protein] which results in increased transport of Iodides]; 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid inhibits the reaction [Colforsin results in increased activity of CFTR protein]; 5-butyl-6-hydroxy-10-chlorobenzo(c)quinolizinium chloride inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]; 5-butyl-7-chloro-6-hydroxybenzo(c)quinolizinium inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]; 6-hydroxy-10-chlorobenzo(c)quinolizinium inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]; [1-Methyl-3-isobutylxanthine co-treated with Colforsin] results in increased activity of CFTR protein; [1-Methyl-3-isobutylxanthine co-treated with Colforsin] results in increased activity of CFTR protein mutant form; [5-butyl-6-hydroxy-10-chlorobenzo(c)quinolizinium chloride co-treated with Colforsin] results in increased activity of CFTR protein mutant form; [[Colforsin co-treated with Genistein] results in increased activity of CFTR protein] which results in increased transport of Iodides; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of CFTR protein; [Colforsin co-treated with Genistein] results in increased activity of CFTR protein; [Colforsin co-treated with lumacaftor] results in increased activity of CFTR protein mutant form; [Colforsin co-treated with NS 004] results in increased activity of CFTR protein mutant form; [ivacaftor co-treated with Colforsin co-treated with lumacaftor] results in increased activity of CFTR protein mutant form; [ivacaftor co-treated with Colforsin] results in increased activity of CFTR protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [5-butyl-7-chloro-6-hydroxybenzo(c)quinolizinium inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [miglustat inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; Brefeldin A inhibits the reaction [5-butyl-7-chloro-6-hydroxybenzo(c)quinolizinium inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; Brefeldin A inhibits the reaction [miglustat inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]; Colforsin binds to and results in decreased activity of CFTR protein; Colforsin promotes the reaction [CFTR protein affects the export of Chlorides]; Colforsin promotes the reaction [Nimodipine results in increased activity of CFTR protein]; Colforsin results in increased phosphorylation of and results in increased activity of CFTR protein; fenamic acid inhibits the reaction [[[Colforsin co-treated with Genistein] results in increased activity of CFTR protein] which results in increased transport of Iodides]; fenamic acid inhibits the reaction [Colforsin results in increased activity of CFTR protein]; geldanamycin promotes the reaction [5-butyl-7-chloro-6-hydroxybenzo(c)quinolizinium inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; geldanamycin promotes the reaction [miglustat inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; Glyburide inhibits the reaction [[[Colforsin co-treated with Genistein] results in increased activity of CFTR protein] which results in increased transport of Iodides]; Glyburide inhibits the reaction [Colforsin results in increased activity of CFTR protein]; miglustat inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased activity of CFTR protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of CFTR protein]; Ozone inhibits the reaction [Colforsin results in increased activity of CFTR protein]; Thapsigargin promotes the reaction [5-butyl-7-chloro-6-hydroxybenzo(c)quinolizinium inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; Thapsigargin promotes the reaction [miglustat inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; VRT 532 analog promotes the reaction [Colforsin results in increased activity of CFTR protein mutant form]; VRT 532 promotes the reaction [Colforsin results in increased activity of CFTR protein mutant form] Colforsin analog results in increased activity of CFTR protein mutant form; Colforsin results in increased activity of CFTR protein; Colforsin results in increased activity of CFTR protein mutant form |
CTD |
PMID:12519745 PMID:12914781 PMID:14502435 PMID:14967738 PMID:15163550 PMID:15194485 PMID:15246976 PMID:15389550 PMID:15517342 PMID:15763242 PMID:15790911 PMID:15986093 PMID:15994425 PMID:16027156 PMID:16038730 PMID:17596272 PMID:18230692 PMID:19061877 PMID:21724857 PMID:22074181 PMID:32374624 PMID:33872679 More...
|
|
NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756
|
|
G |
Cga |
glycoprotein hormones, alpha polypeptide |
increases secretion increases expression multiple interactions |
ISO EXP |
Colforsin results in increased secretion of CGA protein Colforsin results in increased expression of CGA protein Colforsin results in increased expression of CGA mRNA Colforsin promotes the reaction [CGA protein results in increased abundance of Cyclic AMP]; perfluorobutanesulfonic acid inhibits the reaction [Colforsin results in increased expression of CGA protein]; perfluorooctane sulfonic acid inhibits the reaction [Colforsin results in increased expression of CGA protein] Colforsin inhibits the reaction [ESR2 gene mutant form inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]] |
CTD |
PMID:8404651 PMID:16503475 PMID:20378682 PMID:33144174 |
|
NCBI chr 5:49,486,915...49,499,192
Ensembl chr 5:49,487,068...49,499,191
|
|
G |
Cidec |
cell death-inducing DFFA-like effector c |
increases expression |
ISO |
Colforsin results in increased expression of CIDEC protein |
CTD |
PMID:21097823 |
|
NCBI chr 4:146,569,288...146,582,173
Ensembl chr 4:146,569,289...146,582,173
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
multiple interactions affects response to substance increases activity |
ISO |
(1-(2-morpholin-4-yl-ethyl)-1H-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (4-ethyl-1-naphthalenyl)(1-(5-fluoropentyl)-1H-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(cyclohexylmethyl)-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyfluoro-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-3-(1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 2-(4-methoxyphenyl)-1-(1-pentyl-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol inhibits the reaction [Colforsin results in increased activity of CNR1 protein]; [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [Dronabinol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased expression of CNR1 mRNA; AM 6527 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; AM 6527 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; CNR1 protein inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; delta(9)-tetrahydrocannabinolic acid inhibits the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol inhibits the reaction [Colforsin results in increased activity of CNR1 protein]]; delta(9)-tetrahydrocannabinolic acid inhibits the reaction [Colforsin results in increased activity of CNR1 protein]; Dronabinol inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Dronabinol inhibits the reaction [Colforsin results in increased activity of CNR1 protein]; FDU-PB-22 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; FUB-PB-22 compound inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indazoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-pentylindazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; napht-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; THJ-2201 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]] CNR1 protein affects the susceptibility to Colforsin |
CTD |
PMID:27429655 PMID:27527584 PMID:28861508 PMID:31154070 |
|
NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
multiple interactions increases activity affects response to substance |
ISO |
(1-(2-morpholin-4-yl-ethyl)-1H-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (4-ethyl-1-naphthalenyl)(1-(5-fluoropentyl)-1H-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(cyclohexylmethyl)-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyfluoro-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-3-(1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 2-(4-methoxyphenyl)-1-(1-pentyl-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol inhibits the reaction [Colforsin results in increased activity of CNR2 protein]; [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [Dronabinol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased expression of CNR2 mRNA; [virodhamine binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; AM 6527 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; AM 6527 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; CNR2 protein inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; Dronabinol inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Dronabinol inhibits the reaction [Colforsin results in increased activity of CNR2 protein]; FDU-PB-22 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; FUB-PB-22 compound inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indazoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-pentylindazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; napht-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Pertussis Toxin inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; Pertussis Toxin inhibits the reaction [[virodhamine binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; SR 144528 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; SR 144528 inhibits the reaction [[virodhamine binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; THJ-2201 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]] CNR2 protein affects the susceptibility to Colforsin |
CTD |
PMID:17558435 PMID:27429655 PMID:27527584 PMID:28861508 PMID:30504240 PMID:31154070 More...
|
|
NCBI chr 5:148,125,222...148,151,548
Ensembl chr 5:148,125,604...148,151,548
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
increases activity increases expression increases phosphorylation multiple interactions |
ISO EXP |
Colforsin results in increased activity of CREB1 protein Colforsin results in increased expression of CREB1 mRNA; Colforsin results in increased expression of CREB1 protein modified form Colforsin results in increased phosphorylation of CREB1 protein 3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione inhibits the reaction [Resveratrol inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]]; Colforsin inhibits the reaction [Caffeine results in decreased expression of CREB1 mRNA]; Colforsin inhibits the reaction [Carbon Tetrachloride results in decreased expression of CREB1 protein modified form]; Colforsin promotes the reaction [CREB1 protein binds to POU1F1 promoter]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; Okadaic Acid inhibits the reaction [Resveratrol inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]]; Resveratrol inhibits the reaction [Colforsin promotes the reaction [CREB1 protein binds to POU1F1 promoter]]; Resveratrol inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; SIRT1 mutant form inhibits the reaction [Resveratrol inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]]; SIRT1 protein inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; SIRT1 protein mutant form inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein] AKAP13 protein modified form inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; anandamide inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; Colforsin inhibits the reaction [anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]]; Colforsin results in increased phosphorylation of and results in increased activity of CREB1 protein [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased phosphorylation of CREB1 protein; alisol B inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased phosphorylation of CREB1 protein]; oxophenylarsine inhibits the reaction [Colforsin results in increased activity of CREB1 protein]; oxophenylarsine inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; RTKI cpd inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein] |
CTD |
PMID:10908723 PMID:11113530 PMID:15522277 PMID:17141199 PMID:17322281 PMID:17460731 PMID:17680988 PMID:18004999 PMID:20512473 PMID:21745194 PMID:23292070 PMID:24701590 PMID:27509375 PMID:27590029 PMID:28051915 PMID:28601556 PMID:29179997 PMID:30610963 PMID:35917217 More...
|
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Crebbp |
CREB binding protein |
multiple interactions |
ISO |
Colforsin promotes the reaction [GCM1 protein binds to CREBBP protein]; CREBBP protein affects the reaction [Colforsin results in increased activity of GCM1 protein] |
CTD |
PMID:16166624 |
|
NCBI chr10:11,335,551...11,461,888
Ensembl chr10:11,335,953...11,461,888
|
|
G |
Crem |
cAMP responsive element modulator |
increases expression |
EXP |
Colforsin results in increased expression of CREM mRNA; Colforsin results in increased expression of CREM mRNA alternative form; Colforsin results in increased expression of CREM protein |
CTD |
PMID:8810303 PMID:12791704 |
|
NCBI chr17:54,238,889...54,305,989
Ensembl chr17:54,239,030...54,305,989
|
|
G |
Crh |
corticotropin releasing hormone |
multiple interactions increases secretion |
EXP ISO |
CRH protein inhibits the reaction [[Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [[Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Testosterone]; CRH protein inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [Colforsin results in increased chemical synthesis of Testosterone] Colforsin results in increased secretion of CRH protein [perfluorooctane sulfonic acid co-treated with Colforsin] results in increased expression of CRH mRNA |
CTD |
PMID:2153673 PMID:33144174 |
|
NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919
|
|
G |
Crls1 |
cardiolipin synthase 1 |
increases expression |
ISO |
Colforsin results in increased expression of CRLS1 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr 3:120,119,822...120,138,674
Ensembl chr 3:120,119,852...120,138,655
|
|
G |
Cryab |
crystallin, alpha B |
multiple interactions |
EXP |
Colforsin inhibits the reaction [arsenite results in increased expression of CRYAB protein] |
CTD |
PMID:8769853 |
|
NCBI chr 8:51,093,441...51,099,161
Ensembl chr 8:51,093,441...51,099,157
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
affects expression multiple interactions increases expression |
ISO EXP |
Colforsin affects the expression of CYP11A1 mRNA [Colforsin co-treated with Zearalenone] results in increased expression of CYP11A1 mRNA Colforsin results in increased expression of CYP11A1 mRNA [Colforsin co-treated with triptolide] results in decreased expression of CYP11A1 mRNA; Aminoglutethimide inhibits the reaction [Colforsin results in increased expression of CYP11A1 mRNA]; BMP6 protein inhibits the reaction [Colforsin results in increased expression of CYP11A1 mRNA]; Hexachlorocyclohexane inhibits the reaction [Colforsin results in increased expression of CYP11A1 mRNA]; Metyrapone inhibits the reaction [Colforsin results in increased expression of CYP11A1 mRNA]; Valproic Acid affects the reaction [Colforsin affects the expression of CYP11A1 mRNA] [Atrazine co-treated with Colforsin] results in increased expression of CYP11A1 mRNA; RARRES2 protein inhibits the reaction [Colforsin results in increased expression of CYP11A1 protein] |
CTD |
PMID:14691014 PMID:16935330 PMID:17080404 PMID:18936084 PMID:20726872 PMID:22446829 PMID:22948218 PMID:25253736 PMID:25765474 PMID:25871633 PMID:26783879 PMID:28235592 PMID:31557376 More...
|
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp11b2 |
cytochrome P450, family 11, subfamily b, polypeptide 2 |
increases activity increases expression multiple interactions |
ISO |
Colforsin results in increased activity of CYP11B1 protein Colforsin results in increased expression of CYP11B1 mRNA [1-chloro-4-(2,2-dichloro-1-(4-chlorophenyl)ethenyl)-3-(methylsulfonyl)benzene co-treated with Colforsin] affects the expression of CYP11B1 mRNA; [Colforsin co-treated with triptolide] results in decreased expression of CYP11B1 mRNA; Hexachlorocyclohexane inhibits the reaction [Colforsin results in increased expression of CYP11B1 mRNA] |
CTD |
PMID:12525251 PMID:17080404 PMID:19164467 PMID:19900470 PMID:21256172 PMID:25765474 PMID:25871633 PMID:28235592 PMID:31557376 More...
|
|
NCBI chr 7:106,838,590...106,845,004
Ensembl chr 7:106,838,590...106,845,004
|
|
G |
Cyp11b3 |
cytochrome P450, family 11, subfamily b, polypeptide 3 |
increases expression multiple interactions |
ISO |
Colforsin results in increased expression of CYP11B2 mRNA [1-chloro-4-(2,2-dichloro-1-(4-chlorophenyl)ethenyl)-3-(methylsulfonyl)benzene co-treated with Colforsin] affects the expression of CYP11B2 mRNA; [Colforsin co-treated with triptolide] results in decreased expression of CYP11B2 mRNA; Hexachlorocyclohexane inhibits the reaction [Colforsin results in increased expression of CYP11B2 mRNA]; Ketoconazole promotes the reaction [Colforsin results in increased expression of CYP11B2 mRNA] |
CTD |
PMID:16935330 PMID:17080404 PMID:19164467 PMID:19900470 PMID:21256172 PMID:22446829 PMID:25765474 PMID:25871633 PMID:28235592 PMID:31557376 More...
|
|
NCBI chr 7:106,808,559...106,814,048
Ensembl chr 7:106,808,559...106,814,048
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
increases expression multiple interactions |
ISO |
Colforsin results in increased expression of CYP17A1 mRNA [Colforsin co-treated with triptolide] results in decreased expression of CYP17A1 mRNA; Apigenin inhibits the reaction [Colforsin results in increased expression of CYP17A1 mRNA]; Hexachlorocyclohexane inhibits the reaction [Colforsin results in increased expression of CYP17A1 mRNA]; Ketoconazole inhibits the reaction [Colforsin results in increased expression of CYP17A1 mRNA]; Metyrapone inhibits the reaction [Colforsin results in increased expression of CYP17A1 mRNA]; TGFB1 protein inhibits the reaction [Colforsin results in increased expression of CYP17A1 mRNA]; Valproic Acid inhibits the reaction [Colforsin results in increased expression of CYP17A1 mRNA] |
CTD |
PMID:15625562 PMID:15886251 PMID:16935330 PMID:17080404 PMID:20726872 PMID:22446829 PMID:22461451 PMID:23370353 PMID:25871633 PMID:28235592 PMID:31100596 PMID:31557376 More...
|
|
NCBI chr 1:255,476,861...255,484,547
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
increases activity increases expression multiple interactions |
ISO EXP |
Colforsin results in increased activity of CYP19A1 protein Colforsin results in increased expression of CYP19A1 mRNA 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; [Colforsin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CYP19A1 mRNA; [Colforsin results in increased activity of CYP19A1 protein] which results in increased abundance of Estradiol; [Colforsin results in increased activity of CYP19A1 protein] which results in increased abundance of Testosterone; Alitretinoin inhibits the reaction [NR5A2 protein promotes the reaction [[Colforsin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CYP19A1 mRNA]]; Aminoglutethimide inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; Atrazine inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; BMP6 protein inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; Hexachlorocyclohexane inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; mono-(2-ethylhexyl)phthalate inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; NR4A1 protein inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; NR4A2 protein inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; NR4A3 protein inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; NR5A2 protein promotes the reaction [[Colforsin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CYP19A1 mRNA]; Valproic Acid inhibits the reaction [Colforsin results in increased activity of CYP19A1 protein]; Valproic Acid inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; ZNF461 protein inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA] RARRES2 protein inhibits the reaction [Colforsin results in increased expression of CYP19A1 protein] Colforsin results in increased expression of CYP19A1 mRNA; Colforsin results in increased expression of CYP19A1 protein |
CTD |
PMID:14691014 PMID:16357189 PMID:16935330 PMID:16996190 PMID:17080404 PMID:18936084 PMID:19822197 PMID:20087668 PMID:20723554 PMID:20726872 PMID:22446829 PMID:22461451 PMID:22948218 PMID:24361490 PMID:25765474 PMID:25871633 PMID:28235592 PMID:28859905 PMID:29701941 PMID:31100596 PMID:37551828 More...
|
|
NCBI chr 8:63,449,148...63,476,534
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions affects expression |
EXP ISO |
Colforsin inhibits the reaction [Lipopolysaccharides results in decreased activity of CYP1A1 protein] Valproic Acid affects the reaction [Colforsin affects the expression of CYP1A1 mRNA] Colforsin affects the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:1849469 PMID:15710352 PMID:20726872 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
ISO EXP |
Colforsin affects the reaction [Benzo(a)pyrene results in increased expression of CYP1A2 mRNA] Colforsin inhibits the reaction [Lipopolysaccharides results in decreased activity of CYP1A2 protein] |
CTD |
PMID:1849469 PMID:15710352 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases expression |
EXP |
Colforsin results in increased expression of CYP1B1 mRNA; Colforsin results in increased expression of CYP1B1 protein |
CTD |
PMID:7588239 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
ISO |
[S-(1,2-dichlorovinyl)cysteine co-treated with Colforsin] results in decreased expression of CYP2E1 mRNA |
CTD |
PMID:37544576 |
|
NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases expression multiple interactions |
ISO |
Colforsin results in increased expression of CYP3A4 mRNA [S-(1,2-dichlorovinyl)cysteine co-treated with Colforsin] results in increased expression of CYP3A4 mRNA |
CTD |
PMID:37544576 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Dbh |
dopamine beta-hydroxylase |
multiple interactions increases expression |
EXP |
Colforsin inhibits the reaction [Atrazine results in decreased expression of DBH protein]; Colforsin inhibits the reaction [Simazine results in decreased expression of DBH protein] Colforsin results in increased expression of DBH protein |
CTD |
PMID:14550852 |
|
NCBI chr 3:30,886,313...30,903,313
Ensembl chr 3:10,488,260...10,505,248
|
|
G |
Dct |
dopachrome tautomerase |
increases expression |
ISO |
Colforsin results in increased expression of DCT mRNA; Colforsin results in increased expression of DCT protein |
CTD |
PMID:17460731 PMID:28601556 |
|
NCBI chr15:95,062,006...95,100,863
Ensembl chr15:95,062,003...95,100,836
|
|
G |
Dio2 |
iodothyronine deiodinase 2 |
increases activity multiple interactions increases expression |
ISO EXP |
Colforsin results in increased activity of DIO2 protein Buthionine Sulfoximine inhibits the reaction [Colforsin results in increased activity of DIO2 protein]; Hydrogen Peroxide inhibits the reaction [Colforsin results in increased activity of DIO2 protein]; Hydrogen Peroxide inhibits the reaction [Colforsin results in increased expression of DIO2 mRNA]; Sodium Selenite inhibits the reaction [Hydrogen Peroxide inhibits the reaction [Colforsin results in increased activity of DIO2 protein]]; U 0126 inhibits the reaction [Hydrogen Peroxide inhibits the reaction [Colforsin results in increased activity of DIO2 protein]]; U 0126 inhibits the reaction [Hydrogen Peroxide inhibits the reaction [Colforsin results in increased expression of DIO2 mRNA]] |
CTD |
PMID:18420745 PMID:19036883 |
|
NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809
|
|
G |
Dio3 |
iodothyronine deiodinase 3 |
multiple interactions |
EXP |
Colforsin promotes the reaction [Hydrogen Peroxide results in increased expression of DIO3 mRNA] |
CTD |
PMID:18420745 |
|
NCBI chr 6:129,285,747...129,287,608
Ensembl chr 6:129,285,749...129,286,660
|
|
G |
Dnm1l |
dynamin 1-like |
multiple interactions decreases expression |
ISO |
PINK1 protein affects the reaction [Colforsin results in decreased expression of DNM1L protein] |
CTD |
PMID:24792327 |
|
NCBI chr11:84,581,216...84,632,382
Ensembl chr11:84,581,216...84,631,482
|
|
G |
Drd2 |
dopamine receptor D2 |
multiple interactions |
ISO |
[Quinpirole binds to and results in increased activity of DRD2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; epigallocatechin gallate inhibits the reaction [[Quinpirole binds to and results in increased activity of DRD2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]] |
CTD |
PMID:17958328 |
|
NCBI chr 8:58,605,403...58,669,339
Ensembl chr 8:49,708,927...49,772,875
|
|
G |
Dynll2 |
dynein light chain LC8-type 2 |
increases expression |
ISO |
Colforsin results in increased expression of DYNLL2 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr10:72,767,035...72,785,824
Ensembl chr10:72,767,035...72,785,805
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
ISO |
Colforsin inhibits the reaction [EDN1 protein results in increased expression of CALCRL mRNA]; Colforsin inhibits the reaction [EDN1 protein results in increased expression of ICAM2 mRNA] |
CTD |
PMID:25194819 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of HSPD1 mRNA; [EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD1 mRNA; [EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD1 protein; [EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD2 mRNA; [EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD2 protein; Acetylcysteine inhibits the reaction [[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of HSPD1 mRNA]; Acetylcysteine inhibits the reaction [[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD1 mRNA]; Acetylcysteine inhibits the reaction [[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD1 protein]; Acetylcysteine inhibits the reaction [[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD2 mRNA]; Acetylcysteine inhibits the reaction [[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD2 protein] |
CTD |
PMID:32092105 |
|
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egr1 |
early growth response 1 |
decreases expression multiple interactions |
ISO |
Colforsin results in decreased expression of EGR1 mRNA; Colforsin results in decreased expression of EGR1 protein Colforsin inhibits the reaction [Ethanol results in increased expression of EGR1 mRNA]; Colforsin inhibits the reaction [Ethanol results in increased expression of EGR1 protein]; Ethanol inhibits the reaction [Colforsin results in decreased expression of EGR1 mRNA]; Ethanol inhibits the reaction [Colforsin results in decreased expression of EGR1 protein] |
CTD |
PMID:29802914 |
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Eif2b5 |
eukaryotic translation initiation factor 2B subunit epsilon |
increases expression |
ISO |
Colforsin results in increased expression of EIF2B5 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr11:80,394,433...80,404,468
Ensembl chr11:80,394,433...80,404,419
|
|
G |
Eif5a2 |
eukaryotic translation initiation factor 5A2 |
decreases expression |
ISO |
Colforsin results in decreased expression of EIF5A2 mRNA |
CTD |
PMID:30983542 |
|
NCBI chr 2:111,728,587...111,746,087
Ensembl chr 2:111,729,323...111,746,087
|
|
G |
Ephx1 |
epoxide hydrolase 1 |
affects expression multiple interactions |
ISO |
Colforsin affects the expression of EPHX1 mRNA Valproic Acid affects the reaction [Colforsin affects the expression of EPHX1 mRNA] |
CTD |
PMID:20726872 |
|
NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235
|
|
G |
Eps8 |
EGFR pathway substrate 8, signaling adaptor |
decreases expression |
ISO |
Colforsin results in decreased expression of EPS8 mRNA |
CTD |
PMID:15313392 PMID:15967414 |
|
NCBI chr 4:170,388,378...170,486,873
Ensembl chr 4:170,388,378...170,486,873
|
|
G |
Ereg |
epiregulin |
increases expression |
ISO |
Colforsin results in increased expression of EREG mRNA |
CTD |
PMID:15313392 PMID:15474502 PMID:15967414 PMID:20378682 |
|
NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062
|
|
G |
Ervfrd-1 |
endogenous retrovirus group FRD member 1, envelope |
multiple interactions increases expression increases secretion |
ISO |
[Cadmium Chloride results in increased abundance of Cadmium] inhibits the reaction [Colforsin results in increased expression of ERVFRD-1 mRNA]; Colforsin promotes the reaction [Benzo(a)pyrene results in increased expression of ERVFRD-1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide affects the reaction [Colforsin results in increased expression of ERVFRD-1 mRNA]; Valproic Acid inhibits the reaction [Colforsin results in increased expression of ERVFRD-1 mRNA] Colforsin results in increased expression of ERVFRD-1 mRNA; Colforsin results in increased expression of ERVFRD-1 protein Colforsin results in increased secretion of ERVFRD-1 protein |
CTD |
PMID:24361490 PMID:29679653 PMID:31278978 PMID:33144174 PMID:35908931 PMID:36336211 PMID:37385477 PMID:38296531 More...
|
|
NCBI chr12:22,151,211...22,158,264
Ensembl chr12:22,151,211...22,158,264
|
|
G |
Esr1 |
estrogen receptor 1 |
decreases expression |
ISO |
Colforsin results in decreased expression of ESR1 mRNA |
CTD |
PMID:31278978 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions decreases expression |
ISO |
Colforsin inhibits the reaction [ESR2 gene mutant form inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]] Colforsin results in decreased expression of ESR2 mRNA |
CTD |
PMID:20378682 PMID:31278978 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Esrra |
estrogen related receptor, alpha |
increases expression |
ISO |
Colforsin results in increased expression of ESRRA mRNA; Colforsin results in increased expression of ESRRA protein |
CTD |
PMID:20351196 |
|
NCBI chr 1:204,104,100...204,114,182
Ensembl chr 1:204,104,101...204,114,268
|
|
G |
Evi5 |
ecotropic viral integration site 5 |
increases expression |
ISO |
Colforsin results in increased expression of EVI5 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr14:1,875,601...2,021,678
Ensembl chr14:1,875,647...2,021,678
|
|
G |
F2 |
coagulation factor II, thrombin |
multiple interactions |
ISO |
Colforsin inhibits the reaction [F2 protein results in increased uptake of Manganese] |
CTD |
PMID:2125206 |
|
NCBI chr 3:77,596,196...77,609,486
Ensembl chr 3:77,596,198...77,609,486
|
|
G |
F2r |
coagulation factor II (thrombin) receptor |
multiple interactions |
ISO |
[C186 65 binds to and results in increased activity of F2R protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP] |
CTD |
PMID:22207716 |
|
NCBI chr 2:26,869,343...26,885,856
Ensembl chr 2:26,868,404...26,885,870
|
|
G |
F2rl3 |
F2R like thrombin or trypsin receptor 3 |
multiple interactions |
ISO |
[GYPGKF-NH(2) binds to and results in increased activity of F2RL3 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP] |
CTD |
PMID:22207716 |
|
NCBI chr16:17,117,441...17,119,434
Ensembl chr16:17,117,441...17,119,472
|
|
G |
Fads1 |
fatty acid desaturase 1 |
increases expression |
ISO |
Colforsin results in increased expression of FADS1 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr 1:206,827,724...206,842,734
Ensembl chr 1:206,827,765...206,842,734
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
ISO |
[Colforsin co-treated with 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime] results in increased expression of FASN mRNA; [Colforsin co-treated with Leflunomide] results in increased expression of FASN mRNA; [Colforsin co-treated with teriflunomide] results in increased expression of FASN mRNA |
CTD |
PMID:30364229 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fdx1 |
ferredoxin 1 |
multiple interactions increases expression |
ISO |
ferulic acid analog promotes the reaction [Colforsin results in increased expression of FDX1 mRNA] |
CTD |
PMID:36279966 |
|
NCBI chr 8:52,268,536...52,287,344
Ensembl chr 8:52,268,536...52,287,414
|
|
G |
Fgf10 |
fibroblast growth factor 10 |
multiple interactions |
ISO |
Colforsin inhibits the reaction [FGF10 protein results in increased phosphorylation of MAPK1 protein]; Colforsin inhibits the reaction [FGF10 protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:12533312 PMID:14975937 |
|
NCBI chr 2:50,801,171...50,878,218
Ensembl chr 2:50,800,992...50,876,866
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
increases expression |
ISO |
Colforsin results in increased expression of FGF2 mRNA; Colforsin results in increased expression of FGF2 protein |
CTD |
PMID:10320526 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Fgf5 |
fibroblast growth factor 5 |
decreases expression |
EXP |
Colforsin results in decreased expression of FGF5 mRNA |
CTD |
PMID:11598998 |
|
NCBI chr14:11,323,827...11,346,164
Ensembl chr14:11,325,334...11,345,997
|
|
G |
Fgf8 |
fibroblast growth factor 8 |
increases activity |
ISO |
Colforsin results in increased activity of FGF8 protein |
CTD |
PMID:15193767 |
|
NCBI chr 1:244,584,477...244,590,578
Ensembl chr 1:244,584,652...244,590,359
|
|
G |
Fgf9 |
fibroblast growth factor 9 |
multiple interactions |
ISO |
FGF9 protein inhibits the reaction [Colforsin promotes the reaction [IGF1 protein results in increased abundance of Estradiol]]; FGF9 protein inhibits the reaction [IGF1 protein promotes the reaction [Colforsin results in increased abundance of Progesterone]] |
CTD |
PMID:22798350 |
|
NCBI chr15:32,208,993...32,254,952
Ensembl chr15:32,210,074...32,253,309
|
|
G |
Fgfr1 |
Fibroblast growth factor receptor 1 |
increases expression |
ISO |
Colforsin results in increased expression of FGFR1 mRNA |
CTD |
PMID:10320526 |
|
NCBI chr16:66,491,930...66,547,161
Ensembl chr16:66,494,042...66,547,350
|
|
G |
Fgfr2 |
fibroblast growth factor receptor 2 |
increases expression |
ISO |
Colforsin results in increased expression of FGFR2 mRNA |
CTD |
PMID:10320526 |
|
NCBI chr 1:184,745,418...184,850,655
Ensembl chr 1:184,745,420...184,850,626
|
|
G |
Fkbp5 |
FKBP prolyl isomerase 5 |
multiple interactions |
ISO |
Colforsin promotes the reaction [Dexamethasone results in increased expression of FKBP5 mRNA] |
CTD |
PMID:19255438 |
|
NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674
|
|
G |
Flt1 |
Fms related receptor tyrosine kinase 1 |
increases expression |
ISO |
Colforsin results in increased expression of FLT1 mRNA |
CTD |
PMID:33144174 |
|
NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression multiple interactions |
EXP |
Colforsin results in increased expression of FOS protein Dexamethasone inhibits the reaction [Colforsin results in increased expression of FOS protein] |
CTD |
PMID:11113530 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fosb |
FosB proto-oncogene, AP-1 transcription factor subunit |
increases expression |
EXP |
Colforsin results in increased expression of FOSB mRNA; Colforsin results in increased expression of FOSB protein |
CTD |
PMID:11113530 PMID:17324382 |
|
NCBI chr 1:78,954,312...78,961,492
Ensembl chr 1:78,954,115...78,961,465
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
increases expression |
EXP |
Colforsin results in increased expression of FSHB mRNA; Colforsin results in increased expression of FSHB protein |
CTD |
PMID:8404651 |
|
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
Fst |
follistatin |
multiple interactions |
ISO |
FST protein inhibits the reaction [BMP6 protein inhibits the reaction [Colforsin results in increased secretion of Progesterone]]; FST protein inhibits the reaction [INHBA protein inhibits the reaction [Colforsin results in increased secretion of Progesterone]] |
CTD |
PMID:18936084 |
|
NCBI chr 2:46,123,260...46,130,584
Ensembl chr 2:46,123,439...46,130,571
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions |
EXP ISO |
[Dexamethasone co-treated with Colforsin] results in increased expression of G6PC1 mRNA Colforsin inhibits the reaction [Leflunomide results in increased expression of G6PC1 mRNA]; Colforsin inhibits the reaction [teriflunomide results in increased expression of G6PC1 mRNA] |
CTD |
PMID:18972406 PMID:30364229 |
|
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
Gabra1 |
gamma-aminobutyric acid type A receptor subunit alpha 1 |
increases expression |
EXP |
Colforsin results in increased expression of GABRA1 |
CTD |
PMID:9147380 |
|
NCBI chr10:26,595,151...26,650,611
Ensembl chr10:26,595,160...26,650,864
|
|
G |
Gabra6 |
gamma-aminobutyric acid type A receptor subunit alpha6 |
decreases expression |
EXP |
Colforsin results in decreased expression of GABRA6 |
CTD |
PMID:9147380 |
|
NCBI chr10:26,810,411...26,825,768
Ensembl chr10:26,810,423...26,825,769
|
|
G |
Gas6 |
growth arrest specific 6 |
decreases expression |
ISO |
Colforsin results in decreased expression of GAS6 mRNA |
CTD |
PMID:15313392 |
|
NCBI chr16:76,045,430...76,075,904
Ensembl chr16:76,045,426...76,075,904
|
|
G |
Gast |
gastrin |
multiple interactions increases secretion |
ISO EXP |
Calcium promotes the reaction [Colforsin results in increased secretion of GAST protein]; Nitrendipine inhibits the reaction [Colforsin results in increased secretion of GAST protein] 2',5'-dideoxyadenosine inhibits the reaction [Colforsin results in increased secretion of GAST protein] |
CTD |
PMID:9277405 PMID:19208342 |
|
NCBI chr10:85,264,832...85,269,393
Ensembl chr10:85,264,832...85,267,496
|
|
G |
Gcg |
glucagon |
multiple interactions increases secretion |
EXP |
Colforsin promotes the reaction [Pyruvic Acid results in increased secretion of GCG protein] Colforsin results in increased secretion of GCG protein |
CTD |
PMID:15919803 |
|
NCBI chr 3:47,113,914...47,122,958
Ensembl chr 3:47,113,914...47,122,929
|
|
G |
Gcm1 |
glial cells missing transcription factor 1 |
multiple interactions increases expression decreases expression |
ISO |
Colforsin promotes the reaction [GCM1 protein binds to CREBBP protein]; Colforsin results in increased acetylation of and results in increased activity of GCM1 protein; CREBBP protein affects the reaction [Colforsin results in increased activity of GCM1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased activity of GCM1 protein]; trichostatin A promotes the reaction [Colforsin results in increased acetylation of and results in increased activity of GCM1 protein]; Valproic Acid inhibits the reaction [Colforsin results in increased expression of GCM1 mRNA] Colforsin results in decreased expression of GCM1 mRNA |
CTD |
PMID:16166624 PMID:31278978 PMID:37385477 |
|
NCBI chr 8:78,925,687...78,938,924
Ensembl chr 8:78,925,687...78,938,924
|
|
G |
Gfap |
glial fibrillary acidic protein |
decreases expression |
ISO |
Colforsin results in decreased expression of GFAP protein |
CTD |
PMID:34897981 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Gh1 |
growth hormone 1 |
increases secretion multiple interactions |
ISO EXP |
Colforsin results in increased secretion of GH1 protein GH1 protein promotes the reaction [Colforsin results in increased metabolism of Lipids] |
CTD |
PMID:14981226 PMID:19952226 |
|
NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
multiple interactions decreases expression |
ISO |
Valproic Acid inhibits the reaction [Colforsin results in decreased expression of GJA1 mRNA] |
CTD |
PMID:37385477 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Gli1 |
GLI family zinc finger 1 |
decreases expression |
ISO |
Colforsin results in decreased expression of GLI1 mRNA; Colforsin results in decreased expression of GLI1 protein |
CTD |
PMID:30983542 |
|
NCBI chr 7:63,156,926...63,169,579
Ensembl chr 7:63,156,926...63,169,251
|
|
G |
Gli2 |
GLI family zinc finger 2 |
multiple interactions |
EXP |
Colforsin inhibits the reaction [Carbon Tetrachloride results in increased expression of GLI2 mRNA] |
CTD |
PMID:27590029 |
|
NCBI chr13:29,946,882...30,163,589
Ensembl chr13:29,946,809...30,163,574
|
|
G |
Gnai3 |
G protein subunit alpha i3 |
increases expression |
ISO |
Colforsin results in increased expression of GNAI3 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr 2:195,742,765...195,780,720
Ensembl chr 2:195,742,642...195,780,742
|
|
G |
Gpbar1 |
G protein-coupled bile acid receptor 1 |
multiple interactions |
ISO |
[Colforsin binds to and results in increased activity of GPBAR1 protein] which results in increased abundance of Cyclic AMP; Colforsin binds to and results in increased activity of GPBAR1 protein |
CTD |
PMID:17963371 |
|
NCBI chr 9:75,860,758...75,863,260
Ensembl chr 9:75,860,677...75,863,168
|
|
G |
Grin1 |
glutamate ionotropic receptor NMDA type subunit 1 |
increases phosphorylation multiple interactions |
EXP |
Colforsin results in increased phosphorylation of GRIN1 protein N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of GRIN1 protein] |
CTD |
PMID:14622123 |
|
NCBI chr 3:8,103,680...8,130,603
Ensembl chr 3:8,103,680...8,130,603
|
|
G |
Grin2b |
glutamate ionotropic receptor NMDA type subunit 2B |
multiple interactions increases expression |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased expression of GRIN2B protein] Colforsin results in increased expression of GRIN2B mRNA; Colforsin results in increased expression of GRIN2B protein |
CTD |
PMID:20067577 |
|
NCBI chr 4:168,580,824...169,044,110
Ensembl chr 4:168,599,546...169,042,279
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
EXP |
Colforsin results in increased phosphorylation of and results in decreased activity of GSK3B protein |
CTD |
PMID:15950778 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Hamp |
hepcidin antimicrobial peptide |
affects expression multiple interactions |
ISO |
Colforsin affects the expression of HAMP mRNA Colforsin inhibits the reaction [IL6 protein results in increased expression of HAMP mRNA] |
CTD |
PMID:25633564 |
|
NCBI chr 1:86,170,926...86,172,865
Ensembl chr 1:86,170,901...86,172,891
|
|
G |
Hcar2 |
hydroxycarboxylic acid receptor 2 |
multiple interactions |
ISO |
[3-Hydroxybutyric Acid results in increased activity of HCAR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Niacin results in increased activity of HCAR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Nicotinic Acids binds to and results in increased activity of HCAR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Pertussis Toxin inhibits the reaction [[Nicotinic Acids binds to and results in increased activity of HCAR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]] |
CTD |
PMID:17124637 PMID:19223991 |
|
NCBI chr12:32,726,252...32,728,238
Ensembl chr12:32,726,184...32,728,504
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
increases expression multiple interactions |
ISO |
Colforsin results in increased expression of HIF1A protein [cobaltous chloride co-treated with Valproic Acid co-treated with Colforsin] results in increased expression of HIF1A protein; Valproic Acid inhibits the reaction [Colforsin results in increased expression of HIF1A protein] |
CTD |
PMID:38296531 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hk2 |
hexokinase 2 |
increases expression multiple interactions |
ISO |
Colforsin results in increased expression of HK2 mRNA cobaltous chloride inhibits the reaction [Valproic Acid inhibits the reaction [Colforsin results in increased expression of HK2 mRNA]]; Valproic Acid inhibits the reaction [Colforsin results in increased expression of HK2 mRNA] |
CTD |
PMID:38296531 |
|
NCBI chr 4:115,234,509...115,283,530
Ensembl chr 4:115,234,509...115,283,530
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
affects expression increases expression multiple interactions |
ISO |
Colforsin affects the expression of HMGCR mRNA Colforsin results in increased expression of HMGCR mRNA [Colforsin co-treated with Ketoconazole] results in decreased expression of HMGCR mRNA; [Colforsin co-treated with triptolide] results in decreased expression of HMGCR mRNA; AR protein promotes the reaction [Colforsin results in increased expression of HMGCR protein]; Colforsin inhibits the reaction [Caffeine results in increased expression of HMGCR mRNA]; Valproic Acid affects the reaction [Colforsin affects the expression of HMGCR mRNA] |
CTD |
PMID:16751804 PMID:16935330 PMID:20726872 PMID:30825513 PMID:31557376 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
multiple interactions |
ISO |
Colforsin inhibits the reaction [Caffeine results in increased expression of HMGCS1 mRNA] |
CTD |
PMID:30825513 |
|
NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
ISO EXP |
Colforsin results in increased expression of HMOX1 protein N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased expression of HMOX1 protein] Colforsin results in increased expression of HMOX1 mRNA; Colforsin results in increased expression of HMOX1 protein |
CTD |
PMID:15179140 PMID:16439612 PMID:19483313 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hnrnpa1 |
heterogeneous nuclear ribonucleoprotein A1 |
multiple interactions |
EXP |
HNRNPA1 mutant form inhibits the reaction [Colforsin affects the splicing of RUNX1 exon]; HNRNPA1 mutant form inhibits the reaction [Colforsin affects the splicing of SNAP25 exon] |
CTD |
PMID:22684629 |
|
NCBI chr 7:134,375,318...134,381,610
Ensembl chr 7:134,375,150...134,381,609
|
|
G |
Hnrnpk |
heterogeneous nuclear ribonucleoprotein K |
multiple interactions |
EXP |
Colforsin promotes the reaction [HNRNPK protein binds to SNAP25 exon] |
CTD |
PMID:22684629 |
|
NCBI chr17:6,262,936...6,275,001
Ensembl chr17:6,262,998...6,274,997
|
|
G |
Hrh2 |
histamine receptor H 2 |
multiple interactions |
ISO |
Dimaprit inhibits the reaction [HRH2 protein promotes the reaction [Colforsin results in increased abundance of Cyclic AMP]]; HRH2 protein promotes the reaction [Colforsin results in increased abundance of Cyclic AMP] |
CTD |
PMID:9187264 |
|
NCBI chr17:10,366,004...10,407,791
Ensembl chr17:10,368,298...10,407,631
|
|
G |
Hrh3 |
histamine receptor H3 |
multiple interactions |
EXP |
[imetit results in increased activity of HRH3 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; ciproxifan inhibits the reaction [[imetit results in increased activity of HRH3 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; Pertussis Toxin inhibits the reaction [[imetit results in increased activity of HRH3 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; thioperamide inhibits the reaction [[imetit results in increased activity of HRH3 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]] |
CTD |
PMID:21276809 |
|
NCBI chr 3:167,191,551...167,196,642
Ensembl chr 3:167,191,558...167,196,642
|
|
G |
Hsd11b2 |
hydroxysteroid 11-beta dehydrogenase 2 |
multiple interactions increases expression |
ISO |
Colforsin inhibits the reaction [1,7-dimethylxanthine results in decreased expression of and results in decreased activity of HSD11B2 protein]; Colforsin inhibits the reaction [1,7-dimethylxanthine results in decreased expression of HSD11B2 mRNA]; Colforsin inhibits the reaction [Caffeine results in decreased expression of and results in decreased activity of HSD11B2 protein]; Colforsin inhibits the reaction [Caffeine results in decreased expression of HSD11B2 mRNA]; Colforsin inhibits the reaction [Ethanol results in decreased expression of HSD11B2 mRNA]; Colforsin inhibits the reaction [Ethanol results in decreased expression of HSD11B2 protein]; Ethanol inhibits the reaction [Colforsin results in increased expression of HSD11B2 mRNA]; Ethanol inhibits the reaction [Colforsin results in increased expression of HSD11B2 protein] Colforsin results in increased expression of HSD11B2 mRNA; Colforsin results in increased expression of HSD11B2 protein |
CTD |
PMID:22701600 PMID:24361490 PMID:29802914 PMID:33144174 |
|
NCBI chr19:33,397,656...33,402,899
Ensembl chr19:33,397,656...33,402,899
|
|
G |
Hsd17b1 |
hydroxysteroid (17-beta) dehydrogenase 1 |
affects expression increases expression multiple interactions |
ISO |
Colforsin affects the expression of HSD17B1 mRNA Colforsin results in increased expression of HSD17B1 mRNA [Colforsin co-treated with Aminoglutethimide] results in decreased expression of HSD17B1 mRNA; [Colforsin co-treated with Metyrapone] results in decreased expression of HSD17B1 mRNA; Valproic Acid affects the reaction [Colforsin affects the expression of HSD17B1 mRNA] |
CTD |
PMID:16935330 PMID:20726872 PMID:22446829 |
|
NCBI chr10:86,009,728...86,011,928
Ensembl chr10:86,009,728...86,011,927
|
|
G |
Hsd17b3 |
hydroxysteroid (17-beta) dehydrogenase 3 |
increases expression |
ISO |
Colforsin results in increased expression of HSD17B3 mRNA |
CTD |
PMID:22461451 |
|
NCBI chr17:1,027,229...1,058,554
Ensembl chr17:1,027,229...1,058,554
|
|
G |
Hsd17b4 |
hydroxysteroid (17-beta) dehydrogenase 4 |
affects expression multiple interactions increases expression |
ISO |
Colforsin affects the expression of HSD17B4 mRNA Aminoglutethimide inhibits the reaction [Colforsin results in increased expression of HSD17B4 mRNA]; Ketoconazole promotes the reaction [Colforsin results in increased expression of HSD17B4 mRNA]; Valproic Acid affects the reaction [Colforsin affects the expression of HSD17B4 mRNA] |
CTD |
PMID:16935330 PMID:20726872 PMID:22446829 |
|
NCBI chr18:43,328,903...43,417,950
Ensembl chr18:43,328,824...43,417,952
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
multiple interactions |
ISO |
BMP6 protein inhibits the reaction [Colforsin results in increased expression of HSD3B1 mRNA] |
CTD |
PMID:18936084 |
|
NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999
|
|
G |
Hsd3b2 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 |
increases expression multiple interactions |
ISO |
Colforsin results in increased expression of HSD3B2 mRNA [Colforsin co-treated with Ketoconazole] results in decreased expression of HSD3B2 mRNA; [Colforsin co-treated with Metyrapone] results in decreased expression of HSD3B2 mRNA; [Colforsin co-treated with triptolide] results in decreased expression of HSD3B2 mRNA; Apigenin inhibits the reaction [Colforsin results in increased expression of HSD3B2 mRNA]; daidzein inhibits the reaction [Colforsin results in increased expression of HSD3B2 mRNA]; Hexachlorocyclohexane inhibits the reaction [Colforsin results in increased expression of HSD3B2 mRNA]; Valproic Acid inhibits the reaction [Colforsin results in increased expression of HSD3B2 mRNA] |
CTD |
PMID:16935330 PMID:17080404 PMID:20726872 PMID:21256172 PMID:22446829 PMID:23370353 PMID:25765474 PMID:25871633 PMID:28235592 PMID:31100596 PMID:31557376 More...
|
|
NCBI chr 2:188,784,614...188,812,535
Ensembl chr 2:186,095,897...186,101,852
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
increases response to substance |
ISO |
HSPA5 protein results in increased susceptibility to Colforsin |
CTD |
PMID:22912664 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Hspd1 |
heat shock protein family D (Hsp60) member 1 |
multiple interactions |
ISO |
[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of HSPD1 mRNA; Acetylcysteine inhibits the reaction [[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of HSPD1 mRNA] |
CTD |
PMID:32092105 |
|
NCBI chr 9:56,579,195...56,590,011
Ensembl chr 9:56,579,201...56,589,662
|
|
G |
Htr1a |
5-hydroxytryptamine receptor 1A |
multiple interactions |
ISO |
[JB-788 binds to and results in increased activity of HTR1A protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Arachidonic Acid metabolite inhibits the reaction [HTR1A protein inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; HTR1A protein inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Melitten inhibits the reaction [HTR1A protein inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]] |
CTD |
PMID:11356925 PMID:20580787 |
|
NCBI chr 2:36,693,462...36,698,026
Ensembl chr 2:36,694,174...36,695,442
|
|
G |
Htr1b |
5-hydroxytryptamine receptor 1B |
multiple interactions |
ISO |
HTR1B affects the reaction [almotriptan inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]] |
CTD |
PMID:11134654 |
|
NCBI chr 8:82,513,572...82,534,670
Ensembl chr 8:82,517,360...82,534,549
|
|
G |
Htr2a |
5-hydroxytryptamine receptor 2A |
multiple interactions |
EXP |
Colforsin inhibits the reaction [N-(piperidin-1-yl)-1-(2,4-dichlorophenyl)-1,4-dihydro-6-methylindeno(1,2-c)pyrazole-3-carboxamide results in increased expression of HTR2A mRNA] |
CTD |
PMID:22791651 |
|
NCBI chr15:49,950,035...50,022,188
Ensembl chr15:49,950,804...50,020,928
|
|
G |
Htr7 |
5-hydroxytryptamine receptor 7 |
multiple interactions |
ISO |
[Bromocriptine binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Lisuride binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Metergoline binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Methiothepin binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Paliperidone Palmitate binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Risperidone binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP] |
CTD |
PMID:19509219 |
|
NCBI chr 1:233,636,442...233,761,063
Ensembl chr 1:233,636,452...233,760,626
|
|
G |
Iapp |
islet amyloid polypeptide |
increases expression |
EXP |
Colforsin results in increased expression of IAPP mRNA |
CTD |
PMID:9142872 |
|
NCBI chr 4:175,237,107...175,244,373
Ensembl chr 4:175,237,115...175,242,920
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
Colforsin inhibits the reaction [Reactive Oxygen Species results in increased expression of ICAM1 mRNA]; Colforsin inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA] |
CTD |
PMID:10495789 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Icam2 |
intercellular adhesion molecule 2 |
multiple interactions |
ISO |
Colforsin inhibits the reaction [EDN1 protein results in increased expression of ICAM2 mRNA] |
CTD |
PMID:25194819 |
|
NCBI chr10:91,308,608...91,319,536
Ensembl chr10:91,308,538...91,315,293
|
|
G |
Ier3 |
immediate early response 3 |
affects response to substance |
ISO |
IER3 protein affects the susceptibility to Colforsin |
CTD |
PMID:20713914 |
|
NCBI chr20:2,928,378...2,929,582
Ensembl chr20:2,928,378...2,929,583
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
Colforsin inhibits the reaction [IFNG protein promotes the reaction [decitabine results in increased expression of PLA2G2A protein]] |
CTD |
PMID:18953428 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Igf1 |
insulin-like growth factor 1 |
multiple interactions |
ISO |
Colforsin promotes the reaction [IGF1 protein results in increased abundance of Estradiol]; FGF9 protein inhibits the reaction [Colforsin promotes the reaction [IGF1 protein results in increased abundance of Estradiol]]; FGF9 protein inhibits the reaction [IGF1 protein promotes the reaction [Colforsin results in increased abundance of Progesterone]]; IGF1 protein promotes the reaction [Colforsin results in increased abundance of Progesterone] |
CTD |
PMID:22798350 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Igfbp1 |
insulin-like growth factor binding protein 1 |
increases expression multiple interactions |
ISO |
Colforsin results in increased expression of IGFBP1 [Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased expression of IGFBP1 mRNA |
CTD |
PMID:12093828 PMID:31154070 |
|
NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
multiple interactions |
ISO |
Colforsin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of IKBKB mRNA] |
CTD |
PMID:17407152 |
|
NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250
|
|
G |
Il10 |
interleukin 10 |
decreases expression |
ISO |
Colforsin results in decreased expression of IL10 protein |
CTD |
PMID:10996031 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il11 |
interleukin 11 |
increases expression |
ISO |
Colforsin results in increased expression of IL11 mRNA |
CTD |
PMID:22138297 |
|
NCBI chr 1:69,069,829...69,076,129
Ensembl chr 1:69,068,137...69,076,129
|
|
G |
Il12a |
interleukin 12A |
decreases expression |
ISO |
Colforsin results in decreased expression of IL12A protein |
CTD |
PMID:10996031 |
|
NCBI chr 2:152,965,769...152,973,035
Ensembl chr 2:152,965,769...152,972,734
|
|
G |
Il12b |
interleukin 12B |
multiple interactions increases expression |
ISO |
Colforsin inhibits the reaction [oxophenylarsine promotes the reaction [Lipopolysaccharides results in increased expression of IL12B protein]]; Colforsin results in increased expression of [IL12B protein binds to IL23A protein] Colforsin results in increased expression of IL12B protein |
CTD |
PMID:10996031 PMID:15180965 PMID:20512473 |
|
NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il13 |
interleukin 13 |
decreases secretion decreases expression |
ISO |
Colforsin results in decreased secretion of IL13 protein Colforsin results in decreased expression of IL13 mRNA |
CTD |
PMID:16083514 |
|
NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO EXP |
Colforsin promotes the reaction [IL1B protein results in increased expression of PTGS2 protein] Colforsin inhibits the reaction [Carbon Tetrachloride results in increased expression of IL1B protein] |
CTD |
PMID:11112151 PMID:27590029 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il23a |
interleukin 23 subunit alpha |
increases expression multiple interactions |
ISO |
Colforsin results in increased expression of IL23A protein Colforsin results in increased expression of [IL12B protein binds to IL23A protein] |
CTD |
PMID:15180965 |
|
NCBI chr 7:721,809...723,923
Ensembl chr 7:721,809...723,923
|
|
G |
Il2ra |
interleukin 2 receptor subunit alpha |
decreases expression |
ISO |
Colforsin results in decreased expression of IL2RA protein |
CTD |
PMID:1709825 |
|
NCBI chr17:66,849,974...66,898,665
Ensembl chr17:66,849,974...66,898,697
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO |
Colforsin inhibits the reaction [Itraconazole results in decreased expression of IL4 mRNA]; Colforsin inhibits the reaction [Itraconazole results in decreased secretion of IL4 protein]; Colforsin inhibits the reaction [Ketoconazole results in decreased expression of IL4 mRNA]; Colforsin inhibits the reaction [Ketoconazole results in decreased secretion of IL4 protein]; Colforsin inhibits the reaction [Miconazole results in decreased expression of IL4 mRNA]; Colforsin inhibits the reaction [Miconazole results in decreased secretion of IL4 protein]; Colforsin inhibits the reaction [terbinafine results in decreased expression of IL4 mRNA]; Colforsin inhibits the reaction [terbinafine results in decreased secretion of IL4 protein]; Colforsin inhibits the reaction [Tolnaftate results in decreased expression of IL4 mRNA]; Colforsin inhibits the reaction [Tolnaftate results in decreased secretion of IL4 protein] |
CTD |
PMID:11886533 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il5 |
interleukin 5 |
multiple interactions |
ISO |
Colforsin inhibits the reaction [Itraconazole results in decreased expression of IL5 mRNA]; Colforsin inhibits the reaction [Itraconazole results in decreased secretion of IL5 protein]; Colforsin inhibits the reaction [Ketoconazole results in decreased expression of IL5 mRNA]; Colforsin inhibits the reaction [Ketoconazole results in decreased secretion of IL5 protein]; Colforsin inhibits the reaction [Miconazole results in decreased expression of IL5 mRNA]; Colforsin inhibits the reaction [Miconazole results in decreased secretion of IL5 protein]; Colforsin inhibits the reaction [terbinafine results in decreased expression of IL5 mRNA]; Colforsin inhibits the reaction [terbinafine results in decreased secretion of IL5 protein]; Colforsin inhibits the reaction [Tolnaftate results in decreased expression of IL5 mRNA]; Colforsin inhibits the reaction [Tolnaftate results in decreased secretion of IL5 protein] |
CTD |
PMID:11886533 |
|
NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases secretion |
EXP ISO |
Colforsin inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] Colforsin inhibits the reaction [IL6 protein results in increased expression of HAMP mRNA]; Colforsin promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; Colforsin promotes the reaction [TNF protein results in increased expression of IL6 mRNA] Colforsin results in increased secretion of IL6 protein oxophenylarsine inhibits the reaction [Colforsin results in increased secretion of IL6 protein] |
CTD |
PMID:17141199 PMID:20388727 PMID:21803157 PMID:24771768 PMID:25633564 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Inhba |
inhibin subunit beta A |
multiple interactions |
ISO |
FST protein inhibits the reaction [INHBA protein inhibits the reaction [Colforsin results in increased secretion of Progesterone]]; INHBA protein inhibits the reaction [Colforsin results in increased secretion of Progesterone] |
CTD |
PMID:18936084 |
|
NCBI chr17:49,091,635...49,111,573
Ensembl chr17:49,095,920...49,108,982
|
|
G |
Ins1 |
insulin 1 |
multiple interactions increases secretion |
EXP ISO |
1-Methyl-3-isobutylxanthine promotes the reaction [Colforsin results in increased secretion of INS1 protein]; Budesonide inhibits the reaction [Colforsin promotes the reaction [Glucose results in increased secretion of INS1 protein]]; Colforsin promotes the reaction [Glucose results in increased secretion of INS1 protein]; Dexamethasone inhibits the reaction [Colforsin promotes the reaction [Glucose results in increased secretion of INS1 protein]]; Fluticasone inhibits the reaction [Colforsin promotes the reaction [Glucose results in increased secretion of INS1 protein]]; Hydrocortisone inhibits the reaction [Colforsin promotes the reaction [Glucose results in increased secretion of INS1 protein]]; Melatonin inhibits the reaction [Colforsin results in increased secretion of INS1 protein]; Probenecid promotes the reaction [Colforsin results in increased secretion of INS1 protein] |
CTD |
PMID:10221768 PMID:12153439 PMID:25851902 PMID:37217659 |
|
NCBI chr 1:261,186,119...261,186,686
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Insig1 |
insulin induced gene 1 |
multiple interactions increases expression |
ISO |
AR protein promotes the reaction [Colforsin results in increased expression of INSIG1 protein] Colforsin results in increased expression of INSIG1 mRNA; Colforsin results in increased expression of INSIG1 protein |
CTD |
PMID:16751804 |
|
NCBI chr 4:7,315,494...7,323,972
Ensembl chr 4:7,315,495...7,323,952
|
|
G |
Irs1 |
insulin receptor substrate 1 |
multiple interactions |
ISO |
Colforsin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of IRS1 mRNA] |
CTD |
PMID:17407152 |
|
NCBI chr 9:83,552,964...83,605,797
Ensembl chr 9:83,548,944...83,606,122
|
|
G |
Itga1 |
integrin subunit alpha 1 |
affects response to substance |
EXP |
ITGA1 protein affects the susceptibility to Colforsin |
CTD |
PMID:15836982 |
|
NCBI chr 2:46,646,125...46,812,237
Ensembl chr 2:46,653,193...46,812,238
|
|
G |
Itga3 |
integrin subunit alpha 3 |
affects response to substance |
EXP |
ITGA3 protein affects the susceptibility to Colforsin |
CTD |
PMID:15836982 |
|
NCBI chr10:79,990,160...80,022,206
Ensembl chr10:79,990,161...80,022,118
|
|
G |
Itgb1 |
integrin subunit beta 1 |
affects response to substance |
EXP |
ITGB1 protein affects the susceptibility to Colforsin |
CTD |
PMID:15836982 |
|
NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195
|
|
G |
Itgb5 |
integrin subunit beta 5 |
increases expression |
ISO |
Colforsin results in increased expression of ITGB5 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr11:66,828,428...66,944,231
Ensembl chr11:66,829,285...66,944,472
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases expression |
EXP |
Colforsin results in increased expression of JUN protein |
CTD |
PMID:11113530 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Junb |
JunB proto-oncogene, AP-1 transcription factor subunit |
increases expression |
EXP |
Colforsin results in increased expression of JUNB protein |
CTD |
PMID:11113530 |
|
NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035
|
|
G |
Jund |
JunD proto-oncogene, AP-1 transcription factor subunit |
increases expression |
EXP |
Colforsin results in increased expression of JUND protein |
CTD |
PMID:11113530 |
|
NCBI chr16:18,734,121...18,735,799
Ensembl chr16:18,734,122...18,735,799
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions |
ISO |
[[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of [ADRB1 protein binds to ADRB2 protein]] affects the reaction [KCNH2 protein results in increased transport of Potassium] |
CTD |
PMID:19419905 |
|
NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Klhl23 |
kelch-like family member 23 |
multiple interactions |
ISO |
[Colforsin co-treated with Diethylhexyl Phthalate] affects the expression of PHOSPHO2-KLHL23 mRNA |
CTD |
PMID:35892601 |
|
NCBI chr 3:54,580,788...54,594,530
Ensembl chr 3:54,580,961...54,594,530
|
|
G |
Klk1c10 |
kallikrein 1-related peptidase C10 |
multiple interactions increases expression |
ISO |
AR protein promotes the reaction [Colforsin results in increased expression of KLK3 protein] Colforsin results in increased expression of KLK3 mRNA; Colforsin results in increased expression of KLK3 protein |
CTD |
PMID:16751804 |
|
NCBI chr 1:94,402,993...94,407,052
Ensembl chr 1:94,402,993...94,407,052
|
|
G |
Kyat1 |
kynurenine aminotransferase 1 |
multiple interactions increases expression |
ISO |
S-(1,2-dichlorovinyl)cysteine inhibits the reaction [Colforsin results in increased expression of KYAT1 mRNA] |
CTD |
PMID:37544576 |
|
NCBI chr 3:33,857,407...33,891,153
Ensembl chr 3:13,459,591...13,493,355
|
|
G |
Lep |
leptin |
decreases expression decreases secretion multiple interactions |
ISO |
Colforsin results in decreased expression of LEP mRNA Colforsin results in decreased secretion of LEP protein Colforsin inhibits the reaction [Caffeine results in decreased expression of LEP mRNA] |
CTD |
PMID:9002984 PMID:26367767 PMID:27381457 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lhb |
luteinizing hormone subunit beta |
increases expression multiple interactions |
EXP |
Colforsin results in increased expression of LHB protein [Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP; [Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Testosterone; CRH protein inhibits the reaction [[Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [[Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Testosterone]; Tetradecanoylphorbol Acetate inhibits the reaction [[Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; Tetradecanoylphorbol Acetate inhibits the reaction [[Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Testosterone] |
CTD |
PMID:2153673 PMID:8404651 |
|
NCBI chr 1:105,037,457...105,038,446
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Lhcgr |
luteinizing hormone/choriogonadotropin receptor |
multiple interactions |
ISO |
[Colforsin co-treated with deoxynivalenol] results in increased expression of LHCGR mRNA; [Colforsin co-treated with Zearalenone] results in increased expression of LHCGR mRNA |
CTD |
PMID:26783879 |
|
NCBI chr 6:5,661,871...5,728,109
Ensembl chr 6:5,661,871...5,724,521
|
|
G |
Lipe |
lipase E, hormone sensitive type |
affects localization |
EXP |
Colforsin affects the localization of LIPE protein |
CTD |
PMID:11160373 |
|
NCBI chr 1:80,965,612...80,984,313
Ensembl chr 1:80,965,627...80,984,310
|
|
G |
Lpl |
lipoprotein lipase |
increases expression |
EXP |
Colforsin results in increased expression of LPL mRNA |
CTD |
PMID:9032464 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Ltbp2 |
latent transforming growth factor beta binding protein 2 |
decreases expression |
ISO |
Colforsin results in decreased expression of LTBP2 mRNA |
CTD |
PMID:15313392 |
|
NCBI chr 6:104,429,947...104,530,498
Ensembl chr 6:104,429,947...104,526,208
|
|
G |
Ltc4s |
leukotriene C4 synthase |
decreases secretion |
ISO |
Colforsin results in decreased secretion of LTC4S protein |
CTD |
PMID:16083514 |
|
NCBI chr10:34,560,476...34,562,790
Ensembl chr10:34,560,360...34,562,651
|
|
G |
Lyz2 |
lysozyme 2 |
multiple interactions decreases secretion increases secretion |
ISO |
3-((3-trifluoromethyl)phenyl)-5-((3-carboxyphenyl)methylene)-2-thioxo-4-thiazolidinone inhibits the reaction [Colforsin results in increased secretion of LYZ protein]; [Thapsigargin co-treated with Colforsin] results in increased secretion of LYZ protein Colforsin results in decreased secretion of LYZ protein |
CTD |
PMID:15194485 PMID:15234967 |
|
NCBI chr 7:52,906,810...52,912,154
Ensembl chr 7:52,906,811...52,912,106
|
|
G |
Maf |
MAF bZIP transcription factor |
decreases expression |
ISO |
Colforsin results in decreased expression of MAF mRNA |
CTD |
PMID:16751804 |
|
NCBI chr19:43,353,867...43,713,162
Ensembl chr19:43,360,342...43,712,365
|
|
G |
Map2 |
microtubule-associated protein 2 |
increases expression |
ISO |
Colforsin results in increased expression of MAP2 protein |
CTD |
PMID:34897981 |
|
NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
multiple interactions |
ISO |
[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased phosphorylation of MAP2K1 protein; alisol B promotes the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased phosphorylation of MAP2K1 protein] |
CTD |
PMID:28051915 |
|
NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147
|
|
G |
Map2k2 |
mitogen activated protein kinase kinase 2 |
multiple interactions |
ISO |
[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased phosphorylation of MAP2K2 protein; alisol B promotes the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased phosphorylation of MAP2K2 protein] |
CTD |
PMID:28051915 |
|
NCBI chr 7:8,590,729...8,610,279
Ensembl chr 7:8,580,905...8,610,243
|
|
G |
Map7 |
microtubule-associated protein 7 |
increases expression |
ISO |
Colforsin results in increased expression of MAP7 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr 1:14,910,433...15,037,574
Ensembl chr 1:14,910,551...15,037,574
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation increases activity |
ISO EXP |
Colforsin inhibits the reaction [FGF10 protein results in increased phosphorylation of MAPK1 protein]; Colforsin inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK1 protein]; Colforsin inhibits the reaction [Shiga Toxin results in increased activity of MAPK1 protein] 1-Methyl-3-isobutylxanthine promotes the reaction [Colforsin inhibits the reaction [Testosterone results in increased phosphorylation of MAPK1 protein]]; [Colforsin co-treated with Rolipram co-treated with Picrotoxin] results in increased phosphorylation of MAPK1 protein; Colforsin inhibits the reaction [Testosterone results in increased phosphorylation of MAPK1 protein]; Colforsin promotes the reaction [1-Methyl-3-isobutylxanthine inhibits the reaction [Testosterone results in increased phosphorylation of MAPK1 protein]]; Colforsin promotes the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK1 protein]; Dieldrin promotes the reaction [[Colforsin co-treated with Rolipram co-treated with Picrotoxin] results in increased phosphorylation of MAPK1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin promotes the reaction [1-Methyl-3-isobutylxanthine inhibits the reaction [Testosterone results in increased phosphorylation of MAPK1 protein]]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of MAPK1 protein]; Propranolol inhibits the reaction [Colforsin results in increased activity of MAPK1 protein]; Tetradecanoylphorbol Acetate promotes the reaction [Colforsin results in increased phosphorylation of MAPK1 protein] [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased phosphorylation of MAPK1 protein; alisol B promotes the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased phosphorylation of MAPK1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:11093795 PMID:11675405 PMID:12533312 PMID:14975937 PMID:15385614 PMID:17322281 PMID:18004999 PMID:20378682 PMID:21177760 PMID:22875961 PMID:28051915 PMID:35137321 More...
|
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation increases activity multiple interactions |
ISO EXP |
Colforsin results in increased phosphorylation of MAPK3 protein Colforsin results in increased activity of MAPK3 protein 1-Methyl-3-isobutylxanthine promotes the reaction [Colforsin inhibits the reaction [Testosterone results in increased phosphorylation of MAPK3 protein]]; [Colforsin co-treated with Rolipram co-treated with Picrotoxin] results in increased phosphorylation of MAPK3 protein; Colforsin inhibits the reaction [Testosterone results in increased phosphorylation of MAPK3 protein]; Colforsin promotes the reaction [1-Methyl-3-isobutylxanthine inhibits the reaction [Testosterone results in increased phosphorylation of MAPK3 protein]]; Dieldrin promotes the reaction [[Colforsin co-treated with Rolipram co-treated with Picrotoxin] results in increased phosphorylation of MAPK3 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin promotes the reaction [1-Methyl-3-isobutylxanthine inhibits the reaction [Testosterone results in increased phosphorylation of MAPK3 protein]]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of MAPK3 protein]; Propranolol inhibits the reaction [Colforsin results in increased activity of MAPK3 protein] [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased phosphorylation of MAPK3 protein; alisol B promotes the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased phosphorylation of MAPK3 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of MAPK3 protein] Colforsin inhibits the reaction [FGF10 protein results in increased phosphorylation of MAPK3 protein]; Colforsin inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK3 protein]; Colforsin inhibits the reaction [Shiga Toxin results in increased activity of MAPK3 protein] |
CTD |
PMID:11093795 PMID:11675405 PMID:12533312 PMID:14975937 PMID:15385614 PMID:17322281 PMID:18004999 PMID:20378682 PMID:21177760 PMID:22875961 PMID:28051915 PMID:35137321 More...
|
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mc2r |
melanocortin 2 receptor |
multiple interactions increases expression |
ISO |
Valproic Acid inhibits the reaction [Colforsin results in increased expression of MC2R mRNA] |
CTD |
PMID:20726872 PMID:25765474 |
|
NCBI chr18:64,279,878...64,291,775
Ensembl chr18:62,004,948...62,015,488
|
|
G |
Med28 |
mediator complex subunit 28 |
increases expression |
ISO |
Colforsin results in increased expression of MED28 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr14:65,594,785...65,603,583
Ensembl chr14:65,594,647...65,603,583
|
|
G |
Mir190a |
microRNA 190a |
multiple interactions |
ISO |
Colforsin inhibits the reaction [[carvedilol co-treated with ARRB1 protein] results in increased expression of MIR190A mRNA] |
CTD |
PMID:24334028 |
|
NCBI chr 8:67,850,987...67,851,071
Ensembl chr 8:67,850,987...67,851,071
|
|
G |
Mitf |
melanocyte inducing transcription factor |
increases expression multiple interactions |
ISO |
Colforsin results in increased expression of MITF mRNA; Colforsin results in increased expression of MITF protein [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of MITF mRNA; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of MITF protein; alisol B inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of MITF mRNA]; alisol B inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of MITF protein] |
CTD |
PMID:17460731 PMID:28051915 PMID:28601556 |
|
NCBI chr 4:130,409,020...130,621,145
Ensembl chr 4:130,409,217...130,621,145
|
|
G |
Mmp16 |
matrix metallopeptidase 16 |
increases expression |
ISO |
Colforsin results in increased expression of MMP16 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr 5:31,312,280...31,556,276
Ensembl chr 5:31,312,280...31,548,388
|
|
G |
Mterf4 |
mitochondrial transcription termination factor 4 |
decreases expression |
ISO |
Colforsin results in decreased expression of MTERF4 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr 9:93,834,162...93,838,838
Ensembl chr 9:93,834,144...93,838,864
|
|
G |
Muc4 |
mucin 4, cell surface associated |
increases expression |
ISO |
Colforsin results in increased expression of MUC4 protein |
CTD |
PMID:28049186 |
|
NCBI chr11:68,008,245...68,053,242
|
|
G |
Myh7 |
myosin heavy chain 7 |
multiple interactions |
EXP |
Colforsin inhibits the reaction [Dinoprostone results in increased expression of MYH7 protein]; Colforsin inhibits the reaction [Phenylephrine results in increased expression of MYH7 mRNA] |
CTD |
PMID:18851973 |
|
NCBI chr15:28,446,550...28,469,888
Ensembl chr15:28,446,550...28,468,217
|
|
G |
Nav1 |
neuron navigator 1 |
decreases expression |
ISO |
Colforsin results in decreased expression of NAV1 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr13:46,866,972...47,119,368
Ensembl chr13:46,873,689...47,126,449
|
|
G |
Nes |
nestin |
decreases expression |
ISO |
Colforsin results in decreased expression of NES protein |
CTD |
PMID:34897981 |
|
NCBI chr 2:173,437,867...173,447,777
Ensembl chr 2:173,438,734...173,447,777
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
Colforsin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of NFKB1 mRNA] |
CTD |
PMID:17407152 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Ngf |
nerve growth factor |
multiple interactions increases expression |
EXP |
[Colforsin results in increased abundance of Cyclic AMP] which results in increased expression of NGF mRNA Colforsin results in increased expression of NGF mRNA |
CTD |
PMID:2174743 PMID:2853697 |
|
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Ngly1 |
N-glycanase 1 |
increases expression |
ISO |
Colforsin results in increased expression of NGLY1 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr15:9,153,738...9,210,228
Ensembl chr15:9,153,738...9,204,630
|
|
G |
Nmu |
neuromedin U |
increases expression |
EXP |
Colforsin results in increased expression of NMU mRNA |
CTD |
PMID:23423171 |
|
NCBI chr14:31,844,564...31,872,196
Ensembl chr14:31,844,728...31,872,192
|
|
G |
Nppa |
natriuretic peptide A |
multiple interactions |
EXP |
Colforsin inhibits the reaction [Dinoprostone results in increased expression of NPPA protein]; Colforsin inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA] |
CTD |
PMID:11470465 PMID:18851973 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Nr0b1 |
nuclear receptor subfamily 0, group B, member 1 |
decreases expression multiple interactions |
ISO |
Colforsin results in decreased expression of NR0B1 mRNA Valproic Acid inhibits the reaction [Colforsin results in decreased expression of NR0B1 mRNA] |
CTD |
PMID:20726872 |
|
NCBI chr X:50,756,886...50,761,014
Ensembl chr X:50,756,886...50,761,011
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity decreases expression |
EXP ISO |
Colforsin results in increased activity of NR1I2 protein Colforsin results in decreased expression of NR1I2 mRNA |
CTD |
PMID:27732639 PMID:29933105 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
increases activity |
ISO |
Colforsin results in increased activity of NR3C1 protein |
CTD |
PMID:19255438 |
|
NCBI chr18:31,522,783...31,644,508
Ensembl chr18:31,271,681...31,393,375
|
|
G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
increases expression multiple interactions |
ISO |
Colforsin results in increased expression of NR4A1 mRNA; Colforsin results in increased expression of NR4A1 protein [Colforsin co-treated with deoxynivalenol] results in increased expression of NR4A1 mRNA; Colforsin promotes the reaction [Zearalenone results in increased expression of NR4A1 mRNA]; NR4A1 protein inhibits the reaction [Ryanodine inhibits the reaction [Colforsin results in increased expression of STAR protein]]; Ryanodine inhibits the reaction [Colforsin results in increased expression of NR4A1 mRNA]; Ryanodine inhibits the reaction [Colforsin results in increased expression of NR4A1 protein]; W 7 inhibits the reaction [Colforsin results in increased expression of NR4A1 mRNA]; W 7 inhibits the reaction [Colforsin results in increased expression of NR4A1 protein] NR4A1 protein inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA] |
CTD |
PMID:8164692 PMID:19822197 PMID:23183170 PMID:26783879 |
|
NCBI chr 7:132,368,399...132,389,300
Ensembl chr 7:132,374,840...132,389,297
|
|
G |
Nr4a2 |
nuclear receptor subfamily 4, group A, member 2 |
multiple interactions increases expression |
ISO |
666-15 compound inhibits the reaction [Colforsin results in increased expression of NR4A2 mRNA]; NR4A2 protein inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA] Colforsin results in increased expression of NR4A2 mRNA; Colforsin results in increased expression of NR4A2 protein |
CTD |
PMID:19732956 PMID:19822197 PMID:26023867 |
|
NCBI chr 3:41,689,847...41,707,036
Ensembl chr 3:41,689,851...41,697,877
|
|
G |
Nr4a3 |
nuclear receptor subfamily 4, group A, member 3 |
multiple interactions |
ISO |
NR4A3 protein inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA] |
CTD |
PMID:19822197 |
|
NCBI chr 5:62,361,588...62,401,489
Ensembl chr 5:62,361,822...62,402,733
|
|
G |
Nr5a1 |
nuclear receptor subfamily 5, group A, member 1 |
affects expression |
ISO |
Colforsin affects the expression of NR5A1 mRNA |
CTD |
PMID:20726872 |
|
NCBI chr 3:22,464,786...22,486,328
Ensembl chr 3:22,465,502...22,486,328
|
|
G |
Nr5a2 |
nuclear receptor subfamily 5, group A, member 2 |
multiple interactions increases expression |
ISO |
alitretinoin inhibits the reaction [NR5A2 protein promotes the reaction [[Colforsin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CYP19A1 mRNA]]; NR5A2 protein promotes the reaction [[Colforsin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CYP19A1 mRNA] Colforsin results in increased expression of NR5A2 mRNA |
CTD |
PMID:16357189 |
|
NCBI chr13:48,313,634...48,433,494
Ensembl chr13:48,316,301...48,433,326
|
|
G |
Nrg1 |
neuregulin 1 |
multiple interactions |
ISO |
[Colforsin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of NRG1 mRNA; U 0126 inhibits the reaction [[Colforsin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of NRG1 mRNA] |
CTD |
PMID:21047912 |
|
NCBI chr16:59,250,658...60,304,519
Ensembl chr16:59,250,854...60,296,884
|
|
G |
Ntf3 |
neurotrophin 3 |
increases expression |
EXP |
Colforsin results in increased expression of NTF3 protein |
CTD |
PMID:19854260 |
|
NCBI chr 4:158,914,984...158,984,453
Ensembl chr 4:158,914,957...158,984,596
|
|
G |
Ntrk2 |
neurotrophic receptor tyrosine kinase 2 |
increases expression |
EXP |
Colforsin results in increased expression of NTRK2 mRNA |
CTD |
PMID:35917217 |
|
NCBI chr17:5,558,992...5,870,299
Ensembl chr17:5,559,043...5,869,136
|
|
G |
Numa1 |
nuclear mitotic apparatus protein 1 |
decreases expression |
ISO |
Colforsin results in decreased expression of NUMA1 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr 1:156,297,907...156,372,855
Ensembl chr 1:156,326,259...156,372,855
|
|
G |
Oxt |
oxytocin/neurophysin I prepropeptide |
multiple interactions |
ISO |
BMP6 protein inhibits the reaction [Colforsin results in increased expression of OXT mRNA] |
CTD |
PMID:18936084 |
|
NCBI chr 3:117,782,650...117,783,490
Ensembl chr 3:117,782,650...117,783,490
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage |
ISO |
[Colforsin co-treated with Theophylline] inhibits the reaction [Etoposide results in increased cleavage of PARP1 protein] Colforsin results in increased cleavage of PARP1 protein |
CTD |
PMID:9454737 PMID:31278978 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pax8 |
paired box 8 |
increases expression |
ISO |
Colforsin results in increased expression of PAX8 mRNA; Colforsin results in increased expression of PAX8 protein |
CTD |
PMID:15961562 |
|
NCBI chr 3:7,185,721...7,242,363
Ensembl chr 3:7,185,723...7,242,363
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
increases expression multiple interactions |
EXP ISO |
Colforsin results in increased expression of PCK1 mRNA Colforsin inhibits the reaction [Leflunomide results in increased expression of PCK1 mRNA]; Colforsin inhibits the reaction [teriflunomide results in increased expression of PCK1 mRNA] Dexamethasone promotes the reaction [Colforsin results in increased expression of PCK1 mRNA] |
CTD |
PMID:25851902 PMID:30364229 |
|
NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191
|
|
G |
Pde1b |
phosphodiesterase 1B |
multiple interactions |
ISO |
PDE1B protein affects the reaction [Colforsin results in increased phosphorylation of PPP1R1B protein] |
CTD |
PMID:12077213 |
|
NCBI chr 7:134,627,378...134,654,581
Ensembl chr 7:134,627,322...134,654,580
|
|
G |
Pde2a |
phosphodiesterase 2A |
multiple interactions |
ISO |
PDE2A protein inhibits the reaction [Colforsin affects the localization of AHR protein] |
CTD |
PMID:17329248 |
|
NCBI chr 1:155,823,590...155,915,434
Ensembl chr 1:155,813,180...155,915,434
|
|
G |
Pde4b |
phosphodiesterase 4B |
increases expression |
ISO |
Colforsin results in increased expression of PDE4B mRNA |
CTD |
PMID:15967414 |
|
NCBI chr 5:116,799,819...117,369,155
Ensembl chr 5:116,799,971...117,367,696
|
|
G |
Pde4d |
phosphodiesterase 4D |
increases expression |
ISO |
Colforsin results in increased expression of PDE4D mRNA |
CTD |
PMID:15967414 |
|
NCBI chr 2:40,014,933...41,529,190
Ensembl chr 2:40,019,933...41,525,884
|
|
G |
Pdk1 |
pyruvate dehydrogenase kinase 1 |
affects response to substance multiple interactions |
ISO |
PDK1 protein affects the susceptibility to Colforsin [PDK1 protein affects the susceptibility to Colforsin] which affects the abundance of Cyclic AMP; tubacin affects the reaction [[PDK1 protein affects the susceptibility to Colforsin] which affects the abundance of Cyclic AMP] |
CTD |
PMID:28887310 |
|
NCBI chr 3:56,705,824...56,733,040
Ensembl chr 3:56,705,871...56,733,038
|
|
G |
Penk |
proenkephalin |
multiple interactions increases expression |
EXP |
Cycloheximide promotes the reaction [Colforsin results in increased expression of PENK mRNA]; Dexamethasone promotes the reaction [Colforsin results in increased expression of PENK mRNA] |
CTD |
PMID:11113530 |
|
NCBI chr 5:17,183,799...17,189,160
Ensembl chr 5:17,183,806...17,189,129
|
|
G |
Per1 |
period circadian regulator 1 |
multiple interactions increases expression |
ISO |
[Colforsin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of PER1 mRNA; AHR protein inhibits the reaction [[Colforsin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of PER1 mRNA]; beta-Naphthoflavone inhibits the reaction [Colforsin results in increased expression of PER1 mRNA] |
CTD |
PMID:23291558 |
|
NCBI chr10:53,800,126...53,814,963
Ensembl chr10:53,805,535...53,814,431
|
|
G |
Pgf |
placental growth factor |
increases expression multiple interactions |
ISO |
Colforsin results in increased expression of PGF mRNA perfluorooctane sulfonic acid inhibits the reaction [Colforsin results in increased expression of PGF mRNA] |
CTD |
PMID:33144174 |
|
NCBI chr 6:104,816,102...104,826,685
Ensembl chr 6:104,816,104...104,826,685
|
|
G |
Pgr |
progesterone receptor |
increases expression |
ISO |
Colforsin results in increased expression of PGR mRNA |
CTD |
PMID:20378682 |
|
NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Pias1 |
protein inhibitor of activated STAT, 1 |
decreases expression |
ISO |
Colforsin results in decreased expression of PIAS1 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr 8:63,338,150...63,451,670
Ensembl chr 8:63,338,150...63,438,905
|
|
G |
Pink1 |
PTEN induced kinase 1 |
multiple interactions |
ISO |
PINK1 protein affects the reaction [Colforsin results in decreased expression of DNM1L protein] |
CTD |
PMID:24792327 |
|
NCBI chr 5:150,530,523...150,542,635
Ensembl chr 5:150,530,523...150,542,635
|
|
G |
Pla2g2a |
phospholipase A2 group IIA |
multiple interactions |
ISO |
Colforsin inhibits the reaction [IFNG protein promotes the reaction [decitabine results in increased expression of PLA2G2A protein]] |
CTD |
PMID:18953428 |
|
NCBI chr 5:151,076,442...151,079,019
Ensembl chr 5:151,076,442...151,079,014
|
|
G |
Pnpla2 |
patatin-like phospholipase domain containing 2 |
multiple interactions |
ISO |
PNPLA2 protein affects the reaction [Colforsin results in increased phosphorylation of and results in increased activity of PRKAA1 protein] |
CTD |
PMID:18390901 |
|
NCBI chr 1:196,552,723...196,557,805
Ensembl chr 1:196,552,723...196,557,805
|
|
G |
Pnpla6 |
patatin-like phospholipase domain containing 6 |
multiple interactions increases expression |
ISO |
1-Methyl-3-isobutylxanthine promotes the reaction [Colforsin results in increased expression of and results in increased activity of PNPLA6 protein]; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PNPLA6 mRNA; Colforsin results in increased expression of and results in increased activity of PNPLA6 protein; Cycloheximide inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of PNPLA6 protein]; Cycloheximide inhibits the reaction [Colforsin results in increased activity of PNPLA6 protein] Colforsin results in increased expression of PNPLA6 mRNA |
CTD |
PMID:20380879 |
|
NCBI chr12:1,574,387...1,603,735
Ensembl chr12:1,560,363...1,603,734
|
|
G |
Pomc |
proopiomelanocortin |
multiple interactions |
ISO |
Colforsin inhibits the reaction [diethyl phosphate results in decreased secretion of POMC protein] |
CTD |
PMID:35777568 |
|
NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664
|
|
G |
Pou1f1 |
POU class 1 homeobox 1 |
multiple interactions |
EXP |
Colforsin promotes the reaction [CREB1 protein binds to POU1F1 promoter]; resveratrol inhibits the reaction [Colforsin promotes the reaction [CREB1 protein binds to POU1F1 promoter]] |
CTD |
PMID:23292070 |
|
NCBI chr11:3,316,818...3,334,804
Ensembl chr11:3,317,058...3,334,801
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
decreases expression |
ISO |
Colforsin results in decreased expression of PPARG mRNA |
CTD |
PMID:31278978 |
|
NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
increases expression |
ISO |
Colforsin results in increased expression of PPARGC1A mRNA |
CTD |
PMID:16357189 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Ppargc1b |
PPARG coactivator 1 beta |
increases expression |
ISO |
Colforsin results in increased expression of PPARGC1B mRNA |
CTD |
PMID:16357189 |
|
NCBI chr18:54,758,891...54,861,103
Ensembl chr18:54,758,902...54,861,194
|
|
G |
Ppp1r12a |
protein phosphatase 1, regulatory subunit 12A |
increases phosphorylation multiple interactions |
ISO |
Colforsin results in increased phosphorylation of PPP1R12A protein Capsaicin inhibits the reaction [Colforsin results in increased phosphorylation of PPP1R12A protein]; capsazepine inhibits the reaction [Colforsin results in increased phosphorylation of PPP1R12A protein] |
CTD |
PMID:21474433 |
|
NCBI chr 7:43,482,808...43,593,689
Ensembl chr 7:43,482,803...43,593,425
|
|
G |
Ppp1r1b |
protein phosphatase 1, regulatory (inhibitor) subunit 1B |
increases phosphorylation multiple interactions |
ISO |
Colforsin results in increased phosphorylation of PPP1R1B protein PDE1B protein affects the reaction [Colforsin results in increased phosphorylation of PPP1R1B protein] |
CTD |
PMID:12077213 |
|
NCBI chr10:83,347,731...83,356,775
Ensembl chr10:83,347,731...83,356,775
|
|
G |
Prdx2 |
peroxiredoxin 2 |
increases expression multiple interactions decreases expression |
ISO |
Colforsin results in increased expression of PRDX2 mRNA S-(1,2-dichlorovinyl)cysteine inhibits the reaction [Colforsin results in increased expression of PRDX2 mRNA] Colforsin results in decreased expression of PRDX2 mRNA |
CTD |
PMID:36336211 |
|
NCBI chr19:23,180,927...23,186,217
Ensembl chr19:23,180,930...23,186,194
|
|
G |
Prima1 |
proline rich membrane anchor 1 |
increases expression |
EXP |
Colforsin results in increased expression of PRIMA1 mRNA |
CTD |
PMID:18514641 |
|
NCBI chr 6:122,338,365...122,390,955
Ensembl chr 6:122,338,370...122,389,921
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
multiple interactions |
ISO |
Colforsin results in increased phosphorylation of and results in increased activity of PRKAA1 protein; PNPLA2 protein affects the reaction [Colforsin results in increased phosphorylation of and results in increased activity of PRKAA1 protein] |
CTD |
PMID:18390901 |
|
NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978
|
|
G |
Prkaca |
protein kinase cAMP-activated catalytic subunit alpha |
multiple interactions increases activity |
EXP ISO |
Colforsin inhibits the reaction [Oxidopamine results in decreased phosphorylation of PRKACA protein] Colforsin results in increased activity of PRKACA protein |
CTD |
PMID:16339297 PMID:28601556 |
|
NCBI chr19:24,155,081...24,178,430
Ensembl chr19:24,155,090...24,178,430
|
|
G |
Prkacb |
protein kinase cAMP-activated catalytic subunit beta |
multiple interactions |
ISO |
[PRKACB protein mutant form results in increased susceptibility to [Colforsin co-treated with 1-Methyl-3-isobutylxanthine]] results in decreased stability of [PRKACB protein mutant form binds to PRKAR1A protein]; [PRKACB protein mutant form results in increased susceptibility to [Colforsin co-treated with 1-Methyl-3-isobutylxanthine]] results in decreased stability of [PRKACB protein mutant form binds to PRKAR1B protein]; PRKACB protein mutant form results in increased susceptibility to [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] |
CTD |
PMID:29669941 |
|
NCBI chr 2:235,636,878...235,726,928
Ensembl chr 2:235,636,885...235,726,198
|
|
G |
Prkar1a |
protein kinase cAMP-dependent type I regulatory subunit alpha |
multiple interactions |
ISO |
[PRKACB protein mutant form results in increased susceptibility to [Colforsin co-treated with 1-Methyl-3-isobutylxanthine]] results in decreased stability of [PRKACB protein mutant form binds to PRKAR1A protein] |
CTD |
PMID:29669941 |
|
NCBI chr10:94,621,042...94,639,534
Ensembl chr10:94,620,039...94,639,041
|
|
G |
Prkar1b |
protein kinase cAMP-dependent type I regulatory subunit beta |
multiple interactions |
ISO |
[PRKACB protein mutant form results in increased susceptibility to [Colforsin co-treated with 1-Methyl-3-isobutylxanthine]] results in decreased stability of [PRKACB protein mutant form binds to PRKAR1B protein] |
CTD |
PMID:29669941 |
|
NCBI chr12:15,492,233...15,624,942
Ensembl chr12:15,511,801...15,624,942
|
|
G |
Prkar2a |
protein kinase cAMP-dependent type II regulatory subunit alpha |
increases phosphorylation |
ISO |
Colforsin results in increased phosphorylation of PRKAR2A protein |
CTD |
PMID:25943029 |
|
NCBI chr 8:109,393,189...109,458,832
Ensembl chr 8:109,395,833...109,455,628
|
|
G |
Prl |
prolactin |
multiple interactions increases expression |
EXP ISO |
Colforsin inhibits the reaction [Octreotide results in decreased secretion of PRL protein]; Octreotide inhibits the reaction [Colforsin results in increased expression of PRL protein] [Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased expression of PRL mRNA; [Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased secretion of PRL protein; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased expression of PRL mRNA]; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased secretion of PRL protein]; Cannabinol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased expression of PRL mRNA]; Cannabinol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased secretion of PRL protein]; Dronabinol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased expression of PRL mRNA]; Dronabinol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased secretion of PRL protein]; Rimonabant inhibits the reaction [Dronabinol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased expression of PRL mRNA]] |
CTD |
PMID:1322274 PMID:31154070 |
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
G |
Ptcd1 |
pentatricopeptide repeat domain 1 |
multiple interactions |
ISO |
[Colforsin co-treated with Diethylhexyl Phthalate] affects the expression of ATP5MF-PTCD1 mRNA |
CTD |
PMID:35892601 |
|
NCBI chr12:9,445,656...9,463,434
Ensembl chr12:9,445,714...9,463,508
|
|
G |
Ptch1 |
patched 1 |
multiple interactions |
EXP |
Colforsin inhibits the reaction [Carbon Tetrachloride results in increased expression of PTCH1 mRNA] |
CTD |
PMID:27590029 |
|
NCBI chr17:1,542,705...1,607,730
Ensembl chr17:1,542,877...1,607,333
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions increases expression |
ISO EXP |
Colforsin promotes the reaction [bisperoxovanadium results in increased expression of PTGS2 mRNA]; Colforsin promotes the reaction [IL1B protein results in increased expression of PTGS2 protein] Colforsin results in increased expression of PTGS2 mRNA bifenthrin inhibits the reaction [Colforsin results in increased expression of PTGS2 mRNA]; Colforsin inhibits the reaction [Carbon Tetrachloride results in increased expression of PTGS2 protein] Colforsin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA]; Colforsin promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA] |
CTD |
PMID:11112151 PMID:12493747 PMID:15213229 PMID:17407152 PMID:19063610 PMID:20378682 PMID:21251947 PMID:27590029 More...
|
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rap1a |
RAP1A, member of RAS oncogene family |
increases activity multiple interactions |
EXP |
Colforsin results in increased activity of RAP1A protein Rolipram affects the reaction [Colforsin results in increased activity of RAP1A protein] |
CTD |
PMID:10908723 |
|
NCBI chr 2:193,208,631...193,286,513
Ensembl chr 2:193,208,635...193,286,501
|
|
G |
Rap1b |
RAP1B, member of RAS oncogene family |
multiple interactions increases activity |
EXP |
Rolipram affects the reaction [Colforsin results in increased activity of RAP1B protein] |
CTD |
PMID:10908723 |
|
NCBI chr 7:53,423,039...53,456,349
Ensembl chr 7:53,423,130...53,456,370
|
|
G |
Rarres2 |
retinoic acid receptor responder 2 |
multiple interactions |
EXP |
RARRES2 protein inhibits the reaction [Colforsin results in increased expression of CYP11A1 protein]; RARRES2 protein inhibits the reaction [Colforsin results in increased expression of CYP19A1 protein] |
CTD |
PMID:22948218 |
|
NCBI chr 4:77,522,549...77,525,733
Ensembl chr 4:77,522,535...77,525,556
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
multiple interactions |
ISO |
[Colforsin co-treated with Theophylline] inhibits the reaction [Etoposide results in decreased phosphorylation of RB1 protein] |
CTD |
PMID:9454737 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP ISO |
Colforsin inhibits the reaction [Carbon Tetrachloride results in increased expression of RELA protein]; Colforsin inhibits the reaction [Morphine results in increased phosphorylation of RELA protein] RELA affects the reaction [[monobutyl phthalate co-treated with Colforsin] results in increased secretion of Progesterone] |
CTD |
PMID:22258905 PMID:26745512 PMID:27590029 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Relb |
RELB proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
Colforsin promotes the reaction [[AHR protein binds to RELB protein] which binds to CXCL8 promoter]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin promotes the reaction [[AHR protein binds to RELB protein] which binds to CXCL8 promoter]] |
CTD |
PMID:17823304 |
|
NCBI chr 1:79,257,738...79,285,490
Ensembl chr 1:79,257,725...79,285,507
|
|
G |
Ren |
renin |
increases expression multiple interactions increases secretion |
ISO |
Colforsin results in increased expression of REN mRNA [Sodium, Dietary deficiency results in increased susceptibility to Colforsin] which results in increased secretion of REN protein Colforsin results in increased secretion of REN protein |
CTD |
PMID:9256163 PMID:10432392 |
|
NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
|
|
G |
Rnf4 |
ring finger protein 4 |
multiple interactions |
EXP |
[Tetradecanoylphorbol Acetate co-treated with Colforsin] results in increased expression of RNF4 mRNA |
CTD |
PMID:14749358 |
|
NCBI chr14:76,401,292...76,423,270
Ensembl chr14:76,401,299...76,422,566
|
|
G |
Rrp12 |
ribosomal RNA processing 12 |
increases expression |
ISO |
Colforsin results in increased expression of RRP12 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr 1:240,672,378...240,705,992
Ensembl chr 1:240,672,382...240,706,018
|
|
G |
Runx1 |
RUNX family transcription factor 1 |
affects splicing multiple interactions |
EXP |
Colforsin affects the splicing of RUNX1 exon HNRNPA1 mutant form inhibits the reaction [Colforsin affects the splicing of RUNX1 exon] |
CTD |
PMID:22684629 |
|
NCBI chr11:31,839,880...32,074,427
Ensembl chr11:31,843,764...32,074,542
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
increases expression |
EXP |
Colforsin results in increased expression of RUNX2 mRNA |
CTD |
PMID:20197312 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
Sdc1 |
syndecan 1 |
increases expression multiple interactions |
ISO |
Colforsin results in increased expression of SDC1 mRNA [Cadmium Chloride results in increased abundance of Cadmium] inhibits the reaction [Colforsin results in increased expression of SDC1 mRNA] |
CTD |
PMID:35908931 PMID:38296531 |
|
NCBI chr 6:31,562,799...31,585,267
Ensembl chr 6:31,562,739...31,585,264
|
|
G |
Sele |
selectin E |
multiple interactions |
ISO |
[Colforsin co-treated with Rolipram] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of SELE protein]; [Colforsin co-treated with Rolipram] inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of SELE protein]; [Colforsin co-treated with Rolipram] inhibits the reaction [TNF protein results in increased expression of SELE protein]; [Colforsin co-treated with Rolipram] inhibits the reaction [TNF protein results in increased secretion of SELE protein] |
CTD |
PMID:8780174 |
|
NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741
|
|
G |
Selenop |
selenoprotein P |
multiple interactions |
EXP |
Colforsin promotes the reaction [Dexamethasone results in increased expression of SELENOP mRNA] |
CTD |
PMID:18972406 |
|
NCBI chr 2:52,498,123...52,508,409
Ensembl chr 2:52,498,339...52,508,852
|
|
G |
Sesn1 |
sestrin 1 |
decreases expression multiple interactions |
ISO |
Colforsin results in decreased expression of SESN1 mRNA; Colforsin results in decreased expression of SESN1 protein AR protein affects the reaction [Colforsin results in decreased expression of SESN1 protein] |
CTD |
PMID:16751804 |
|
NCBI chr20:45,294,876...45,387,698
Ensembl chr20:45,294,871...45,387,697
|
|
G |
Sftpc |
surfactant protein C |
increases expression |
ISO |
Colforsin results in increased expression of SFTPC mRNA |
CTD |
PMID:2539393 |
|
NCBI chr15:45,596,565...45,599,615
Ensembl chr15:45,596,574...45,610,777
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions |
EXP ISO |
SIRT1 mutant form inhibits the reaction [Resveratrol inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]]; SIRT1 protein inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; SIRT1 protein mutant form inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein] Colforsin inhibits the reaction [Caffeine results in decreased expression of SIRT1 mRNA] |
CTD |
PMID:23292070 PMID:30825513 |
|
NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Slc1a5 |
solute carrier family 1 member 5 |
multiple interactions decreases expression |
ISO |
Valproic Acid promotes the reaction [Colforsin results in decreased expression of SLC1A5 protein] Colforsin results in decreased expression of SLC1A5 mRNA; Colforsin results in decreased expression of SLC1A5 protein |
CTD |
PMID:37385477 |
|
NCBI chr 1:77,456,849...77,470,952
Ensembl chr 1:77,456,694...77,470,952
|
|
G |
Slc26a4 |
solute carrier family 26 member 4 |
increases expression |
ISO |
Colforsin results in increased expression of SLC26A4 protein |
CTD |
PMID:22811483 |
|
NCBI chr 6:48,107,575...48,153,762
Ensembl chr 6:48,107,588...48,145,703
|
|
G |
Slc2a1 |
solute carrier family 2 member 1 |
multiple interactions increases expression |
ISO |
cobaltous chloride inhibits the reaction [Valproic Acid inhibits the reaction [Colforsin results in increased expression of SLC2A1 protein]]; Valproic Acid inhibits the reaction [Colforsin results in increased expression of SLC2A1 protein] |
CTD |
PMID:38296531 |
|
NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
multiple interactions |
ISO |
Colforsin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of SLC2A4 mRNA] |
CTD |
PMID:17407152 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Slc2a5 |
solute carrier family 2 member 5 |
multiple interactions increases expression |
ISO EXP |
Colforsin promotes the reaction [Fructose results in increased expression of SLC2A5 mRNA]; Colforsin promotes the reaction [Glucose results in increased expression of SLC2A5 mRNA] [[Colforsin results in increased abundance of Cyclic AMP] which results in increased expression of SLC2A5 protein] which results in increased uptake of Fructose; [Colforsin results in increased abundance of Cyclic AMP] which results in increased expression of SLC2A5 protein; Colforsin results in increased expression of and results in decreased degradation of SLC2A5 mRNA Colforsin results in increased expression of SLC2A5 mRNA |
CTD |
PMID:8037665 PMID:12820898 |
|
NCBI chr 5:160,583,055...160,609,994
Ensembl chr 5:160,583,234...160,611,106
|
|
G |
Slc30a1 |
solute carrier family 30 member 1 |
increases expression |
ISO |
Colforsin results in increased expression of SLC30A1 mRNA |
CTD |
PMID:16503475 |
|
NCBI chr13:103,491,037...103,494,910
Ensembl chr13:103,491,037...103,494,910
|
|
G |
Slc30a2 |
solute carrier family 30 member 2 |
increases expression |
ISO |
Colforsin results in increased expression of SLC30A2 mRNA |
CTD |
PMID:16503475 |
|
NCBI chr 5:146,559,733...146,571,957
Ensembl chr 5:146,559,733...146,571,956
|
|
G |
Slc30a4 |
solute carrier family 30 member 4 |
increases expression |
ISO |
Colforsin results in increased expression of SLC30A4 mRNA |
CTD |
PMID:16503475 |
|
NCBI chr 3:109,753,270...109,775,306
Ensembl chr 3:109,753,273...109,775,306
|
|
G |
Slc30a7 |
solute carrier family 30 member 7 |
decreases expression |
ISO |
Colforsin results in decreased expression of SLC30A7 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr 2:203,855,484...203,922,155
Ensembl chr 2:203,859,175...203,922,132
|
|
G |
Slc3a2 |
solute carrier family 3 member 2 |
increases expression |
ISO |
Colforsin results in increased expression of SLC3A2 mRNA |
CTD |
PMID:28786956 |
|
NCBI chr 1:205,604,468...205,618,931
Ensembl chr 1:205,604,468...205,618,931
|
|
G |
Slc45a2 |
solute carrier family 45, member 2 |
increases expression |
ISO |
Colforsin results in increased expression of SLC45A2 mRNA |
CTD |
PMID:17460731 |
|
NCBI chr 2:59,963,599...59,996,408
Ensembl chr 2:59,963,706...59,996,317
|
|
G |
Slc5a5 |
solute carrier family 5 member 5 |
multiple interactions increases expression |
ISO EXP |
Colforsin inhibits the reaction [[Tretinoin co-treated with Hydrocortisone] results in increased activity of SLC5A5 protein] Colforsin results in increased expression of SLC5A5 mRNA; Colforsin results in increased expression of SLC5A5 protein |
CTD |
PMID:16439463 PMID:16954431 |
|
NCBI chr16:18,546,709...18,556,698
Ensembl chr16:18,546,709...18,556,697
|
|
G |
Slc7a5 |
solute carrier family 7 member 5 |
increases expression |
ISO |
Colforsin results in increased expression of SLC7A5 mRNA; Colforsin results in increased expression of SLC7A5 protein |
CTD |
PMID:28786956 |
|
NCBI chr19:49,935,220...49,963,823
Ensembl chr19:49,935,220...49,963,823
|
|
G |
Slc7a8 |
solute carrier family 7 member 8 |
increases expression |
ISO |
Colforsin results in increased expression of SLC7A8 mRNA |
CTD |
PMID:28786956 |
|
NCBI chr15:28,183,013...28,242,717
Ensembl chr15:28,183,015...28,242,717
|
|
G |
Smo |
smoothened, frizzled class receptor |
multiple interactions |
EXP |
Colforsin inhibits the reaction [Carbon Tetrachloride results in increased expression of SMO mRNA] |
CTD |
PMID:27590029 |
|
NCBI chr 4:58,343,626...58,373,823
Ensembl chr 4:58,343,529...58,373,829
|
|
G |
Snai1 |
snail family transcriptional repressor 1 |
decreases expression |
ISO |
Colforsin results in decreased expression of SNAI1 mRNA |
CTD |
PMID:30983542 |
|
NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969
|
|
G |
Snai2 |
snail family transcriptional repressor 2 |
decreases expression |
ISO |
Colforsin results in decreased expression of SNAI2 mRNA |
CTD |
PMID:30983542 |
|
NCBI chr11:86,182,788...86,186,203
Ensembl chr11:86,181,909...86,186,200
|
|
G |
Snap25 |
synaptosome associated protein 25 |
affects splicing multiple interactions |
EXP |
Colforsin affects the splicing of SNAP25 exon Colforsin promotes the reaction [HNRNPK protein binds to SNAP25 exon]; HNRNPA1 mutant form inhibits the reaction [Colforsin affects the splicing of SNAP25 exon]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin affects the splicing of SNAP25 exon] |
CTD |
PMID:22684629 |
|
NCBI chr 3:124,041,898...124,123,761
Ensembl chr 3:124,041,898...124,123,760
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
multiple interactions increases expression |
ISO |
Colforsin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of SOCS3 mRNA] Colforsin results in increased expression of SOCS3 protein 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide inhibits the reaction [[[Colforsin co-treated with Rolipram] results in increased abundance of Cyclic AMP] which results in increased expression of SOCS3 protein]; [[Colforsin co-treated with Rolipram] results in increased abundance of Cyclic AMP] which results in increased expression of SOCS3 protein; dorsomorphin inhibits the reaction [[[Colforsin co-treated with Rolipram] results in increased abundance of Cyclic AMP] which results in increased expression of SOCS3 protein] |
CTD |
PMID:17407152 PMID:23782265 |
|
NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
ISO |
[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD1 mRNA; [EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD1 protein; Acetylcysteine inhibits the reaction [[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD1 mRNA]; Acetylcysteine inhibits the reaction [[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD1 protein] |
CTD |
PMID:32092105 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
increases expression multiple interactions increases activity |
ISO |
Colforsin results in increased expression of SOD2 mRNA [EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD2 mRNA; [EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD2 protein; Acetylcysteine inhibits the reaction [[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD2 mRNA]; Acetylcysteine inhibits the reaction [[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD2 protein] Colforsin results in increased activity of SOD2 protein |
CTD |
PMID:12093828 PMID:32092105 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sox2 |
SRY-box transcription factor 2 |
decreases expression |
ISO |
Colforsin results in decreased expression of SOX2 protein |
CTD |
PMID:34897981 |
|
NCBI chr 2:117,536,929...117,539,340
Ensembl chr 2:117,536,929...117,539,338
|
|
G |
Spcs3 |
signal peptidase complex subunit 3 |
increases expression |
ISO |
Colforsin results in increased expression of SPCS3 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr16:37,305,358...37,310,792
Ensembl chr16:37,305,305...37,331,746
|
|
G |
Sqstm1 |
sequestosome 1 |
increases degradation |
ISO |
Colforsin results in increased degradation of SQSTM1 protein |
CTD |
PMID:25943029 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Srd5a1 |
steroid 5 alpha-reductase 1 |
increases expression |
ISO |
Colforsin results in increased expression of SRD5A1 mRNA |
CTD |
PMID:22461451 |
|
NCBI chr 1:33,686,069...33,720,468
Ensembl chr 1:33,686,391...33,720,461
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
ISO |
Colforsin promotes the reaction [Diethylhexyl Phthalate results in decreased expression of SREBF1 protein] |
CTD |
PMID:37536456 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Srebf2 |
sterol regulatory element binding transcription factor 2 |
multiple interactions |
ISO |
Colforsin inhibits the reaction [Caffeine results in increased expression of SREBF2 mRNA] |
CTD |
PMID:30825513 |
|
NCBI chr 7:113,663,202...113,720,850
Ensembl chr 7:113,663,202...113,720,848
|
|
G |
Sst |
somatostatin |
multiple interactions |
ISO |
[SST protein co-treated with SSTR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP] |
CTD |
PMID:22056254 |
|
NCBI chr11:76,956,896...76,958,173
Ensembl chr11:76,956,896...76,958,173
|
|
G |
Sstr2 |
somatostatin receptor 2 |
multiple interactions |
ISO |
[64Cu-CB-TE2A-Y3-TATE co-treated with SSTR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [SST protein co-treated with SSTR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP] |
CTD |
PMID:22056254 |
|
NCBI chr10:98,664,204...98,671,370
Ensembl chr10:98,664,216...98,674,351
|
|
G |
Star |
steroidogenic acute regulatory protein |
multiple interactions increases expression |
ISO EXP |
[Colforsin co-treated with Diethylhexyl Phthalate] results in increased expression of STAR protein; BMP6 protein inhibits the reaction [Colforsin results in increased expression of STAR mRNA]; Hexachlorocyclohexane inhibits the reaction [Colforsin results in increased expression of STAR mRNA]; Valproic Acid inhibits the reaction [Colforsin results in increased expression of STAR mRNA] [Colforsin co-treated with deoxynivalenol] results in increased expression of STAR mRNA; Colforsin affects the reaction [Zearalenone results in increased expression of STAR mRNA]; ferulic acid analog promotes the reaction [Colforsin results in increased expression of STAR mRNA]; ferulic acid analog promotes the reaction [Colforsin results in increased expression of STAR protein]; NR4A1 protein inhibits the reaction [Ryanodine inhibits the reaction [Colforsin results in increased expression of STAR protein]]; Ryanodine inhibits the reaction [Colforsin results in increased expression of STAR mRNA]; Ryanodine inhibits the reaction [Colforsin results in increased expression of STAR protein]; W 7 inhibits the reaction [Colforsin results in increased expression of STAR mRNA]; W 7 inhibits the reaction [Colforsin results in increased expression of STAR protein] Colforsin results in increased expression of STAR mRNA; Colforsin results in increased expression of STAR protein [Atrazine co-treated with Colforsin] results in increased expression of STAR mRNA |
CTD |
PMID:14691014 PMID:15967414 PMID:16254025 PMID:16935330 PMID:17080404 PMID:18936084 PMID:20726872 PMID:22461451 PMID:23183170 PMID:25253736 PMID:25765474 PMID:25871633 PMID:26745512 PMID:26783879 PMID:28235592 PMID:28859905 PMID:31100596 PMID:34929288 PMID:35892601 PMID:36279966 PMID:37536456 More...
|
|
NCBI chr16:72,969,824...72,974,447
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Sult1e1 |
sulfotransferase family 1E member 1 |
decreases expression |
ISO |
Colforsin results in decreased expression of SULT1E1 mRNA |
CTD |
PMID:22446829 |
|
NCBI chr14:20,422,324...20,439,562
Ensembl chr14:20,422,324...20,439,275
|
|
G |
Sult2a1 |
sulfotransferase family 2A member 1 |
decreases expression multiple interactions |
ISO |
Colforsin results in decreased expression of SULT2A1 mRNA Hexachlorocyclohexane promotes the reaction [Colforsin results in decreased expression of SULT2A1 mRNA] |
CTD |
PMID:17080404 PMID:22446829 |
|
NCBI chr 1:75,451,178...75,508,113
Ensembl chr 1:74,911,100...75,508,134
|
|
G |
Sult2b1 |
sulfotransferase family 2B member 1 |
decreases expression |
ISO |
Colforsin results in decreased expression of SULT2B1 mRNA |
CTD |
PMID:22446829 |
|
NCBI chr 1:96,200,155...96,261,295
Ensembl chr 1:96,200,156...96,261,295
|
|
G |
Tac1 |
tachykinin, precursor 1 |
multiple interactions |
EXP |
Colforsin promotes the reaction [Capsaicin results in increased secretion of TAC1 protein]; HU 211 inhibits the reaction [Colforsin promotes the reaction [Capsaicin results in increased secretion of TAC1 protein]] |
CTD |
PMID:15750287 |
|
NCBI chr 4:35,679,183...35,687,180
Ensembl chr 4:35,679,704...35,687,178
|
|
G |
Tbr1 |
T-box brain transcription factor 1 |
multiple interactions |
EXP |
Colforsin promotes the reaction [CASK protein modified form binds to TBR1 protein] |
CTD |
PMID:20067577 |
|
NCBI chr 3:46,350,237...46,368,397
Ensembl chr 3:46,351,213...46,361,041
|
|
G |
Testin |
testin gene |
affects expression |
EXP |
Colforsin affects the expression of TESTIN mRNA |
CTD |
PMID:11090432 |
|
NCBI chr17:3,824,222...3,859,385
Ensembl chr17:3,846,899...3,859,385
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO EXP |
Colforsin inhibits the reaction [Dronabinol results in increased expression of TGFB1 protein]; TGFB1 protein inhibits the reaction [Colforsin results in increased expression of CYP17A1 mRNA] Colforsin inhibits the reaction [Carbon Tetrachloride results in increased expression of TGFB1 protein] |
CTD |
PMID:11779138 PMID:15625562 PMID:27590029 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tgs1 |
trimethylguanosine synthase 1 |
increases expression |
ISO |
Colforsin results in increased expression of TGS1 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr 5:16,524,864...16,558,399
Ensembl chr 5:16,524,874...16,558,399
|
|
G |
Th |
tyrosine hydroxylase |
multiple interactions increases expression increases activity |
EXP ISO |
3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol inhibits the reaction [Colforsin results in increased expression of TH mRNA]; bisindolylmaleimide I inhibits the reaction [Colforsin results in increased expression of TH mRNA]; HU 211 inhibits the reaction [Colforsin results in increased expression of TH mRNA]; KT 5720 inhibits the reaction [Colforsin results in increased expression of TH mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased expression of TH mRNA] Colforsin results in increased expression of TH protein Colforsin results in increased activity of TH protein Colforsin results in increased expression of TH mRNA; Colforsin results in increased expression of TH protein |
CTD |
PMID:9288946 PMID:14550852 PMID:18992715 PMID:34897981 |
|
NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
increases expression |
ISO |
Colforsin results in increased expression of TIMP1 mRNA |
CTD |
PMID:20378682 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Timp2 |
TIMP metallopeptidase inhibitor 2 |
multiple interactions increases expression |
EXP |
Colforsin inhibits the reaction [mono-(2-ethylhexyl)phthalate results in decreased expression of TIMP2 protein] Colforsin results in increased expression of TIMP2 protein |
CTD |
PMID:21832167 |
|
NCBI chr10:103,541,199...103,590,611
Ensembl chr10:103,531,505...103,590,611
|
|
G |
Tmem50a |
transmembrane protein 50A |
increases expression |
ISO |
Colforsin results in increased expression of TMEM50A mRNA |
CTD |
PMID:16751804 |
|
NCBI chr 5:147,123,670...147,138,859
Ensembl chr 5:147,123,688...147,138,849
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases expression |
ISO EXP |
Colforsin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of TNF mRNA]; Colforsin inhibits the reaction [TNF protein results in increased expression of CCL5 mRNA]; Colforsin inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA] [Colforsin co-treated with Rolipram] inhibits the reaction [TNF protein results in increased expression of SELE protein]; [Colforsin co-treated with Rolipram] inhibits the reaction [TNF protein results in increased secretion of SELE protein]; Colforsin inhibits the reaction [3,4-dihydroxyphenylethanol promotes the reaction [Lipopolysaccharides results in increased secretion of TNF protein]]; Colforsin inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Colforsin inhibits the reaction [Shiga Toxin results in increased expression of TNF mRNA]; Colforsin promotes the reaction [TNF protein results in increased expression of IL6 mRNA] Colforsin inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein]; Colforsin inhibits the reaction [Dopamine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]]; Colforsin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF protein]; Colforsin inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] Colforsin results in decreased expression of TNF protein |
CTD |
PMID:8780174 PMID:10495789 PMID:10996031 PMID:11675405 PMID:12509806 PMID:15081246 PMID:17407152 PMID:20388727 PMID:21803157 PMID:24771768 PMID:25866079 PMID:27590029 More...
|
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tob1 |
transducer of ErbB-2.1 |
increases expression |
ISO |
Colforsin results in increased expression of TOB1 mRNA |
CTD |
PMID:15313392 |
|
NCBI chr10:79,163,093...79,165,131
Ensembl chr10:79,160,154...79,165,215
|
|
G |
Tp53 |
tumor protein p53 |
increases expression |
ISO |
Colforsin results in increased expression of TP53 protein |
CTD |
PMID:10642304 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions |
EXP ISO |
Colforsin promotes the reaction [Capsaicin results in increased activity of TRPV1] Colforsin promotes the reaction [Capsaicin results in increased activity of TRPV1 protein]; Colforsin promotes the reaction [Capsaicin results in increased activity of TRPV1] |
CTD |
PMID:12886029 PMID:17913835 |
|
NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513
|
|
G |
Tubb3 |
tubulin, beta 3 class III |
increases expression |
ISO |
Colforsin results in increased expression of TUBB3 protein |
CTD |
PMID:34897981 |
|
NCBI chr19:51,457,187...51,466,243
Ensembl chr19:51,457,184...51,466,243
|
|
G |
Txnip |
thioredoxin interacting protein |
increases activity |
EXP |
Colforsin results in increased activity of TXNIP mRNA |
CTD |
PMID:21832250 |
|
NCBI chr 2:184,093,079...184,096,882
Ensembl chr 2:184,092,991...184,096,886
|
|
G |
Tyr |
tyrosinase |
increases activity decreases expression increases expression multiple interactions |
ISO |
Colforsin results in increased activity of TYR protein Colforsin results in decreased expression of TYR protein Colforsin results in increased expression of TYR protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one promotes the reaction [Colforsin results in increased expression of TYR protein]; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of TYR protein; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of TYR mRNA; [Colforsin co-treated with 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one] results in decreased expression of TYR protein; [Colforsin co-treated with Wortmannin co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in decreased expression of TYR protein; [Wortmannin co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] promotes the reaction [Colforsin results in increased expression of TYR protein]; alisol B inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of TYR protein]; alisol B inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of TYR mRNA]; glabridin inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of TYR protein] Colforsin results in increased expression of TYR mRNA [resveratrol co-treated with Colforsin] results in decreased activity of TYR protein; [Zinc analog co-treated with Copper analog] inhibits the reaction [Colforsin results in increased expression of TYR mRNA]; Colforsin results in increased expression of and results in increased activity of TYR protein; Particulate Matter inhibits the reaction [Colforsin results in increased expression of TYR mRNA] |
CTD |
PMID:17460731 PMID:23700242 PMID:28051915 PMID:28601556 PMID:28849034 |
|
NCBI chr 1:141,115,036...141,210,207
Ensembl chr 1:141,115,036...141,210,207
|
|
G |
Tyrp1 |
tyrosinase-related protein 1 |
increases expression multiple interactions |
ISO |
Colforsin results in increased expression of TYRP1 mRNA; Colforsin results in increased expression of TYRP1 protein [Zinc analog co-treated with Copper analog] inhibits the reaction [Colforsin results in increased expression of TYRP1 mRNA]; Particulate Matter inhibits the reaction [Colforsin results in increased expression of TYRP1 mRNA] |
CTD |
PMID:17460731 PMID:23700242 PMID:28601556 |
|
NCBI chr 5:95,280,982...95,299,516
Ensembl chr 5:95,280,982...95,299,516
|
|
G |
Ube2j1 |
ubiquitin-conjugating enzyme E2, J1 |
increases expression |
ISO |
Colforsin results in increased expression of UBE2J1 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr 5:47,422,476...47,441,476
Ensembl chr 5:47,422,587...47,441,461
|
|
G |
Ucp1 |
uncoupling protein 1 |
multiple interactions |
ISO |
Colforsin inhibits the reaction [geniposide results in decreased expression of UCP1 mRNA]; Colforsin inhibits the reaction [geniposide results in decreased expression of UCP1 protein] |
CTD |
PMID:34718029 |
|
NCBI chr19:24,808,782...24,816,853
Ensembl chr19:24,808,783...24,816,852
|
|
G |
Usf1 |
upstream transcription factor 1 |
multiple interactions |
ISO |
USF1 gene polymorphism promotes the reaction [Colforsin results in increased metabolism of Lipids]; USF1 protein affects the reaction [Colforsin results in increased metabolism of Lipids] |
CTD |
PMID:15985485 |
|
NCBI chr13:83,845,230...83,854,875
Ensembl chr13:83,822,035...83,854,885
|
|
G |
Vasp |
vasodilator-stimulated phosphoprotein |
increases phosphorylation multiple interactions |
ISO |
Colforsin results in increased phosphorylation of VASP protein N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of VASP protein] |
CTD |
PMID:18182247 PMID:32409581 |
|
NCBI chr 1:78,910,009...78,925,791
Ensembl chr 1:78,910,011...78,925,061
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions increases expression |
ISO |
Colforsin promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of VEGFA mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased expression of VEGFA mRNA] |
CTD |
PMID:10788502 PMID:19063610 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vim |
vimentin |
multiple interactions |
ISO |
VIM affects the reaction [[monobutyl phthalate co-treated with Colforsin] results in increased secretion of Progesterone] |
CTD |
PMID:26745512 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
G |
Wt1 |
WT1 transcription factor |
increases expression |
ISO |
Colforsin results in increased expression of WT1 mRNA |
CTD |
PMID:15961562 |
|
NCBI chr 3:91,566,540...91,613,653
Ensembl chr 3:91,567,001...91,613,643
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
multiple interactions |
ISO |
[[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of XIAP protein] which results in decreased susceptibility to Cisplatin; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of XIAP mRNA; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of XIAP protein |
CTD |
PMID:21255191 |
|
NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700
|
|
G |
Zbtb10 |
zinc finger and BTB domain containing 10 |
decreases expression |
ISO |
Colforsin results in decreased expression of ZBTB10 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr 2:92,475,254...92,509,892
Ensembl chr 2:92,479,014...92,512,515
|
|
G |
Zfp36l1 |
zinc finger protein 36, C3H type-like 1 |
increases expression |
EXP |
Colforsin results in increased expression of ZFP36L1 mRNA |
CTD |
PMID:23423171 |
|
NCBI chr 6:98,930,705...98,935,748
Ensembl chr 6:98,930,718...98,935,748
|
|
G |
Zfp36l2 |
zinc finger protein 36, C3H type-like 2 |
decreases expression |
ISO |
Colforsin results in decreased expression of ZFP36L2 mRNA |
CTD |
PMID:15967414 |
|
NCBI chr 6:10,490,032...10,494,073
Ensembl chr 6:10,490,032...10,494,064
|
|
|
G |
Ache |
acetylcholinesterase |
decreases activity affects binding multiple interactions affects activity |
ISO EXP |
Donepezil results in decreased activity of ACHE protein Donepezil binds to ACHE protein Donepezil inhibits the reaction [Celecoxib results in increased activity of ACHE protein]; Donepezil inhibits the reaction [Scopolamine results in increased activity of ACHE protein]; Donepezil inhibits the reaction [Streptozocin results in increased activity of ACHE protein] ALB protein affects the reaction [Donepezil results in decreased activity of ACHE protein]; Donepezil binds to and results in decreased activity of ACHE protein; Donepezil inhibits the reaction [asoxime chloride inhibits the reaction [Sarin results in decreased activity of ACHE protein]]; Donepezil inhibits the reaction [Obidoxime Chloride metabolite results in decreased activity of ACHE protein]; Donepezil promotes the reaction [Obidoxime Chloride inhibits the reaction [Sarin results in decreased activity of ACHE protein]] Donepezil affects the activity of ACHE protein [Donepezil co-treated with Sodium Azide] results in increased activity of ACHE protein; AFDX 384 affects the reaction [Donepezil affects the activity of ACHE protein]; Donepezil inhibits the reaction [Streptozocin results in increased activity of ACHE protein] |
CTD |
PMID:9228650 PMID:12111444 PMID:12589378 PMID:14535624 PMID:15135892 PMID:18061284 PMID:18208924 PMID:18343489 PMID:18571635 PMID:19345205 PMID:19705549 PMID:23060470 PMID:25522658 PMID:26902639 PMID:27238725 PMID:30481507 PMID:31176713 PMID:34371027 PMID:36249784 More...
|
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Alb |
albumin |
multiple interactions |
ISO |
ALB protein affects the reaction [Donepezil results in decreased activity of ACHE protein] |
CTD |
PMID:26902639 |
|
NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,607,381...17,622,836
|
|
G |
App |
amyloid beta precursor protein |
increases abundance decreases response to substance multiple interactions |
ISO EXP |
Donepezil results in increased abundance of APP protein Donepezil results in decreased susceptibility to APP protein Donepezil inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in increased expression of APP protein alternative form]; Donepezil inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in increased expression of APP protein]; Donepezil inhibits the reaction [APP protein modified form results in increased expression of TNF protein] Donepezil inhibits the reaction [APP protein modified form affects the localization of RELA protein]; Donepezil inhibits the reaction [APP protein modified form results in increased expression of NOS2 protein]; Donepezil inhibits the reaction [APP protein modified form results in increased expression of PTGS2 protein]; Donepezil inhibits the reaction [APP protein modified form results in increased expression of TNF protein]; Donepezil inhibits the reaction [Streptozocin results in increased expression of APP protein] |
CTD |
PMID:18061284 PMID:18571635 PMID:24189446 PMID:28734741 PMID:30481507 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Arg1 |
arginase 1 |
multiple interactions |
ISO |
Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium inhibits the reaction [IL4 protein results in increased expression of ARG1 mRNA]]; Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium inhibits the reaction [IL4 protein results in increased expression of ARG1 protein]] |
CTD |
PMID:26114860 |
|
NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422
|
|
G |
Bace1 |
beta-secretase 1 |
multiple interactions |
ISO |
Donepezil inhibits the reaction [Streptozocin results in increased expression of BACE1 protein] |
CTD |
PMID:30481507 |
|
NCBI chr 8:46,142,060...46,166,268
Ensembl chr 8:46,142,116...46,165,876
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
Donepezil inhibits the reaction [Scopolamine results in increased expression of BAX protein] |
CTD |
PMID:34371027 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bche |
butyrylcholinesterase |
decreases activity |
ISO EXP |
Donepezil results in decreased activity of BCHE protein |
CTD |
PMID:16036213 PMID:18656440 PMID:19345205 |
|
NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP ISO |
Donepezil inhibits the reaction [Hydrogen Peroxide results in decreased expression of BCL2 protein] Donepezil inhibits the reaction [Scopolamine results in decreased expression of BCL2 protein] |
CTD |
PMID:19345205 PMID:34371027 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions |
ISO |
Donepezil inhibits the reaction [Scopolamine results in decreased expression of BDNF mRNA] |
CTD |
PMID:34371027 |
|
NCBI chr 3:116,619,633...116,670,212
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Casp3 |
caspase 3 |
increases activity multiple interactions |
ISO EXP |
Donepezil results in increased activity of CASP3 protein Donepezil inhibits the reaction [Scopolamine results in increased activity of CASP3 protein] Donepezil inhibits the reaction [Hydrogen Peroxide results in decreased expression of CASP3 protein] |
CTD |
PMID:19345205 PMID:20522977 PMID:34371027 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
increases activity |
ISO |
Donepezil results in increased activity of CASP8 protein |
CTD |
PMID:20522977 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases activity |
ISO |
Donepezil results in increased activity of CASP9 protein |
CTD |
PMID:20522977 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
Donepezil inhibits the reaction [Scopolamine results in decreased activity of CAT protein]; Donepezil inhibits the reaction [Streptozocin results in decreased activity of CAT protein] |
CTD |
PMID:30481507 PMID:34371027 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cdk5 |
cyclin-dependent kinase 5 |
multiple interactions |
EXP |
Donepezil inhibits the reaction [amyloid beta-protein (1-42) results in increased expression of CDK5 protein] |
CTD |
PMID:36474082 |
|
NCBI chr 4:10,754,682...10,760,110
Ensembl chr 4:10,754,687...10,760,112
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions affects expression |
ISO |
Donepezil inhibits the reaction [Scopolamine results in decreased expression of EGR1 protein] EGR1 protein affects the reaction [Donepezil affects the expression of ICAM1 protein] Donepezil affects the expression of EGR1 mRNA; Donepezil affects the expression of EGR1 protein |
CTD |
PMID:29133030 PMID:32174113 |
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
F3 |
coagulation factor III, tissue factor |
affects expression |
ISO |
Donepezil affects the expression of F3 mRNA; Donepezil affects the expression of F3 protein |
CTD |
PMID:32174113 |
|
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Fiz1 |
FLT3-interacting zinc finger 1 |
multiple interactions |
ISO |
Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium inhibits the reaction [IL4 protein results in increased expression of FIZ1 mRNA]]; Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium inhibits the reaction [IL4 protein results in increased expression of FIZ1 protein]] |
CTD |
PMID:26114860 |
|
NCBI chr 1:68,822,741...68,835,723
Ensembl chr 1:68,829,130...68,835,723
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
Donepezil inhibits the reaction [Scopolamine results in decreased expression of FOS protein] |
CTD |
PMID:29133030 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
ISO EXP |
Donepezil inhibits the reaction [Lipopolysaccharides results in decreased phosphorylation of GSK3B protein] Donepezil inhibits the reaction [amyloid beta-protein (1-42) results in increased phosphorylation of GSK3B protein] |
CTD |
PMID:34874107 PMID:36474082 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions affects expression |
ISO |
EGR1 protein affects the reaction [Donepezil affects the expression of ICAM1 protein] Donepezil affects the expression of ICAM1 mRNA; Donepezil affects the expression of ICAM1 protein |
CTD |
PMID:32174113 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium inhibits the reaction [IL4 protein results in increased expression of IL10]] |
CTD |
PMID:26114860 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il13 |
interleukin 13 |
multiple interactions |
ISO |
Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium inhibits the reaction [IL4 protein results in increased expression of IL13]] |
CTD |
PMID:26114860 |
|
NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO EXP |
Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL1B mRNA]; Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL1B protein]; Donepezil inhibits the reaction [Streptozocin results in increased expression of IL1B protein]; Donepezil inhibits the reaction [Valproic Acid results in increased expression of IL1B protein] [Sodium Azide co-treated with Donepezil] results in increased expression of IL1B protein |
CTD |
PMID:26114860 PMID:30481507 PMID:31369746 PMID:36249784 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO |
Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium inhibits the reaction [IL4 protein results in increased expression of ARG1 mRNA]]; Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium inhibits the reaction [IL4 protein results in increased expression of ARG1 protein]]; Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium inhibits the reaction [IL4 protein results in increased expression of CHIL3 mRNA]]; Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium inhibits the reaction [IL4 protein results in increased expression of CHIL3 protein]]; Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium inhibits the reaction [IL4 protein results in increased expression of FIZ1 mRNA]]; Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium inhibits the reaction [IL4 protein results in increased expression of FIZ1 protein]]; Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium inhibits the reaction [IL4 protein results in increased expression of IL10]]; Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium inhibits the reaction [IL4 protein results in increased expression of IL13]]; Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium inhibits the reaction [IL4 protein results in increased expression of TGFB2]]; Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium inhibits the reaction [IL4 protein results in increased phosphorylation of STAT6 protein]] |
CTD |
PMID:26114860 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il6 |
interleukin 6 |
multiple interactions affects expression affects secretion |
ISO |
Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL6 mRNA]; Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL6 protein]; Donepezil inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; Donepezil inhibits the reaction [Streptozocin results in increased expression of IL6 protein]; Donepezil inhibits the reaction [Valproic Acid results in increased expression of IL6 protein] Donepezil affects the expression of IL6 mRNA Donepezil affects the secretion of IL6 protein |
CTD |
PMID:26114860 PMID:30481507 PMID:31369746 PMID:32174113 PMID:34874107 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
Donepezil inhibits the reaction [Scopolamine results in decreased expression of JUN protein] |
CTD |
PMID:29133030 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
EXP |
Donepezil inhibits the reaction [Streptozocin results in decreased phosphorylation of MAPK1 protein] |
CTD |
PMID:23562514 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
EXP |
Donepezil inhibits the reaction [Streptozocin results in decreased phosphorylation of MAPK3 protein] |
CTD |
PMID:23562514 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
EXP |
Donepezil inhibits the reaction [Hydrogen Peroxide results in decreased phosphorylation of MAPK8 protein] |
CTD |
PMID:19345205 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions |
EXP |
Donepezil inhibits the reaction [Hydrogen Peroxide results in decreased phosphorylation of MAPK9 protein] |
CTD |
PMID:19345205 |
|
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mapt |
microtubule-associated protein tau |
multiple interactions |
EXP |
Donepezil inhibits the reaction [amyloid beta-protein (1-42) results in increased phosphorylation of MAPT protein] |
CTD |
PMID:36474082 |
|
NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases expression multiple interactions |
ISO |
Donepezil results in decreased expression of MMP9 protein Donepezil results in decreased expression of and results in decreased activity of MMP9 protein |
CTD |
PMID:21750701 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO EXP |
Donepezil inhibits the reaction [Streptozocin results in increased activity of MPO protein] [Sodium Azide co-treated with Donepezil] results in increased activity of MPO protein |
CTD |
PMID:23060470 PMID:36249784 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
Donepezil inhibits the reaction [APP protein modified form results in increased expression of NOS2 protein]; Donepezil inhibits the reaction [Valproic Acid results in increased expression of NOS2 protein] |
CTD |
PMID:24189446 PMID:31369746 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nppb |
natriuretic peptide B |
decreases expression |
ISO |
Donepezil results in decreased expression of NPPB protein |
CTD |
PMID:19879468 |
|
NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
|
|
G |
Olr1 |
oxidized low density lipoprotein receptor 1 |
affects expression |
ISO |
Donepezil affects the expression of OLR1 mRNA; Donepezil affects the expression of OLR1 protein |
CTD |
PMID:32174113 |
|
NCBI chr 4:162,926,436...162,949,057
Ensembl chr 4:162,926,439...162,948,523
|
|
G |
Ppp1ca |
protein phosphatase 1 catalytic subunit alpha |
multiple interactions |
EXP |
Donepezil inhibits the reaction [amyloid beta-protein (1-42) results in decreased expression of PPP1CA protein] |
CTD |
PMID:36474082 |
|
NCBI chr 1:201,485,117...201,488,734
Ensembl chr 1:201,485,085...201,497,327
|
|
G |
Ppp2ca |
protein phosphatase 2 catalytic subunit alpha |
multiple interactions |
EXP |
Donepezil inhibits the reaction [amyloid beta-protein (1-42) results in decreased expression of PPP2CA protein] |
CTD |
PMID:36474082 |
|
NCBI chr10:36,358,110...36,377,864
Ensembl chr10:36,358,101...36,377,862
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
decreases expression multiple interactions affects expression |
ISO |
Donepezil results in decreased expression of PTGS1 mRNA [Rivastigmine co-treated with Donepezil] results in decreased expression of PTGS1 mRNA; [Rivastigmine co-treated with Donepezil] results in decreased expression of PTGS1 protein; [Sodium Fluoride co-treated with Donepezil] results in increased expression of PTGS1 mRNA; [Sodium Fluoride co-treated with Donepezil] results in increased expression of PTGS1 protein; [Sodium Fluoride co-treated with Rivastigmine co-treated with Donepezil] results in increased expression of PTGS1 mRNA; [Sodium Fluoride co-treated with Rivastigmine co-treated with Donepezil] results in increased expression of PTGS1 protein Donepezil affects the expression of PTGS1 protein |
CTD |
PMID:29777723 |
|
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions decreases expression |
ISO |
[Donepezil co-treated with Rivastigmine] results in decreased expression of PTGS2 protein; [Rivastigmine co-treated with Donepezil] results in decreased expression of PTGS2 mRNA Donepezil inhibits the reaction [APP protein modified form results in increased expression of PTGS2 protein]; Donepezil inhibits the reaction [Valproic Acid results in increased expression of PTGS2 protein] Donepezil results in decreased expression of PTGS2 mRNA; Donepezil results in decreased expression of PTGS2 protein |
CTD |
PMID:24189446 PMID:29777723 PMID:31369746 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
Donepezil inhibits the reaction [APP protein modified form affects the localization of RELA protein]; Donepezil inhibits the reaction [Lipopolysaccharides results in increased expression of RELA protein]; Donepezil inhibits the reaction [Valproic Acid results in increased expression of RELA protein] |
CTD |
PMID:24189446 PMID:31369746 PMID:34874107 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Donepezil inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
EXP |
Donepezil inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in decreased expression of SOD1 mRNA] |
CTD |
PMID:28734741 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod3 |
superoxide dismutase 3 |
multiple interactions |
EXP |
Donepezil inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in decreased expression of SOD3 mRNA] |
CTD |
PMID:28734741 |
|
NCBI chr14:58,610,104...58,615,845
Ensembl chr14:58,609,958...58,615,990
|
|
G |
Stat6 |
signal transducer and activator of transcription 6 |
multiple interactions |
ISO |
Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium inhibits the reaction [IL4 protein results in increased phosphorylation of STAT6 protein]] |
CTD |
PMID:26114860 |
|
NCBI chr 7:63,480,229...63,497,551
Ensembl chr 7:63,479,642...63,498,495
|
|
G |
Syp |
synaptophysin |
multiple interactions |
ISO |
Donepezil inhibits the reaction [Scopolamine results in decreased expression of SYP mRNA] |
CTD |
PMID:34371027 |
|
NCBI chr X:14,849,444...14,864,553
Ensembl chr X:14,849,444...14,864,745
|
|
G |
Tgfb2 |
transforming growth factor, beta 2 |
multiple interactions |
ISO |
Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium inhibits the reaction [IL4 protein results in increased expression of TGFB2]] |
CTD |
PMID:26114860 |
|
NCBI chr13:98,160,075...98,261,771
Ensembl chr13:98,160,087...98,261,405
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions affects expression affects secretion |
ISO EXP |
Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TNF mRNA]; Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TNF protein]; Donepezil inhibits the reaction [APP protein modified form results in increased expression of TNF protein]; Donepezil inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Donepezil inhibits the reaction [Streptozocin results in increased expression of TNF protein]; Donepezil inhibits the reaction [Valproic Acid results in increased expression of TNF protein] Donepezil affects the expression of TNF mRNA Donepezil affects the secretion of TNF protein [Sodium Azide co-treated with Donepezil] results in increased expression of TNF protein; Donepezil inhibits the reaction [APP protein modified form results in increased expression of TNF protein] |
CTD |
PMID:24189446 PMID:26114860 PMID:30481507 PMID:31369746 PMID:32174113 PMID:34874107 PMID:36249784 More...
|
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
EXP |
Donepezil inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 protein] |
CTD |
PMID:19345205 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
multiple interactions |
EXP |
Donepezil inhibits the reaction [Hydrogen Peroxide results in decreased expression of XIAP protein] |
CTD |
PMID:19345205 |
|
NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700
|
|
|
G |
Car2 |
carbonic anhydrase 2 |
multiple interactions |
ISO |
dorzolamide binds to and results in decreased activity of CA2 protein |
CTD |
PMID:17826101 |
|
NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818
|
|
G |
Car3 |
carbonic anhydrase 3 |
multiple interactions |
ISO |
dorzolamide binds to and results in decreased activity of CA3 protein |
CTD |
PMID:17826101 |
|
NCBI chr 2:86,770,418...86,780,011
Ensembl chr 2:86,770,420...86,784,280
|
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions |
ISO |
Erlotinib Hydrochloride inhibits the reaction [ABCG2 gene mutant form results in decreased susceptibility to Mitoxantrone]; Erlotinib Hydrochloride inhibits the reaction [ABCG2 protein results in decreased susceptibility to Mitoxantrone]; Erlotinib Hydrochloride inhibits the reaction [ABCG2 protein results in increased export of Methotrexate]; Erlotinib Hydrochloride inhibits the reaction [ABCG2 results in increased export of Methotrexate] |
CTD |
PMID:18829547 PMID:19232821 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
increases phosphorylation |
ISO |
Erlotinib Hydrochloride results in increased phosphorylation of ACACA protein |
CTD |
PMID:23707608 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Adgre1 |
adhesion G protein-coupled receptor E1 |
multiple interactions |
ISO |
[Interleukin 1 Receptor Antagonist Protein co-treated with Erlotinib Hydrochloride] results in decreased expression of ADGRE1 protein |
CTD |
PMID:27738319 |
|
NCBI chr 9:2,242,476...2,398,000
Ensembl chr 9:2,242,474...2,398,000
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation multiple interactions |
ISO |
Erlotinib Hydrochloride results in decreased phosphorylation of AKT1 protein Erlotinib Hydrochloride inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:21195724 PMID:30623574 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
multiple interactions |
ISO |
[Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in increased expression of APAF1 mRNA |
CTD |
PMID:29274334 |
|
NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540
|
|
G |
Areg |
amphiregulin |
affects response to substance |
ISO |
AREG protein affects the susceptibility to Erlotinib Hydrochloride |
CTD |
PMID:18980991 |
|
NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535
|
|
G |
Arf1 |
ARF GTPase 1 |
decreases response to substance |
ISO |
ARF1 mRNA results in decreased susceptibility to Erlotinib Hydrochloride |
CTD |
PMID:23125191 |
|
NCBI chr10:43,997,983...44,014,461
Ensembl chr10:43,997,986...44,014,434
|
|
G |
Atf4 |
activating transcription factor 4 |
increases expression |
EXP |
Erlotinib Hydrochloride results in increased expression of ATF4 protein |
CTD |
PMID:24768708 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Atg5 |
autophagy related 5 |
decreases response to substance increases expression |
ISO |
ATG5 protein results in decreased susceptibility to Erlotinib Hydrochloride Erlotinib Hydrochloride results in increased expression of ATG5 protein |
CTD |
PMID:21655094 PMID:23917044 |
|
NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209
|
|
G |
Atg7 |
autophagy related 7 |
increases expression |
ISO |
Erlotinib Hydrochloride results in increased expression of ATG7 protein |
CTD |
PMID:21655094 |
|
NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593
|
|
G |
Atm |
ATM serine/threonine kinase |
multiple interactions |
ISO |
Erlotinib Hydrochloride promotes the reaction [Arsenic Trioxide results in increased expression of ATM mRNA] |
CTD |
PMID:29274334 |
|
NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
|
|
G |
Atr |
ATR serine/threonine kinase |
multiple interactions increases expression |
ISO |
Erlotinib Hydrochloride promotes the reaction [Arsenic Trioxide results in increased expression of ATR mRNA] Erlotinib Hydrochloride results in increased expression of ATR mRNA |
CTD |
PMID:29274334 |
|
NCBI chr 8:96,426,704...96,524,152
Ensembl chr 8:96,426,724...96,524,136
|
|
G |
Axl |
Axl receptor tyrosine kinase |
decreases response to substance multiple interactions |
ISO |
AXL results in decreased susceptibility to Erlotinib Hydrochloride [amuvatinib results in decreased activity of AXL protein] which results in increased susceptibility to Erlotinib Hydrochloride; [GSK 1363089 results in decreased activity of AXL protein] which results in increased susceptibility to Erlotinib Hydrochloride |
CTD |
PMID:22751098 |
|
NCBI chr 1:81,265,088...81,296,278
Ensembl chr 1:81,265,088...81,296,265
|
|
G |
Bad |
BCL2-associated agonist of cell death |
multiple interactions |
ISO |
Erlotinib Hydrochloride promotes the reaction [Arsenic Trioxide results in increased expression of BAD mRNA] |
CTD |
PMID:29274334 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
Erlotinib Hydrochloride promotes the reaction [Arsenic Trioxide results in increased expression of BAX mRNA] |
CTD |
PMID:29274334 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
multiple interactions increases expression |
ISO |
[Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in increased expression of BBC3 mRNA; Erlotinib Hydrochloride promotes the reaction [Resveratrol results in increased expression of BBC3 protein]; Resveratrol promotes the reaction [Erlotinib Hydrochloride results in increased expression of BBC3 protein] |
CTD |
PMID:25895606 PMID:29274334 |
|
NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
increases expression multiple interactions |
ISO |
Erlotinib Hydrochloride results in increased expression of BCL2 mRNA; Erlotinib Hydrochloride results in increased expression of BCL2 protein [Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in decreased expression of BCL2 mRNA; [Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased expression of BCL2 protein]] which results in increased susceptibility to Erlotinib Hydrochloride; Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased expression of BCL2 protein] |
CTD |
PMID:23894143 PMID:29274334 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l11 |
Bcl2-like 11 |
multiple interactions increases expression |
ISO |
Harmine promotes the reaction [Erlotinib Hydrochloride results in increased expression of BCL2L11 protein] |
CTD |
PMID:30171258 |
|
NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
|
|
G |
Bcl2l2 |
Bcl2-like 2 |
increases expression multiple interactions |
ISO |
Erlotinib Hydrochloride results in increased expression of BCL2L2 mRNA; Erlotinib Hydrochloride results in increased expression of BCL2L2 protein [Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased expression of BCL2L2 protein]] which results in increased susceptibility to Erlotinib Hydrochloride; Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased expression of BCL2L2 protein] |
CTD |
PMID:23894143 |
|
NCBI chr15:28,346,449...28,361,627
Ensembl chr15:28,356,807...28,361,624
|
|
G |
Becn1 |
beclin 1 |
decreases response to substance |
ISO |
BECN1 protein results in decreased susceptibility to Erlotinib Hydrochloride |
CTD |
PMID:23917044 |
|
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions decreases expression |
ISO |
[Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in decreased expression of BIRC5 mRNA; Erlotinib Hydrochloride inhibits the reaction [Betulinic Acid results in decreased expression of BIRC5 protein]; Erlotinib Hydrochloride promotes the reaction [Resveratrol results in decreased expression of BIRC5 protein]; Resveratrol promotes the reaction [Erlotinib Hydrochloride results in decreased expression of BIRC5 protein] |
CTD |
PMID:25895606 PMID:29274334 PMID:30136359 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
multiple interactions |
ISO |
Erlotinib Hydrochloride inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 protein] |
CTD |
PMID:25981168 |
|
NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359
|
|
G |
Braf |
B-Raf proto-oncogene, serine/threonine kinase |
decreases activity |
ISO |
Erlotinib Hydrochloride results in decreased activity of BRAF protein mutant form |
CTD |
PMID:29407956 |
|
NCBI chr 4:68,375,484...68,510,652
Ensembl chr 4:68,384,649...68,510,463
|
|
G |
Brca1 |
BRCA1, DNA repair associated |
multiple interactions |
ISO |
[Erlotinib Hydrochloride results in decreased activity of EGFR protein] which results in decreased phosphorylation of BRCA1 protein |
CTD |
PMID:23548265 |
|
NCBI chr10:86,417,441...86,477,762
Ensembl chr10:86,418,000...86,477,304
|
|
G |
Casp3 |
caspase 3 |
increases cleavage multiple interactions increases activity |
ISO |
Erlotinib Hydrochloride results in increased cleavage of CASP3 protein [TWIST1 protein results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased cleavage of CASP3 protein Erlotinib Hydrochloride results in increased activity of CASP3 protein Erlotinib Hydrochloride promotes the reaction [resveratrol results in increased activity of CASP3 protein]; resveratrol promotes the reaction [Erlotinib Hydrochloride results in increased activity of CASP3 protein] |
CTD |
PMID:23125191 PMID:25895606 PMID:30171258 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased expression of CCL2 mRNA; [Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in increased expression of CCL2 mRNA |
CTD |
PMID:27738319 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccnb1 |
cyclin B1 |
multiple interactions |
ISO |
[Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in decreased expression of CCNB1 mRNA |
CTD |
PMID:29274334 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
Erlotinib Hydrochloride inhibits the reaction [sodium arsenite results in increased expression of CCND1 protein] |
CTD |
PMID:19168569 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cd69 |
Cd69 molecule |
decreases expression |
ISO |
Erlotinib Hydrochloride results in decreased expression of CD69 protein |
CTD |
PMID:21195724 |
|
NCBI chr 4:162,725,446...162,733,364
Ensembl chr 4:162,725,446...162,733,542
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions decreases expression |
ISO EXP |
Erlotinib Hydrochloride promotes the reaction [Deoxycholic Acid results in decreased glycosylation of and results in increased degradation of CDH1 protein]; Erlotinib Hydrochloride results in decreased glycosylation of and results in increased degradation of CDH1 protein Erlotinib Hydrochloride results in decreased expression of CDH1 mRNA; Erlotinib Hydrochloride results in decreased expression of CDH1 protein DDIT3 mutant form inhibits the reaction [Erlotinib Hydrochloride results in decreased expression of CDH1 protein] |
CTD |
PMID:22223758 PMID:24768708 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
decreases phosphorylation |
ISO |
Erlotinib Hydrochloride results in decreased phosphorylation of CDK4 protein |
CTD |
PMID:21195724 |
|
NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdk6 |
cyclin-dependent kinase 6 |
multiple interactions decreases expression |
ISO |
Betulinic Acid promotes the reaction [Erlotinib Hydrochloride results in decreased expression of CDK6 protein] |
CTD |
PMID:30136359 |
|
NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression multiple interactions |
ISO |
Erlotinib Hydrochloride results in increased expression of CDKN1A mRNA Erlotinib Hydrochloride promotes the reaction [Arsenic Trioxide results in increased expression of CDKN1A mRNA] |
CTD |
PMID:29274334 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Chfr |
checkpoint with forkhead and ring finger domains |
multiple interactions |
ISO |
CHFR protein affects the susceptibility to [Cisplatin co-treated with Erlotinib Hydrochloride] |
CTD |
PMID:20705357 |
|
NCBI chr12:46,504,497...46,538,104
Ensembl chr12:46,504,497...46,538,014
|
|
G |
Chrdl2 |
chordin-like 2 |
multiple interactions |
ISO |
[Gemcitabine co-treated with Erlotinib Hydrochloride] affects the expression of CHRDL2 protein |
CTD |
PMID:24979617 |
|
NCBI chr 1:154,343,201...154,370,651
Ensembl chr 1:154,343,201...154,370,640
|
|
G |
Csf3 |
colony stimulating factor 3 |
increases secretion |
ISO |
Erlotinib Hydrochloride results in increased secretion of CSF3 protein |
CTD |
PMID:27738319 |
|
NCBI chr10:83,660,787...83,664,569
Ensembl chr10:83,661,207...83,663,603
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions affects phosphorylation decreases expression |
ISO |
[Betulinic Acid co-treated with Erlotinib Hydrochloride] results in decreased expression of CTNNB1 protein Erlotinib Hydrochloride affects the phosphorylation of CTNNB1 protein Erlotinib Hydrochloride results in decreased expression of CTNNB1 protein |
CTD |
PMID:30136359 PMID:34463000 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Cxcl11 |
C-X-C motif chemokine ligand 11 |
multiple interactions |
ISO |
[Gemcitabine co-treated with Erlotinib Hydrochloride] affects the expression of CXCL11 protein |
CTD |
PMID:24979617 |
|
NCBI chr14:15,689,432...15,692,207
Ensembl chr14:15,689,424...15,692,271
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
decreases activity |
ISO |
Erlotinib Hydrochloride results in decreased activity of CYP19A1 protein |
CTD |
PMID:26141389 |
|
NCBI chr 8:63,449,148...63,476,534
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity |
ISO |
Erlotinib Hydrochloride results in decreased activity of CYP1A1 protein |
CTD |
PMID:33814510 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity |
ISO |
Erlotinib Hydrochloride results in decreased activity of CYP1B1 protein |
CTD |
PMID:33814510 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
increases expression |
ISO |
Erlotinib Hydrochloride results in increased expression of CYP2B6 mRNA |
CTD |
PMID:30364229 |
|
NCBI chr 1:90,780,468...90,859,852
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases activity increases expression |
ISO |
Erlotinib Hydrochloride results in decreased activity of CYP3A4 protein Erlotinib Hydrochloride results in increased expression of CYP3A4 mRNA |
CTD |
PMID:18839173 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
increases response to substance |
ISO |
CYP51A1 mRNA results in increased susceptibility to Erlotinib Hydrochloride |
CTD |
PMID:23125191 |
|
NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410 Ensembl chr 6:30,036,865...30,055,410
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression multiple interactions |
ISO EXP |
Erlotinib Hydrochloride results in increased expression of DDIT3 protein DDIT3 mutant form inhibits the reaction [Erlotinib Hydrochloride results in decreased expression of CDH1 protein]; DDIT3 mutant form inhibits the reaction [Erlotinib Hydrochloride results in increased expression of IL6 mRNA]; DDIT3 mutant form inhibits the reaction [Erlotinib Hydrochloride results in increased secretion of IL6 protein] |
CTD |
PMID:24768708 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Dennd6b |
DENN domain containing 6B |
decreases expression |
ISO |
Erlotinib Hydrochloride results in decreased expression of DENND6B mRNA |
CTD |
PMID:27720938 |
|
NCBI chr 7:120,261,679...120,273,667
Ensembl chr 7:120,261,679...120,273,494
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
multiple interactions |
ISO |
[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in increased expression of DUSP1 mRNA |
CTD |
PMID:27738319 |
|
NCBI chr10:16,680,478...16,683,275
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO EXP |
Erlotinib Hydrochloride inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Cisplatin]]; Erlotinib Hydrochloride inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Gemcitabine]]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in decreased susceptibility to Crizotinib]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased activity of ELK1 protein]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of ELK1 protein]; Erlotinib Hydrochloride promotes the reaction [EGF protein binds to EGFR protein] Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:21613822 PMID:21787763 PMID:22553343 PMID:25625231 PMID:27427493 PMID:30364229 More...
|
|
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egfr |
epidermal growth factor receptor |
affects response to substance decreases expression decreases phosphorylation decreases activity multiple interactions decreases response to substance |
ISO |
EGFR protein affects the susceptibility to Erlotinib Hydrochloride; EGFR protein mutant form affects the susceptibility to Erlotinib Hydrochloride Erlotinib Hydrochloride results in decreased expression of EGFR protein modified form Erlotinib Hydrochloride results in decreased phosphorylation of EGFR protein Erlotinib Hydrochloride results in decreased activity of EGFR protein [Erlotinib Hydrochloride results in decreased activity of EGFR protein] which results in decreased expression of RAD50 protein; [Erlotinib Hydrochloride results in decreased activity of EGFR protein] which results in decreased expression of RAD51 protein; [Erlotinib Hydrochloride results in decreased activity of EGFR protein] which results in decreased phosphorylation of BRCA1 protein; EGFR gene mutant form results in increased susceptibility to [Gemcitabine co-treated with Cisplatin co-treated with Erlotinib Hydrochloride]; Erlotinib Hydrochloride inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of and results in increased activity of EGFR protein]; Erlotinib Hydrochloride inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased phosphorylation of EGFR protein]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of FOXG1 mRNA]; Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of FOXG1 protein]; Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of SOX9 mRNA]; Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of SOX9 protein]; Erlotinib Hydrochloride inhibits the reaction [Particulate Matter analog results in increased phosphorylation of EGFR protein]; Erlotinib Hydrochloride inhibits the reaction [sodium arsenite results in increased phosphorylation of EGFR protein]; Erlotinib Hydrochloride promotes the reaction [Deoxycholic Acid results in decreased glycosylation of and results in decreased expression of EGFR protein]; Erlotinib Hydrochloride promotes the reaction [EGF protein binds to EGFR protein]; Erlotinib Hydrochloride results in decreased activity of and results in decreased phosphorylation of EGFR protein; Erlotinib Hydrochloride results in decreased glycosylation of and results in decreased expression of EGFR protein EGFR protein mutant form results in decreased susceptibility to Erlotinib Hydrochloride |
CTD |
PMID:12907618 PMID:16407879 PMID:16891461 PMID:19168569 PMID:21080748 PMID:21541241 PMID:21787763 PMID:22223758 PMID:22751098 PMID:23099361 PMID:23440206 PMID:23548265 PMID:23894143 PMID:25625231 PMID:26455392 PMID:28101945 PMID:30136359 PMID:30364229 PMID:30623574 More...
|
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
increases expression |
EXP |
Erlotinib Hydrochloride results in increased expression of EIF2S1 protein modified form |
CTD |
PMID:24768708 |
|
NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
|
|
G |
Elk1 |
ETS transcription factor ELK1 |
multiple interactions |
ISO |
Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased activity of ELK1 protein]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of ELK1 protein] |
CTD |
PMID:25625231 PMID:30364229 |
|
NCBI chr X:1,138,826...1,155,713
Ensembl chr X:1,139,756...1,155,713
|
|
G |
Erbb3 |
erb-b2 receptor tyrosine kinase 3 |
decreases response to substance |
ISO |
ERBB3 mRNA results in decreased susceptibility to Erlotinib Hydrochloride |
CTD |
PMID:23125191 |
|
NCBI chr 7:994,549...1,015,876
Ensembl chr 7:996,225...1,015,525
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
Erlotinib Hydrochloride affects the expression of and affects the phosphorylation of ESR1 protein |
CTD |
PMID:34463000 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Foxg1 |
forkhead box G1 |
multiple interactions decreases expression |
ISO |
Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of FOXG1 mRNA]; Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of FOXG1 protein] Erlotinib Hydrochloride results in decreased expression of FOXG1 protein |
CTD |
PMID:26455392 |
|
NCBI chr 6:66,674,797...66,677,611
Ensembl chr 6:66,666,587...66,678,607
|
|
G |
Foxo3 |
forkhead box O3 |
decreases phosphorylation |
ISO |
Erlotinib Hydrochloride results in decreased phosphorylation of FOXO3 protein |
CTD |
PMID:23099361 |
|
NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561
|
|
G |
Gdf15 |
growth differentiation factor 15 |
multiple interactions |
ISO |
[Gemcitabine co-treated with Erlotinib Hydrochloride] affects the expression of GDF15 protein |
CTD |
PMID:24979617 |
|
NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055
|
|
G |
Gmpr |
guanosine monophosphate reductase |
decreases expression |
ISO |
Erlotinib Hydrochloride results in decreased expression of GMPR mRNA |
CTD |
PMID:27720938 |
|
NCBI chr17:19,151,820...19,189,626
Ensembl chr17:19,151,815...19,189,621
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
decreases expression |
ISO |
Erlotinib Hydrochloride results in decreased expression of GSK3B protein modified form |
CTD |
PMID:30136359 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions increases expression |
ISO |
Erlotinib Hydrochloride promotes the reaction [Resveratrol results in increased expression of H2AX protein modified form]; Resveratrol promotes the reaction [Erlotinib Hydrochloride results in increased expression of H2AX protein modified form] |
CTD |
PMID:25895606 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239 Ensembl chr 4:44,671,786...44,673,239
|
|
G |
Hbegf |
heparin-binding EGF-like growth factor |
multiple interactions |
ISO |
Erlotinib Hydrochloride inhibits the reaction [HBEGF protein results in decreased susceptibility to crizotinib] |
CTD |
PMID:22553343 |
|
NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441
|
|
G |
Ifitm3 |
interferon induced transmembrane protein 3 |
decreases expression |
ISO |
Erlotinib Hydrochloride results in decreased expression of IFITM3 mRNA |
CTD |
PMID:27720938 |
|
NCBI chr 1:196,111,026...196,112,135
Ensembl chr 1:196,111,043...196,112,203
|
|
G |
Ifng |
interferon gamma |
decreases secretion |
ISO |
Erlotinib Hydrochloride results in decreased secretion of IFNG protein |
CTD |
PMID:21195724 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il17f |
interleukin 17F |
increases expression |
ISO EXP |
Erlotinib Hydrochloride results in increased expression of IL17F mRNA |
CTD |
PMID:24768708 |
|
NCBI chr 9:23,190,094...23,201,482
Ensembl chr 9:23,190,100...23,201,482
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
ISO |
[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in increased expression of IL1A mRNA |
CTD |
PMID:27738319 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases secretion |
ISO |
[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in increased expression of IL1B mRNA Erlotinib Hydrochloride results in increased secretion of IL1B protein |
CTD |
PMID:27738319 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il1r1 |
interleukin 1 receptor type 1 |
multiple interactions |
ISO |
[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased expression of IL1R1 mRNA |
CTD |
PMID:27738319 |
|
NCBI chr 9:42,504,917...42,580,958
Ensembl chr 9:42,504,735...42,579,937
|
|
G |
Il1r2 |
interleukin 1 receptor type 2 |
multiple interactions |
ISO |
[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which affects the expression of IL1R2 mRNA |
CTD |
PMID:27738319 |
|
NCBI chr 9:42,384,280...42,424,726
Ensembl chr 9:42,384,433...42,424,725
|
|
G |
Il1rap |
interleukin 1 receptor accessory protein |
multiple interactions |
ISO |
[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in increased expression of IL1RAP mRNA |
CTD |
PMID:27738319 |
|
NCBI chr11:74,062,999...74,199,530
Ensembl chr11:74,070,304...74,199,530
|
|
G |
Il1rn |
interleukin 1 receptor antagonist |
multiple interactions |
ISO |
[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which affects the expression of IL1RN mRNA; [Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased expression of IL1RN mRNA; [Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased secretion of IL1RN protein |
CTD |
PMID:27738319 |
|
NCBI chr 3:7,111,567...7,127,451
Ensembl chr 3:7,111,550...7,127,445
|
|
G |
Il2 |
interleukin 2 |
decreases secretion |
ISO |
Erlotinib Hydrochloride results in decreased secretion of IL2 protein |
CTD |
PMID:21195724 |
|
NCBI chr 2:121,932,968...121,937,672
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il25 |
interleukin 25 |
increases expression |
ISO EXP |
Erlotinib Hydrochloride results in increased expression of IL25 mRNA |
CTD |
PMID:24768708 |
|
NCBI chr15:28,408,766...28,412,157
Ensembl chr15:28,408,842...28,411,893
|
|
G |
Il2ra |
interleukin 2 receptor subunit alpha |
decreases expression |
ISO |
Erlotinib Hydrochloride results in decreased expression of IL2RA protein |
CTD |
PMID:21195724 |
|
NCBI chr17:66,849,974...66,898,665
Ensembl chr17:66,849,974...66,898,697
|
|
G |
Il6 |
interleukin 6 |
increases expression increases secretion multiple interactions |
ISO EXP |
Erlotinib Hydrochloride results in increased expression of IL6 mRNA Erlotinib Hydrochloride results in increased secretion of IL6 protein Erlotinib Hydrochloride inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased expression of IL6 mRNA]; Erlotinib Hydrochloride inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased secretion of IL6 protein]; Interleukin 1 Receptor Antagonist Protein inhibits the reaction [Erlotinib Hydrochloride results in increased secretion of IL6 protein] DDIT3 mutant form inhibits the reaction [Erlotinib Hydrochloride results in increased expression of IL6 mRNA]; DDIT3 mutant form inhibits the reaction [Erlotinib Hydrochloride results in increased secretion of IL6 protein] |
CTD |
PMID:24768708 PMID:27738319 PMID:30623574 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Irak1 |
interleukin-1 receptor-associated kinase 1 |
multiple interactions |
ISO |
[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased expression of IRAK1 mRNA |
CTD |
PMID:27738319 |
|
NCBI chr X:151,768,621...151,778,521
Ensembl chr X:151,768,777...151,778,521
|
|
G |
Itgb1 |
integrin subunit beta 1 |
decreases expression |
EXP |
Erlotinib Hydrochloride results in decreased expression of ITGB1 mRNA |
CTD |
PMID:24768708 |
|
NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195
|
|
G |
Jak2 |
Janus kinase 2 |
decreases phosphorylation |
ISO |
Erlotinib Hydrochloride results in decreased phosphorylation of JAK2 protein |
CTD |
PMID:23894143 |
|
NCBI chr 1:236,408,905...236,468,769
Ensembl chr 1:226,995,334...227,054,189
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
affects activity decreases activity |
ISO |
Erlotinib Hydrochloride affects the activity of KCNH2 protein Erlotinib Hydrochloride results in decreased activity of KCNH2 protein |
CTD |
PMID:23707608 PMID:35680041 |
|
NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Kitlg |
KIT ligand |
multiple interactions |
ISO |
[Gemcitabine co-treated with Erlotinib Hydrochloride] affects the expression of KITLG protein |
CTD |
PMID:24979617 |
|
NCBI chr 7:34,896,075...34,977,215
Ensembl chr 7:34,896,053...34,977,214
|
|
G |
Kras |
KRAS proto-oncogene, GTPase |
increases response to substance |
ISO |
KRAS protein results in increased susceptibility to Erlotinib Hydrochloride |
CTD |
PMID:20705357 |
|
NCBI chr 4:178,185,418...178,218,484
|
|
G |
Ldha |
lactate dehydrogenase A |
increases secretion |
ISO |
Erlotinib Hydrochloride results in increased secretion of LDHA protein |
CTD |
PMID:37660997 |
|
NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions |
ISO |
Erlotinib Hydrochloride promotes the reaction [Betulinic Acid results in increased expression of MAP1LC3B protein modified form] |
CTD |
PMID:30136359 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690 Ensembl chr16:49,665,791...49,677,690
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
decreases phosphorylation multiple interactions |
ISO EXP |
Erlotinib Hydrochloride results in decreased phosphorylation of MAPK1 protein Erlotinib Hydrochloride inhibits the reaction [Particulate Matter analog results in increased phosphorylation of MAPK1 protein] Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein] Erlotinib Hydrochloride inhibits the reaction [Alprenolol results in increased phosphorylation of MAPK1 protein]; Erlotinib Hydrochloride inhibits the reaction [carvedilol results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:18787115 PMID:18980991 PMID:21195724 PMID:27427493 PMID:28101945 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases phosphorylation multiple interactions |
ISO EXP |
Erlotinib Hydrochloride results in decreased phosphorylation of MAPK3 protein Erlotinib Hydrochloride inhibits the reaction [Particulate Matter analog results in increased phosphorylation of MAPK3 protein] Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein] Erlotinib Hydrochloride inhibits the reaction [Alprenolol results in increased phosphorylation of MAPK3 protein]; Erlotinib Hydrochloride inhibits the reaction [carvedilol results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:18787115 PMID:18980991 PMID:21195724 PMID:27427493 PMID:28101945 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
decreases expression multiple interactions |
ISO |
Erlotinib Hydrochloride results in decreased expression of MCL1 protein resveratrol promotes the reaction [Erlotinib Hydrochloride results in decreased expression of MCL1 protein] |
CTD |
PMID:25895606 |
|
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Met |
MET proto-oncogene, receptor tyrosine kinase |
multiple interactions decreases phosphorylation |
ISO |
[Erlotinib Hydrochloride co-treated with Dasatinib] results in decreased phosphorylation of MET protein Erlotinib Hydrochloride results in decreased phosphorylation of MET protein |
CTD |
PMID:21106725 PMID:23894143 |
|
NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876
|
|
G |
Micb |
MHC class I polypeptide-related sequence B |
increases expression |
ISO |
Erlotinib Hydrochloride results in increased expression of MICB protein |
CTD |
PMID:21951556 |
|
NCBI chr 1:78,495,779...78,513,030
Ensembl chr 1:78,495,779...78,512,827
|
|
G |
Mmp14 |
matrix metallopeptidase 14 |
multiple interactions |
ISO |
Erlotinib Hydrochloride inhibits the reaction [Acrolein results in increased expression of MMP14 mRNA] |
CTD |
PMID:19661247 |
|
NCBI chr15:27,887,795...27,897,020
Ensembl chr15:27,887,727...27,899,864
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
ISO |
[Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in decreased expression of MMP2 mRNA |
CTD |
PMID:29274334 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
[Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in decreased expression of MMP9 mRNA |
CTD |
PMID:29274334 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Msmo1 |
methylsterol monooxygenase 1 |
decreases response to substance multiple interactions |
ISO |
MSMO1 protein results in decreased susceptibility to Erlotinib Hydrochloride MSMO1 protein inhibits the reaction [Erlotinib Hydrochloride results in decreased expression of RPS6 protein modified form] |
CTD |
PMID:23125191 |
|
NCBI chr16:24,980,680...24,997,927
Ensembl chr16:24,980,697...24,998,016
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
decreases phosphorylation multiple interactions |
ISO |
Erlotinib Hydrochloride results in decreased phosphorylation of MTOR protein resveratrol promotes the reaction [Erlotinib Hydrochloride results in decreased phosphorylation of MTOR protein] |
CTD |
PMID:21655094 PMID:25895606 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Muc5ac |
mucin 5AC, oligomeric mucus/gel-forming |
multiple interactions |
ISO |
Erlotinib Hydrochloride inhibits the reaction [Acrolein results in increased expression of MUC5AC mRNA] |
CTD |
PMID:18006877 PMID:19661247 |
|
NCBI chr 1:196,864,336...196,896,475
Ensembl chr 1:196,864,336...196,896,475
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
affects expression |
ISO |
Erlotinib Hydrochloride affects the expression of MYC protein |
CTD |
PMID:34463000 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
multiple interactions |
ISO |
[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which affects the expression of MYD88 mRNA |
CTD |
PMID:27738319 |
|
NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which affects the expression of NFKBIA mRNA |
CTD |
PMID:27738319 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nol10 |
nucleolar protein 10 |
decreases expression |
ISO |
Erlotinib Hydrochloride results in decreased expression of NOL10 mRNA |
CTD |
PMID:27720938 |
|
NCBI chr 6:40,144,217...40,225,353
Ensembl chr 6:40,144,235...40,225,353
|
|
G |
Nox4 |
NADPH oxidase 4 |
multiple interactions decreases response to substance increases expression |
ISO |
Erlotinib Hydrochloride results in increased expression of and results in increased stability of NOX4 mRNA NOX4 protein results in decreased susceptibility to Erlotinib Hydrochloride Erlotinib Hydrochloride results in increased expression of NOX4 protein |
CTD |
PMID:23917044 |
|
NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions |
ISO |
Erlotinib Hydrochloride binds to and results in increased activity of NR1I2 protein |
CTD |
PMID:18839173 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
affects localization |
ISO |
Erlotinib Hydrochloride affects the localization of NR1I3 protein mutant form |
CTD |
PMID:30364229 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Nsdhl |
NAD(P) dependent 3-beta-hydroxysteroid dehydrogenase NSDHL |
decreases response to substance |
ISO |
NSDHL protein results in decreased susceptibility to Erlotinib Hydrochloride |
CTD |
PMID:23125191 |
|
NCBI chr X:150,775,034...150,807,161
Ensembl chr X:150,775,080...150,807,142
|
|
G |
Osm |
oncostatin M |
multiple interactions |
ISO |
[Gemcitabine co-treated with Erlotinib Hydrochloride] affects the expression of OSM protein |
CTD |
PMID:24979617 |
|
NCBI chr14:79,103,638...79,108,500
Ensembl chr14:79,104,344...79,108,313
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage multiple interactions increases expression |
ISO |
Erlotinib Hydrochloride results in increased cleavage of PARP1 protein [TWIST1 protein results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased cleavage of PARP1 protein; Harmine promotes the reaction [Erlotinib Hydrochloride results in increased cleavage of PARP1 protein]; Resveratrol promotes the reaction [Erlotinib Hydrochloride results in increased expression of PARP1 protein modified form]; TWIST1 protein inhibits the reaction [Erlotinib Hydrochloride results in increased cleavage of PARP1 protein] |
CTD |
PMID:23125191 PMID:25895606 PMID:30171258 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pik3ca |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha |
multiple interactions |
ISO |
Erlotinib Hydrochloride inhibits the reaction [carvacrol results in increased phosphorylation of PIK3CA protein] |
CTD |
PMID:32535744 |
|
NCBI chr 2:115,175,275...115,249,034
Ensembl chr 2:115,174,984...115,249,032
|
|
G |
Pml |
PML nuclear body scaffold |
increases expression decreases response to substance increases localization |
ISO |
Erlotinib Hydrochloride results in increased expression of PML protein PML protein results in decreased susceptibility to Erlotinib Hydrochloride Erlotinib Hydrochloride results in increased localization of PML protein |
CTD |
PMID:23440206 |
|
NCBI chr 8:58,627,347...58,661,927
Ensembl chr 8:58,628,837...58,658,971
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in increased expression of PTGS2 mRNA |
CTD |
PMID:27738319 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptpn9 |
protein tyrosine phosphatase, non-receptor type 9 |
decreases expression decreases response to substance |
ISO |
Erlotinib Hydrochloride results in decreased expression of PTPN9 protein PTPN9 mutant form results in decreased susceptibility to Erlotinib Hydrochloride |
CTD |
PMID:23894143 |
|
NCBI chr 8:57,391,290...57,472,352
Ensembl chr 8:57,391,259...57,470,952
|
|
G |
Rad50 |
RAD50 double strand break repair protein |
multiple interactions |
ISO |
[Erlotinib Hydrochloride results in decreased activity of EGFR protein] which results in decreased expression of RAD50 protein |
CTD |
PMID:23548265 |
|
NCBI chr10:37,809,353...37,861,309
Ensembl chr10:37,808,726...37,861,396
|
|
G |
Rad51 |
RAD51 recombinase |
multiple interactions |
ISO |
[Erlotinib Hydrochloride results in decreased activity of EGFR protein] which results in decreased expression of RAD51 protein |
CTD |
PMID:23548265 |
|
NCBI chr 3:106,099,753...106,125,038
Ensembl chr 3:106,100,381...106,125,035
|
|
G |
Raf1 |
Raf-1 proto-oncogene, serine/threonine kinase |
decreases phosphorylation multiple interactions |
ISO |
Erlotinib Hydrochloride results in decreased phosphorylation of RAF1 protein Erlotinib Hydrochloride inhibits the reaction [[Air Pollutants results in increased abundance of Particulate Matter] which results in increased phosphorylation of RAF1 protein] |
CTD |
PMID:21195724 PMID:36442402 |
|
NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
decreases phosphorylation multiple interactions decreases expression |
ISO |
Erlotinib Hydrochloride results in decreased phosphorylation of RB1 protein Betulinic Acid promotes the reaction [Erlotinib Hydrochloride results in decreased expression of RB1 protein modified form]; Erlotinib Hydrochloride promotes the reaction [Betulinic Acid results in decreased expression of RB1 protein modified form] |
CTD |
PMID:21195724 PMID:30136359 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
Erlotinib Hydrochloride inhibits the reaction [carvacrol results in increased phosphorylation of RELA protein]; Erlotinib Hydrochloride inhibits the reaction [Particulate Matter analog results in increased acetylation of RELA protein] |
CTD |
PMID:28101945 PMID:32535744 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rps6 |
ribosomal protein S6 |
decreases phosphorylation decreases expression multiple interactions |
ISO |
Erlotinib Hydrochloride results in decreased phosphorylation of RPS6 protein Erlotinib Hydrochloride results in decreased expression of RPS6 protein modified form MSMO1 protein inhibits the reaction [Erlotinib Hydrochloride results in decreased expression of RPS6 protein modified form] |
CTD |
PMID:23125191 PMID:23440206 |
|
NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602 Ensembl chr 5:101,371,136...101,374,602
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
decreases phosphorylation multiple interactions |
ISO |
Erlotinib Hydrochloride results in decreased phosphorylation of RPS6KB1 protein resveratrol promotes the reaction [Erlotinib Hydrochloride results in decreased phosphorylation of RPS6KB1 protein] |
CTD |
PMID:21655094 PMID:25895606 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Selenbp1 |
selenium binding protein 1 |
decreases expression |
ISO |
Erlotinib Hydrochloride results in decreased expression of SELENBP1 mRNA |
CTD |
PMID:27720938 |
|
NCBI chr 2:182,494,004...182,504,594
Ensembl chr 2:182,493,978...182,504,594
|
|
G |
Siah2 |
siah E3 ubiquitin protein ligase 2 |
decreases expression |
ISO |
Erlotinib Hydrochloride results in decreased expression of SIAH2 mRNA |
CTD |
PMID:27720938 |
|
NCBI chr 2:142,913,924...142,931,752
Ensembl chr 2:142,914,003...142,931,950
|
|
G |
Snai1 |
snail family transcriptional repressor 1 |
multiple interactions |
ISO |
[Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in decreased expression of SNAI1 mRNA |
CTD |
PMID:29274334 |
|
NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969
|
|
G |
Snai2 |
snail family transcriptional repressor 2 |
multiple interactions |
ISO |
[Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in decreased expression of SNAI2 mRNA |
CTD |
PMID:29274334 |
|
NCBI chr11:86,182,788...86,186,203
Ensembl chr11:86,181,909...86,186,200
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
increases expression |
EXP |
Erlotinib Hydrochloride results in increased expression of SOCS3 mRNA |
CTD |
PMID:24768708 |
|
NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787
|
|
G |
Sox9 |
SRY-box transcription factor 9 |
multiple interactions decreases expression |
ISO |
Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of SOX9 mRNA]; Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of SOX9 protein] Erlotinib Hydrochloride results in decreased expression of SOX9 protein |
CTD |
PMID:26455392 |
|
NCBI chr10:97,806,485...97,811,994
Ensembl chr10:97,806,485...97,811,994
|
|
G |
Sqstm1 |
sequestosome 1 |
increases expression |
ISO |
Erlotinib Hydrochloride results in increased expression of SQSTM1 protein |
CTD |
PMID:30136359 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
decreases phosphorylation |
ISO |
Erlotinib Hydrochloride results in decreased phosphorylation of SRC protein |
CTD |
PMID:23894143 |
|
NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
increases phosphorylation decreases expression increases response to substance decreases response to substance multiple interactions |
ISO |
Erlotinib Hydrochloride results in increased phosphorylation of STAT3 protein Erlotinib Hydrochloride results in decreased expression of STAT3 protein modified form STAT3 mutant form results in increased susceptibility to Erlotinib Hydrochloride STAT3 mRNA results in decreased susceptibility to Erlotinib Hydrochloride [Betulinic Acid co-treated with Erlotinib Hydrochloride] results in decreased expression of STAT3 protein modified form; [Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased phosphorylation of STAT3 protein]] which results in increased susceptibility to Erlotinib Hydrochloride; Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:23125191 PMID:23894143 PMID:30136359 |
|
NCBI chr10:86,311,528...86,363,513
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tent5c |
terminal nucleotidyltransferase 5C |
decreases expression |
ISO |
Erlotinib Hydrochloride results in decreased expression of TENT5C mRNA |
CTD |
PMID:27720938 |
|
NCBI chr 2:187,853,026...187,875,260
Ensembl chr 2:187,853,024...187,894,744
|
|
G |
Tfap2a |
transcription factor AP-2 alpha |
multiple interactions |
ISO |
Erlotinib Hydrochloride inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]; Tetradecanoylphorbol Acetate inhibits the reaction [Erlotinib Hydrochloride inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]] |
CTD |
PMID:21499124 PMID:21951556 |
|
NCBI chr17:24,028,716...24,047,507
Ensembl chr17:24,024,432...24,047,507
|
|
G |
Tgfa |
transforming growth factor alpha |
multiple interactions |
ISO |
Erlotinib Hydrochloride inhibits the reaction [TGFA protein results in decreased susceptibility to crizotinib] |
CTD |
PMID:22553343 |
|
NCBI chr 4:118,618,043...118,700,897
Ensembl chr 4:118,618,269...118,700,894
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
Erlotinib Hydrochloride inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Cisplatin]]; Erlotinib Hydrochloride inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Gemcitabine]] |
CTD |
PMID:21613822 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tmed2 |
transmembrane p24 trafficking protein 2 |
decreases response to substance |
ISO |
TMED2 mRNA results in decreased susceptibility to Erlotinib Hydrochloride |
CTD |
PMID:23125191 |
|
NCBI chr12:32,052,542...32,061,628
Ensembl chr12:32,052,543...32,071,903
|
|
|